

**VIBHAVADI MEDICAL CENTER PUBLIC COMPANY LIMITED
AND ITS SUBSIDIARIES**

**CONSOLIDATED AND SEPARATE FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2020**

INDEPENDENT AUDITOR'S REPORT

To The Shareholders and Board of Directors of
Vibhavadi Medical Center Public Company Limited

Opinion

I have audited the consolidated financial statements of Vibhavadi Medical Center Public Company Limited and its subsidiaries (the Group), which comprise the consolidated statement of financial position as at December 31, 2020, the consolidated statement of comprehensive income, consolidated statement of changes in shareholders' equity and consolidated statement of cash flows for the year then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies, and I have audited the separate financial statements of Vibhavadi Medical Center Public Company Limited (the Company), which comprise the statement of financial position as at December 31, 2020, the statement of comprehensive income, statement of changes in shareholders' equity and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In my opinion, the accompanying financial statements present fairly, in all material respects, the consolidated financial position of Vibhavadi Medical Center Public Company Limited and its subsidiaries as at December 31, 2020, its consolidated financial performance and its consolidated cash flows for the year then ended and the separate financial position of Vibhavadi Medical Center Public Company Limited as at December 31, 2020, its financial performance and its cash flows for the year then ended in accordance with Thai Financial Reporting Standards.

Basis for Opinion

I conducted my audit in accordance with Thai Standards on Auditing. My responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of my report. I am independent of the Group and the Company in accordance with the Federation of Accounting Professions Code of Ethics for Professional Accountants together with the ethical requirements that are relevant to my audit of the financial statements, and I have fulfilled my other ethical responsibilities in accordance with these requirements. I believe that the audit evidence I have obtained is sufficient and appropriate to provide a basis for my opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in my audit of the consolidated financial statements and separate financial statements of the current period. These matters were addressed in the context of my audit of the consolidated financial statements and separate financial statements as a whole, and in forming my opinion thereon, and I do not provide a separate opinion on these matters.

Revenue recognition from general medical treatment

The Group has the revenue from general medical treatment that is considered as a significant account to the financial statements. The consolidated financial statements amounted Baht 5,909.50 million (93.24% of total revenues) and the separate financial statements amounted Baht 2,129.85 million (78.23% of total revenues). The amount of money is derived from a large number of transactions including the medical treatment expenses that have many components such as revenue from the sale of medicines and medical supplies, medical services revenue, patient room revenue, etc. It also includes the discounts for parties. The conditions specified in the agreement with the parties are diverse. Therefore, the Group is exposed to the risks associated with the value and period of revenue recognition.

I have audited the revenue recognition of the Group by assessing information system and testing the internal control system relating to the revenue cycle, inquiring the responsible persons, understanding and selecting the sample to test the operation of control designed by the Group. Moreover, I conducted the sampling of sales and service transactions that occurred during the year to check with sales and service documentation and cut-off audit of the revenue recognition. It includes the comparative analysis of subgroup data of revenue account, analysis of key revenue ratios with historical and industry group data to check the irregularities that may incur in sales and service transactions throughout the accounting period, especially the accounts made through the general voucher.

Revenue recognition from Social Security

The subsidiaries have the revenue from Social Security by entering into medical service provider agreement under Social Security Act, B. E. 2533. The revenues from Social Security in the consolidated financial statements represent 16.24% of total revenues. The subsidiaries will receive the money from the Social Security Office in terms of insured persons who select the medical treatment with the hospitals. In addition, the subsidiaries will also gain the income from medical service fee for the cases with burden of disease risk and high-cost disease but the additional revenue from earnings each time has to be approved by the Social Security Office. However, the consideration process of the Social Security Office takes a long time. In the event that the subsidiaries have already provided the medical service to the insured persons, the subsidiaries have its right to gain the medical treatment fee according to the medical service agreement. The management then consider the estimation of medical service revenue for the cases with burden of disease risk and high-cost disease. This is significant estimation requiring the management to apply the high judgment. The specialists' opinion is also needed in considering the severity rate of the disease to estimate the revenue. I therefore focus with respect to the revenue recognition from Social Security as it has a significant risk to the financial statements.

I made an understanding for the process of estimating the medical service revenue for the cases with burden of disease risk and high-cost disease by investigating the sources and reliability of the insured persons' information used in calculating the revenue estimate, assessing the appropriateness of severity rate of the disease by comparing with rules, method and conditions as announced by the Social Security Office, testing the calculation of revenue estimation for medical service in case burden of disease risk and high-cost disease including the comparison of receipts during the period and analyzing the difference cause compared to the estimated medical service revenue and reviewing the receiving of medical service fee for the cases with burden of disease risk and high-cost disease after the end of period.

Impairment of investment in the subsidiary and associate

The Company has investment in the subsidiary and associate in an amount with high value as presented in the separate financial statements of Baht 3,445.34 million or 32.22 percent of total assets. Due to the uncertainty of the current economic situation, such subsidiary and associate cannot make profit in line with the expectation of the company, this indicates an impairment of such investment. In the impairment assessment of investment in the subsidiary and associate taking into account of the book value of the assets or cash generating assets whether it is higher than the recovery amount, the management is required to use considerable judgment in identifying cash generating assets and the estimation of future cash flow that the Company expects to receive from that asset group.

I assessed the qualification of the independent appraiser and method used by the management in specifying the cash generating assets and financial business model selected by the management by understanding the management's consideration process. Furthermore, I tested the significant assumptions used by the management in estimating the expected future cash flow to be received from the assets, especially revenue growth and operating profit forecasts of the company group above, the use of appropriate discount rate for discounted future cash flow, including the calculation test of the realisable value and the information disclosure relating to the assumptions which affect the most sensitive impairment testing result with the most significant effect in determining the recovery value of investment above.

Emphasis of Matter

I draw attention to Note 2.3 to the financial statements. Due to the impact of COVID-19 pandemic, in preparing the financial information for the year ended December 31 2020, the Group has adopted the Accounting Guidance on "Temporary relief measures on accounting alternatives in response to the impact of the COVID-19 situation" announced by the Federation of Accounting Professions. My conclusion is not modified in respect of this matter.

Other Information

Management is responsible for the other information. The other information comprises the information included in the annual report, but does not include the financial statements and my auditor's report thereon. The annual report is expected to be made available to me after the date of this auditor's report.

My opinion on the financial statements does not cover the other information and I will not express any form of assurance conclusion thereon.

In connection with my audit of the financial statements, my responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the financial statements or my knowledge obtained in the audit, or otherwise appears to be materially misstated.

When I read the annual report, if I conclude that there is a material misstatement therein, I am required to communicate the matter to those charged with governance in order for those charged with governance to correct the misstatement

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements and separate financial statements in accordance with Thai Financial Reporting Standards, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements and separate financial statements, management is responsible for assessing the Group's and the Company's ability to continue as a going concern, disclosing, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group and the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Group's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

My objectives are to obtain reasonable assurance about whether the consolidated financial statements and separate financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes my opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Thai Standards on Auditing will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements and separate financial statements.

As part of an audit in accordance with Thai Standards on Auditing, I exercise professional judgment and maintain professional skepticism throughout the audit. I also:

- Identify and assess the risks of material misstatement of the consolidated financial statements and separate financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for my opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's and the Company's internal control.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's and the Company's ability to continue as a going concern. If I conclude that a material uncertainty exists, I am required to draw attention in my auditor's report to the related disclosures in the consolidated financial statements and separate financial statements or, if such disclosures are inadequate, to modify my opinion. My conclusions are based on the audit evidence obtained up to the date of my auditor's report. However, future events or conditions may cause the Group and the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the consolidated financial statements and separate financial statements, including the disclosures, and whether the consolidated financial statements and separate financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. I am responsible for the direction, supervision and performance of the group audit. I remain solely responsible for my audit opinion.

I communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that I identify during my audit.

I also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on my independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, I determine those matters that were of most significance in the audit of the consolidated financial statements and separate financial statements of the current period and are therefore the key audit matters. I describe these matters in my auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, I determine that a matter should not be communicated in my report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partner responsible for the audit resulting in this independent auditor's report is Mr. Peradate Pongsathiansak.

(Mr. Peradate Pongsathiansak)
Certified Public Accountant
Registration No. 4752

Dharmniti Auditing Company Limited
Bangkok, Thailand
February 25, 2021

VIBHAVADI MEDICAL CENTER PUBLIC COMPANY LIMITED AND ITS SUBSIDIARIES

STATEMENT OF FINANCIAL POSITION

AS AT DECEMBER 31, 2020

		<u>ASSETS</u>				
		Baht				
		Consolidated financial statements		Separate financial statements		
Notes		2020	2019	2020	2019	
Current assets						
	Cash and cash equivalents	7	338,293,191	602,855,047	40,881,085	70,346,919
	Trade receivables	6, 8	639,659,569	592,595,058	141,639,038	131,271,650
	Short-term loans to related parties	6, 9	240,665,200	305,125,000	138,290,200	117,419,494
	Short-term loans to other person		1,180,000	-	-	-
	Inventories	10	164,931,210	174,559,361	46,920,599	49,432,004
	Capital decrease receivable	6, 14	-	-	75,949,597	-
	Accrued dividend	6	68,650,075	-	67,450,075	-
	Other current assets	6	67,954,978	43,657,426	19,086,600	13,598,981
	Total current assets		1,521,334,223	1,718,791,892	530,217,194	382,069,048
Non-current assets						
	Fixed deposits pledged as collateral	11	39,406,478	36,252,346	-	-
	Other non-current financial assets	6, 12	7,900,167,417	-	5,145,443,263	-
	Available-for-sale investments	5	-	6,314,275,539	-	3,674,474,522
	Investments in associates	13	2,150,082,246	2,353,951,866	1,641,360,168	1,777,365,788
	Investments in subsidiaries	14	-	-	1,804,025,065	1,998,150,070
	Other long-term investments	5	-	971,836,651	-	726,821,891
	Long-term loans to related parties	6	24,000,000	24,000,000	-	-
	Long-term loans to other persons		18,945,000	5,370,000	-	-
	Investment property	15	451,924,898	376,959,359	374,541,949	297,380,686
	Property, plant and equipment	16	7,970,092,761	7,024,739,789	1,172,849,944	1,295,948,091
	Right-of-use assets	17	302,927,373	-	17,658,399	-
	Goodwill	18	723,215,731	723,215,731	-	-
	Intangible assets		10,506,156	7,305,354	1,135,806	2,750,076
	Deferred tax assets	19	12,578,546	27,156,447	-	-
	Advance payment for assets		42,582,093	38,687,428	-	-
	Other non-current assets		7,255,642	7,312,284	4,873,391	5,112,224
	Total non-current assets		19,653,684,341	17,911,062,794	10,161,887,985	9,778,003,348
	Total assets		21,175,018,564	19,629,854,686	10,692,105,179	10,160,072,396

Notes to the financial statements form an integral part of these statements.

VIBHAVADI MEDICAL CENTER PUBLIC COMPANY LIMITED AND ITS SUBSIDIARIES

STATEMENT OF FINANCIAL POSITION (CONT.)

AS AT DECEMBER 31, 2020

LIABILITIES AND SHAREHOLDERS' EQUITY

	Notes	Baht			
		Consolidated financial statements		Separate financial statements	
		2020	2019	2020	2019
Current liabilities					
Bank overdrafts and short-term loans					
from financial institutions	20	2,605,899,659	2,677,944,206	1,870,000,000	2,045,000,000
Trade payables	6	335,023,990	342,149,832	101,292,198	109,712,596
Current portion of long-term liabilities					
Long-term loans	23	1,065,160,006	843,183,339	563,345,720	447,679,053
Lease liabilities	24	24,963,097	4,952,300	7,264,729	4,464,212
Short-term loans from related parties	6, 21	375,253,818	633,053,818	-	-
Short-term loans from other persons	22	85,300,000	70,800,000	-	-
Payable from acquisition of assets	6	41,912,631	89,305,075	746,305	1,148,032
Accrued doctor fee		167,994,806	178,189,331	76,968,097	81,413,327
Accrued expenses	6	82,644,684	76,334,388	25,989,851	23,649,754
Accrued dividends		66,083,872	20,919,323	13,669,991	12,048,712
Income tax payable		69,410,471	84,977,134	34,720,172	44,953,519
Advance received from social security office	30	331,690,576	251,324,642	-	-
Advance received from shares	6	-	36,378,150	-	-
Payable from transfer share	6, 14	-	-	-	185,845,281
Other current liabilities	6	53,562,050	49,504,782	10,867,110	11,733,506
Total current liabilities		5,304,899,660	5,359,016,320	2,704,864,173	2,967,647,992
Non-current liabilities					
Long-term loans from financial institutions	23	3,491,305,507	2,660,207,169	1,475,829,510	1,375,573,360
Lease liabilities	24	297,208,412	8,292,719	18,597,705	7,354,911
Long-term loans from related parties	6, 21	284,000,000	176,000,000	284,000,000	176,000,000
Liabilities under operating lease agreements	5	-	78,752,461	-	-
Deferred tax liabilities	19	716,825,460	699,937,849	168,000,082	107,907,433
Provisions for employee benefit	25	268,327,340	241,720,015	79,704,508	72,541,329
Other non-current liabilities	6	78,431,810	34,260,782	17,748,132	25,761,851
Total non-current liabilities		5,136,098,529	3,899,170,995	2,043,879,937	1,765,138,884
Total liabilities		10,440,998,189	9,258,187,315	4,748,744,110	4,732,786,876

Notes to the financial statements form an integral part of these statements.

VIBHAVADI MEDICAL CENTER PUBLIC COMPANY LIMITED AND ITS SUBSIDIARIES

STATEMENT OF FINANCIAL POSITION (CONT.)

AS AT DECEMBER 31, 2020

LIABILITIES AND SHAREHOLDERS' EQUITY (CONT.)

	Notes	Baht			
		Consolidated financial statements		Separate financial statements	
		2020	2019	2020	2019
Shareholders' equity					
Share capital	26				
Authorized share capital					
14,939,082,816 ordinary shares, Baht 0.10 each		1,493,908,282		1,493,908,282	
14,937,849,936 ordinary shares, Baht 0.10 each			1,493,784,994		1,493,784,994
Issued and paid-up share capital					
13,575,865,582 ordinary shares, Baht 0.10 each		1,357,586,558		1,357,586,558	
13,264,617,278 ordinary shares, Baht 0.10 each			1,326,461,728		1,326,461,728
Share premium accounts		2,718,137,663	2,438,325,437	2,718,137,663	2,438,325,437
Retained earnings					
Appropriated					
Legal reserve	27	149,390,828	149,378,499	149,390,828	149,378,499
Unappropriated		2,449,130,766	2,464,706,000	980,203,060	1,023,110,009
Other components of shareholders' equity	12.3, 13.3	1,496,407,944	1,409,714,749	738,042,960	490,009,847
Total equity attributable to owners of the parent		8,170,653,759	7,788,586,413	5,943,361,069	5,427,285,520
Non-controlling interests		2,563,366,616	2,583,080,958	-	-
Total shareholders' equity		10,734,020,375	10,371,667,371	5,943,361,069	5,427,285,520
Total liabilities and shareholders' equity		21,175,018,564	19,629,854,686	10,692,105,179	10,160,072,396

Notes to the financial statements form an integral part of these statements.

VIBHAVADI MEDICAL CENTER PUBLIC COMPANY LIMITED AND ITS SUBSIDIARIES

STATEMENT OF COMPREHENSIVE INCOME

FOR THE YEAR ENDED DECEMBER 31, 2020

	Notes	Baht			
		Consolidated financial statements		Separate financial statements	
		2020	2019	2020	2019
Revenues					
Revenues from medical treatment	6	5,909,504,131	6,450,680,338	2,129,848,549	2,436,546,704
Rental and service income	6	114,944,776	95,213,190	67,815,329	34,305,865
Dividend income	6, 12, 13, 14	192,089,968	210,425,919	463,757,907	369,333,425
Gain on sale of investments		-	180,526	-	-
Other income	6	121,711,160	116,161,383	61,016,787	66,997,591
Total revenues		6,338,250,035	6,872,661,356	2,722,438,572	2,907,183,585
Expenses					
Cost of medical treatment	6	4,406,035,846	4,678,123,924	1,459,287,093	1,587,913,190
Cost of rental and service	6	79,845,496	100,459,102	36,141,840	18,724,476
Impairment of investments	13	-	-	136,005,080	-
Administrative and services expenses	6	925,035,511	953,466,030	370,070,797	392,703,708
Total expenses		5,410,916,853	5,732,049,056	2,001,504,810	1,999,341,374
Profit from operating activities		927,333,182	1,140,612,300	720,933,762	907,842,211
Finance costs	6	202,720,725	201,101,377	116,302,404	111,798,669
Share of profit (loss) of associates	13.2	(62,354,689)	259,733,939	-	-
Profit before income tax expenses		662,257,768	1,199,244,862	604,631,358	796,043,542
Income tax expenses	33	123,738,982	206,445,299	50,129,182	82,387,041
Profit for the year		538,518,786	992,799,563	554,502,176	713,656,501
Other comprehensive income					
Item that may be reclassified subsequently to profit or loss					
Gain on valuation of available-for-sale securities	12.1	-	737,195,256	-	382,297,617
Share of other comprehensive income (loss) of associates	13.3	-	(100,932,506)	-	-
Income tax relating to items that may be reclassified	33	-	(147,439,051)	-	(76,459,523)
		-	488,823,699	-	305,838,094
Item that will not be reclassified subsequently to profit or loss					
Gain (loss) on investments in equity		49,603,506	-	310,041,393	-
Actuarial gain (loss) on define employee benefit plans	25	4,032,757	(33,017,126)	-	(5,213,964)
Share of other comprehensive loss of associates		(7,415,971)	-	-	-
Income tax relating to items that will not be reclassified	33	(9,920,701)	6,603,425	(62,008,280)	1,042,793
		36,299,591	(26,413,701)	248,033,113	(4,171,171)
Other comprehensive income (loss) for the year, net of income tax		36,299,591	462,409,998	248,033,113	301,666,923
Total comprehensive income for the year		574,818,377	1,455,209,561	802,535,289	1,015,323,424

Notes to the financial statements form an integral part of these statements.

VIBHAVADI MEDICAL CENTER PUBLIC COMPANY LIMITED AND ITS SUBSIDIARIES
STATEMENT OF COMPREHENSIVE INCOME (CONT.)
FOR THE YEAR ENDED DECEMBER 31, 2020

		Baht			
		Consolidated financial statements		Separate financial statements	
Notes		2020	2019	2020	2019
Profit attributable to					
	Owners of the parent	449,799,642	809,045,597	554,502,176	713,656,501
	Non-controlling interests	88,719,144	183,753,966	-	-
		<u>538,518,786</u>	<u>992,799,563</u>	<u>554,502,176</u>	<u>713,656,501</u>
Total comprehensive income (loss) attributable to					
	Owners of the parent	573,282,260	1,134,550,074	802,535,289	1,015,323,424
	Non-controlling interests	1,536,117	320,659,487	-	-
		<u>574,818,377</u>	<u>1,455,209,561</u>	<u>802,535,289</u>	<u>1,015,323,424</u>
Earnings per share					
	Basic earnings per share				
	Attributable to owners of the parent	<u>0.0335</u>	<u>0.0612</u>	<u>0.0413</u>	<u>0.0540</u>
Diluted earnings per share					
	Attributable to owners of the parent	<u>0.0304</u>	<u>0.0550</u>	<u>0.0375</u>	<u>0.0485</u>

Notes to the financial statements form an integral part of these statements.

VIBHAVADI MEDICAL CENTER PUBLIC COMPANY LIMITED AND ITS SUBSIDIARIES

STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (CONT.)

FOR THE YEAR ENDED DECEMBER 31, 2020

Baht													
Consolidated financial statements													
Equity attributable to owners of the parent										Non-controlling	Total		
	Notes	Issued and paid-up share capital	Share premium account	Retained earnings		Other components of shareholders' equity				Total equity attributable to owners of the parent	interests	Shareholders' equity	
				Appropriated	Unappropriated	Unrealized gain (loss) on investments in equity	Unrealized gain (loss) on investment in associate	Unrealized loss on investment in associates	Difference from change in shareholding proportion in subsidiary				Total other components shareholders' equity
Balance as at January 1, 2020		1,326,461,728	2,438,325,437	149,378,499	2,464,706,000	1,214,261,868	180,453,606	(592,389)	15,591,664	1,409,714,749	7,788,586,413	2,583,080,958	10,371,667,371
Impact of changes in accounting policies	5	-	-	-	118,515,872	(32,321,528)	-	-	-	(32,321,528)	86,194,344	28,340,238.00	114,534,582
Beginning balance as at January 1, 2020 - Restated		1,326,461,728	2,438,325,437	149,378,499	2,583,221,872	1,181,940,340	180,453,606	(592,389)	15,591,664	1,377,393,221	7,874,780,757	2,611,421,196	10,486,201,953
Increase in share capital	26	31,124,830	279,812,226	-	-	-	-	-	-	-	310,937,056	-	310,937,056
Legal reserve	27	-	-	12,329	(12,329)	-	-	-	-	-	-	-	-
Paid-up share capital by subsidiary		-	-	-	-	-	-	-	-	-	-	375,005	375,005
Dividend paid	28	-	-	-	(588,346,315)	-	-	-	-	-	(588,346,315)	(87,344,702)	(675,691,017)
Non - controlling interest increased from acquisition of investments in subsidiaries		-	-	-	-	-	-	-	-	-	-	37,379,000	37,379,000
Total comprehensive income for the year													
Profit for the year		-	-	-	449,799,642	-	-	-	-	-	449,799,642	88,719,144	538,518,786
Other comprehensive income (loss) for the period, net of income tax													
Actuarial gain on define employee benefit plans		-	-	-	4,032,757	-	-	-	-	-	4,032,757	-	4,032,757
Gain on valuation of investments		-	-	-	-	126,865,833	-	-	-	126,865,833	126,865,833	(87,183,027)	39,682,806
Share of other comprehensive loss of associates		-	-	-	435,139	-	(7,851,110)	-	-	(7,851,110)	(7,415,971)	-	(7,415,971)
Balance as at December 31, 2020		1,357,586,558	2,718,137,663	149,390,828	2,449,130,766	1,308,806,173	172,602,496	(592,389)	15,591,664	1,496,407,944	8,170,653,759	2,563,366,616	10,734,020,375

Notes to the financial statements form an integral part of these financial statements.

VIBHAVADI MEDICAL CENTER PUBLIC COMPANY LIMITED AND ITS SUBSIDIARIES
STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (CONT.)
FOR THE YEAR ENDED DECEMBER 31, 2020

Baht												
Consolidated financial statements												
Equity attributable to owners of the parent										Non-controlling	Total	
	Issued and paid-up share capital	Share premium account	Retained earnings		Other components of shareholders' equity				Total equity attributable to owners of the parent	interests	Shareholders' equity	
			Appropriated Legal reserve	Unappropriated	Unrealized gain (loss) on valuation of available-for-sale securities - net of tax	Unrealized gain (loss) on investment in associate	Unrealized loss on investment in associates	Difference from change in shareholding proportion in subsidiary				Total other components shareholders' equity
Notes												
Balance as at January 1, 2019	1,319,936,825	2,379,358,913	146,449,093	2,195,567,576	771,894,012	279,119,889	(592,389)	15,591,664	1,066,013,176	7,107,325,583	2,268,160,793	9,375,486,376
Increase in share capital	26	6,524,903	58,966,524	-	-	-	-	-	-	65,491,427	-	65,491,427
Legal reserve	27	-	-	2,929,406	(2,929,406)	-	-	-	-	-	-	-
Dividend paid	28	-	-	-	(518,780,671)	-	-	-	-	(518,780,671)	(85,038,555)	(603,819,226)
Non - controlling interest increased from acquisition of investments in subsidiaries		-	-	-	-	-	-	-	-	-	79,299,233	79,299,233
Total comprehensive income for the year												
Profit for the year		-	-	-	809,045,597	-	-	-	-	809,045,597	183,753,966	992,799,563
Other comprehensive income for the year, net of income tax												
Actuarial loss on define employee benefit plans		-	-	-	(16,091,939)	-	-	-	-	(16,091,939)	(10,321,762)	(26,413,701)
Gain on valuation of available-for-sale investment		-	-	-	-	442,367,856	-	-	442,367,856	442,367,856	147,388,349	589,756,205
Share of other comprehensive loss of associates		-	-	-	(2,105,157)	-	(98,666,283)	-	(98,666,283)	(100,771,440)	(161,066)	(100,932,506)
Balance as at December 31, 2019	1,326,461,728	2,438,325,437	149,378,499	2,464,706,000	1,214,261,868	180,453,606	(592,389)	15,591,664	1,409,714,749	7,788,586,413	2,583,080,958	10,371,667,371

Notes to the financial statements form an integral part of these financial statements.

VIBHAVADI MEDICAL CENTER PUBLIC COMPANY LIMITED AND ITS SUBSIDIARIES
STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (CONT.)
FOR THE YEAR ENDED DECEMBER 31, 2020

		Baht					
		Separate financial statements					
		Issued and paid-up	Share premium	Retained earnings		Other components of	Total
		share capital	account	Appropriated	Unappropriated	shareholders' equity	shareholder's equity
				Legal reserve	Unrealized gain (loss) on		
						investments in equity	
Notes							
	Balance as at January 1, 2019	1,319,936,825	2,379,358,913	146,449,093	844,528,660	184,171,753	4,874,445,244
26	Increase in share capital	6,524,903	58,966,524	-	-	-	65,491,427
27	Legal reserve	-	-	2,929,406	(2,929,406)	-	-
28	Dividend paid	-	-	-	(527,974,575)	-	(527,974,575)
	Total comprehensive income for the year						
	Profit for the year	-	-	-	713,656,501	-	713,656,501
	Other comprehensive income for the year, net of income tax						
	Gain on valuation of available-for-sale investments	-	-	-	-	305,838,094	305,838,094
	Actuarial loss on define employee benefit plans	-	-	-	(4,171,171)	-	(4,171,171)
	Balance as at December 31, 2019	1,326,461,728	2,438,325,437	149,378,499	1,023,110,009	490,009,847	5,427,285,520
5	Impact of changes in accounting policies	-	-	-	(489,153)	-	(489,153)
	Beginning balance as at January 1, 2020 - Restated	1,326,461,728	2,438,325,437	149,378,499	1,022,620,856	490,009,847	5,426,796,367
26	Increase in share capital	31,124,830	279,812,226	-	-	-	310,937,056
27	Legal reserve	-	-	12,329	(12,329)	-	-
28	Dividend paid	-	-	-	(596,907,643)	-	(596,907,643)
	Total comprehensive income for the year						
	Profit for the year	-	-	-	554,502,176	-	554,502,176
	Other comprehensive income for the year, net of income tax						
	Gain on valuation of investments	-	-	-	-	248,033,113	248,033,113
	Balance as at December 31, 2020	1,357,586,558	2,718,137,663	149,390,828	980,203,060	738,042,960	5,943,361,069

Notes to the financial statements form an integral part of these statements.

VIBHAVADI MEDICAL CENTER PUBLIC COMPANY LIMITED AND ITS SUBSIDIARIES

STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED DECEMBER 31, 2020

	Baht			
	Consolidated financial statements		Separate financial statements	
	2020	2019	2020	2019
<u>Cash flows from operating activities</u>				
Profit for the year	538,518,786	992,799,563	554,502,176	713,656,501
Adjustments to reconcile profit for the year to net cash provided by (used in) operating activities				
Bad debts and doubtful accounts	5,242,786	8,624,856	369,325	223,771
Depreciation	434,091,746	408,348,771	132,079,098	125,312,364
Amortization of intangible assets	4,595,978	5,035,840	2,010,920	2,223,556
(Gain) loss on disposal of equipment	2,238,242	(36,689)	9,339	(19,817)
Loss from write-off of fixed assets	-	25,046	-	25,046
Share of (profit) loss of associates	62,354,689	(259,733,939)	-	-
Dividend income	(192,089,968)	(210,425,919)	(463,757,907)	(369,333,425)
Loss on sale investments	-	7,571,747	-	56,087
Loss from impairment of investment	-	11,400	136,005,080	-
Write-off withholding tax at source	8,970,009	97,144	-	-
Expense for employee benefit	44,504,732	65,651,116	10,539,987	16,879,134
Interest incomes	(15,079,949)	(15,050,305)	(6,665,496)	(5,885,035)
Finance costs	202,720,725	201,101,377	116,302,404	111,798,669
Income tax expenses	123,744,168	206,445,299	50,129,182	82,387,041
Profit from operating activities before change in operational assets and liabilities	1,219,811,944	1,410,465,307	531,524,108	677,323,892
(Increase) decrease in operational assets				
Trade receivables	(64,670,878)	76,470,403	(11,225,866)	(1,722,829)
Inventories	9,628,151	(9,278,161)	2,511,406	(5,191,093)
Other current assets	(18,495,354)	(3,283,985)	(5,741,260)	385,538
Other non-current assets	290,236	(589,412)	238,833	(413,296)
Increase (decrease) in operational liabilities				
Trade payables	(7,125,842)	31,033,186	(8,420,398)	9,548,095
Accrued doctor fee	(10,194,525)	9,724,976	(4,445,230)	4,103,968
Accrued expenses	7,030,263	(1,643,594)	2,094,238	3,303,322

Notes to the financial statements form an integral part of these statements.

VIBHAVADI MEDICAL CENTER PUBLIC COMPANY LIMITED AND ITS SUBSIDIARIES
STATEMENT OF CASH FLOWS (CONT.)
FOR THE YEAR ENDED DECEMBER 31, 2020

	Baht			
	Consolidated financial statements		Separate financial statements	
	2020	2019	2020	2019
Advance received from Social Security Office	77,079,832	196,785,395	-	-
Other current liabilities	14,031,778	5,672,946	3,139,603	3,506,506
Liabilities under operating lease contracts	-	5,809,616	-	-
Employee benefit obligations	(13,864,650)	(6,085,030)	(3,376,808)	(3,019,401)
Other non-current liabilities	44,165,027	20,083,030	(8,019,718)	15,060,722
Cash received from operation	1,257,685,982	1,735,164,677	498,278,908	702,885,424
Interest received	586,333	492,947	156,804	410,350
Interest paid	(4,795)	(11,084)	-	-
Income tax paid	(163,531,577)	(209,088,124)	(62,278,159)	(80,883,852)
Net cash provided by operating activities	1,094,735,943	1,526,558,416	436,157,553	622,411,922
<u>Cash flows from investing activities</u>				
(Increase) decrease in short-term loan to related company	64,459,800	(15,220,000)	(32,840,200)	(3,220,000)
(Increase) decrease in fixed deposits pledged as collateral	(3,154,132)	8,235,611	-	-
Cash received from sale of investments in equity	-	35,204,312	-	1,422,168
Cash paid for purchase investments in equity	(490,129,802)	(1,962,541,102)	(488,545,457)	(1,944,585,440)
Cash paid for investments in associates	540	-	540	-
Cash received from sale investment in subsidiary	-	(29,276,701)	(874,995)	-
Cash paid for other long-term investments	-	(92,000,000)	-	(82,000,000)
Cash paid for long-term loans to other persons	(14,755,000)	(1,385,000)	-	-
Cash paid for acquisition of Investment property	(8,282,102)	(101,861)	(8,282,103)	(101,861)
Cash paid for acquisition of property, plant and equipment	(1,484,575,182)	(1,358,414,060)	(74,882,145)	(224,986,290)
Proceed from disposal of equipment	633,213	937,507	14,019	19,823
Cash paid for acquisition of intangible assets	(7,864,465)	(614,063)	(396,650)	(482,818)
Cash paid for advance payment of assets	(3,894,666)	24,262,682	-	-
Cash paid for share	(4,000,000)	-	(4,000,000)	-
Dividend received	266,099,642	289,722,708	396,307,832	369,333,425
Interest received	16,185,097	13,357,630	6,376,948	5,180,002
Net cash by used in investing activities	(1,669,277,057)	(3,087,832,337)	(207,122,211)	(1,879,420,991)

Notes to the financial statements form an integral part of these statements.

VIBHAVADI MEDICAL CENTER PUBLIC COMPANY LIMITED AND ITS SUBSIDIARIES

STATEMENT OF CASH FLOWS (CONT.)

FOR THE YEAR ENDED DECEMBER 31, 2020

	Baht			
	Consolidated financial statements		Separate financial statements	
	2020	2019	2020	2019
<u>Cash flows from financing activities</u>				
Increase in bank overdrafts and short-term loans				
from financial institutions	(72,044,547)	1,092,149,246	(175,000,000)	1,130,000,000
Increase (decrease) in loans from related parties	(149,825,850)	32,420,000	108,000,000	(16,000,000)
Increase in short-term loans from other persons	14,500,000	2,400,000	-	-
Cash received from long-term loans from financial institutions	2,013,000,000	2,364,858,130	760,000,000	1,414,858,130
Cash paid for long-term loans from financial institutions	(959,924,996)	(966,821,719)	(544,077,183)	(659,267,433)
Cash paid for lease liabilities	(16,870,664)	(9,964,263)	(7,018,139)	(8,738,427)
Cash received from increasing in share capital	310,937,056	65,491,427	310,937,056	65,491,427
Cash received advance from shares	-	36,378,150	-	-
Cash received from share payment	375,005	57,790,000	-	-
Cash received from share payment of non-controlling interests	1,000,850	-	-	-
Dividend paid	(639,087,797)	(614,824,534)	(595,286,365)	(527,210,475)
Interest paid	(192,079,799)	(202,868,007)	(116,056,545)	(113,077,765)
Net cash provided by (used in) financing activities	309,979,258	1,857,008,430	(258,501,176)	1,286,055,457
Net increase (decrease) in cash and cash equivalents	(264,561,856)	295,734,509	(29,465,834)	29,046,388
Cash and cash equivalents, at the beginning of the year	602,855,047	307,120,538	70,346,919	41,300,531
Cash and cash equivalents, at the end of the year	338,293,191	602,855,047	40,881,085	70,346,919
<u>Supplement disclosures of cash flows information</u>				
1. Reconciliation of cash paid for acquisition of property, plant and equipment				
Acquisition of property, plant and equipment for the year	(1,436,702,308)	(1,401,021,257)	(74,480,418)	(216,995,053)
Interest expenses are recongnized to fixed assets	-	7,375,469	-	2,880,624
Increase in liabilities under financial lease agreements	-	3,382,725	-	3,382,726
Increase (decrease) in payable from acquisition of assets	(47,872,874)	31,849,003	(401,727)	(14,254,587)
Cash paid for acquisition of property, plant and equipment	(1,484,575,182)	(1,358,414,060)	(74,882,145)	(224,986,290)
2. Reconciliation of proceed from disposal of equipment				
Disposal of equipment	633,213	937,507	14,019	19,823
Decrease in receivable from disposal of equipment	-	-	-	-
Cash received from disposal of equipment	633,213	937,507	14,019	19,823

Notes to the financial statements form an integral part of these statements.

VIBHAVADI MEDICAL CENTER PUBLIC COMPANY LIMITED AND ITS SUBSIDIARIES
STATEMENT OF CASH FLOWS (CONT.)
FOR THE YEAR ENDED DECEMBER 31, 2020

	Baht			
	Consolidated financial statements		Separate financial statements	
	2020	2019	2020	2019
3. Reconciliation of dividend received				
Dividend income for the year	334,749,717	289,722,708	463,757,907	369,333,425
(Increase) decrease accrued dividend	(68,650,075)	-	(67,450,075)	-
Dividend received	<u>266,099,642</u>	<u>289,722,708</u>	<u>396,307,832</u>	<u>369,333,425</u>
4. Reconciliation of dividend paid				
Dividend paid for the year	(684,253,400)	(617,481,252)	(596,907,644)	(527,974,574)
Increase in accrued dividend	45,165,603	2,656,718	1,621,279	764,099
Dividend paid	<u>(639,087,797)</u>	<u>(614,824,534)</u>	<u>(595,286,365)</u>	<u>(527,210,475)</u>

Notes to the financial statements form an integral part of these statements.

VIBHAVADI MEDICAL CENTER PUBLIC COMPANY LIMITED AND ITS SUBSIDIARIES
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2020

1. GENERAL INFORMATION

The Company was registered as a public company incorporated and resident in Thailand.

The principal business operations of the Company is to provide the medical services known as “Vibhavadi Hospital”.

The Company’s registered office is located at 51/3 Ngam Wong Wan Road, Latyao sub-district, Chatuchak district, Bangkok.

2. BASIS FOR THE PREPARATION OF FINANCIAL STATEMENTS

2.1 Basis for preparation of the financial statements

The financial statements have been prepared in accordance with the accounting standards prescribed by Thai Accounts Act enunciated under the Accounting Profession Act B.E.2547 by complying with Thai Financial Reporting Standards. The presentation of the financial statements has been made in compliance with the Notification of the Department of Business Development, the Ministry of Commerce, re : the financial statements presentation for public limited company, issued under the Accounting Act B.E. 2543.

The financial statements have been prepared on a historical cost basis except where otherwise disclosed in the accounting policies.

The financial statements in Thai language are the official statutory financial statements of the Company. The financial statements in English language have been translated from such financial statements in Thai language.

2.2 Basis for the preparation of consolidated financial statements

2.2.1 The consolidated financial statements have included the financial statements of Vibhavadi Medical Center Public Co., Ltd., subsidiaries and associated companies as follows;

Name of Company	Type of business	Percentage of holding % of share capital		Head office location
		2020	2019	
<u>Direct subsidiary and associated companies</u>				
<u>Subsidiary companies</u>				
Princeton Park Suites Co., Ltd.	Hotel	99.99	99.99	Bangkok
Chiang Mai Ram Medical Business Public Co., Ltd.	Hospital	83.55	83.55	Chiang Mai
Beauty Design Center Co., Ltd. **	Beauty Business	50.00	50.00	Bangkok
V.precision Co., Ltd.	Anti Aging Center	70.00	-	Bangkok

Company name	Type of business	Percentage of holding % of share capital		Head office location
		2020	2019	
<u>Associated company</u>				
Vibharam Hospital Co., Ltd.	Hospital	33.73	40.76	Bangkok
Thipayabadin Co., Ltd.	Trading medical instruments	38.18	33.33	Bangkok
Bangpo General Hospital Co., Ltd.	Hospital	28.57	28.57	Bangkok
<u>Indirect subsidiary and associated companies</u>				
<u>held by Chiang Mai Ram Medical Business Public Co., Ltd.</u>				
<u>Subsidiary company</u>				
Chiang Mai Ram Hospital Co., Ltd.	Hospital	47.09	47.09	Chiang Mai
Hariphunchai Memorial Co., Ltd.	Hospital	72.43	72.43	Lamphun
<u>held by Chiang Mai Ram Hospital Co., Ltd.</u>				
<u>Subsidiary company</u>				
Theppanya Business Co., Ltd.	Hospital	47.09	47.09	Chiang Mai
Ramkhamhaeng Chiangmai Hospital Co., Ltd.*	Hospital	45.14	45.14	Chiang Mai
<u>Associated company</u>				
Khelang Nakorn Hospital Co., Ltd.	Hospital	11.99	11.99	Lampang
Pawo Hospital Co., Ltd.	Hospital	23.54	23.54	Tak

* According to the Board of Directors' subsidiary Meeting No. 7/2018 dated December 25, 2018, it had the resolution for Chiang Mai Ram Medical Business Public Co., Ltd. and Chiang Mai Ram Hospital Co., Ltd. to invest in Ramkhamhaeng Chiangmai Hospital Co., Ltd. On March 1, 2019, its subsidiary had held the shares in such company for 18% and the indirect subsidiary - Chiang Mai Ram Hospital Co., Ltd. had held the shares for 63% totaled 81%. From investing and having control over such business, it had resulted for Ramkhamhaeng Chiangmai Hospital Co., Ltd. to be considered as the subsidiary of Chiang Mai Ram Hospital Co., Ltd. The subsidiaries have adopted the financial statements of such companies to prepare the consolidated financial statements from the first quarter of 2019, onwards.

On May 2, 2019, such company has call up Baht 7 per share, from its subsidiary - Chiang Mai Ram Medical Business Public Co., Ltd. had paid for the shares amounted Baht 50.40 million and from the indirect subsidiary - Chiang Mai Ram Hospital Co., Ltd. had paid for the shares amounted Baht 179.79 million totaled Baht 230.19 million, resulting in indirect subsidiary - Chiang Mai Ram Hospital Co., Ltd. held in that company to increase from 63.00% to 63.85% totaled 81.85%.

And on July 26, 2019, such company has registered the capital increase for 4 million shares at Baht 10 per share, amounted Baht 40.00 million. Its subsidiary - Chiang Mai Ram Medical Business Public Co., Ltd. had paid the shares amounted Baht 7.20 million and from the indirect subsidiary, Chiang Mai Ram Hospital Co., Ltd. had paid the shares amounted Baht 25.82 million totaled Baht 33.02 million, resulting in the indirect subsidiary - Chiang Mai Ram Hospital Co., Ltd. held in such company to increase from 63.85% to 63.91% totaled 81.91%.

On February 24, 2020, Ramkhamhaeng Chiangmai Hospital Co., Ltd. had registered the capital increase for 56 million shares at Baht 10 per share, amounted Baht 560 million. Chiang Mai Ram Medical Business Public Company Limited had paid the share amounted Baht 40.32 million and from its subsidiary, Chiang Mai Ram Hospital Co., Ltd. amounted Baht 146.48 million totaled Baht 186.80 million, resulting in subsidiary - Chiang Mai Ram Hospital Co., Ltd. Held in that company to increase from 63.91% to 64.74% totaled of the group subsidiaries in held 82.74%.

** According to the Board of Directors' Extra Meeting No. 4/2019 dated September 25, 2019, it had the adjustment of investment structure to approved the Princeton Park Suites Co., Ltd. transfer all of shares of Beauty Design Center Co., Ltd., of shareholding 50 percent to be considered as the subsidiary and Legacy Golf (Thailand) Co., Ltd. of shareholding 10 percent to be considered as the other long-term investments to the company as discussed in Note 12 to the financial statements.

2.2.2 Accounting policy for subsidiary companies will utilize the same policy as Vibhavadi Medical Center Public Company Limited.

2.2.3 Outstanding balances and significant transactions between the Company and its subsidiaries have been eliminated from the consolidated financial statements.

2.2.4 Non-controlling interests represent the portion of profit or loss and net assets of the subsidiaries that are not held by the Company and are presented separately from the portion of owners of the parent.

2.3 Financial reporting standards that became effective in the current year

During the year, the Company and its subsidiaries have adopted the revised and new financial reporting standards, interpretations and the accounting guidance, which are effective for fiscal years beginning on or after January 1, 2020. These financial reporting standards were aimed at alignment with the corresponding International Financial Reporting Standards with most of the changes directed towards clarifying accounting treatment and providing accounting guidance for users of the standards. Except, the new standard involves changes to key principles, as summarized below.

Financial reporting standards related to financial instruments:

A set of TFRSs related to financial instruments, which consists of five accounting standards and interpretations, as follows:

TFRS 7	Financial Instruments: Disclosures
TFRS 9	Financial Instruments
TAS 32	Financial Instruments: Presentation
TFRIC 16	Hedges of a Net Investment in a Foreign Operation
TFRIC 19	Extinguishing Financial Liabilities with Equity Instruments

These TFRSs related to financial instruments make stipulations relating to the classification of financial instruments and their measurement at fair value or amortized cost (taking into account the type of instrument, the characteristics of the contractual cash flows and the Company's business model), calculation of impairment using the expected credit loss method, and hedge accounting. These include stipulations regarding the presentation and disclosure of financial instruments. When the TFRSs related to financial instruments are effective, some accounting standards, interpretations and guidance which are currently effective will be cancelled.

The Company and its subsidiaries has adopted TFRS related to financial instruments the first-time in its financial statements by applying modified retrospective approach of adoption of which the cumulative effect as an adjustment to the retained earnings as at January 1, 2020 and the comparative information was not restated. The cumulative effect of the change is described in Note 5 to the financial statements.

TFRS 16 Leases

TFRS 16 Leases supersedes TAS 17 Leases together with related Interpretations. The standard sets out the principles for the recognition, measurement, presentation and disclosure of leases, and requires a lessee to recognize assets and liabilities for all leases with a term of more than 12 months, unless the underlying asset is low value.

Accounting by lessors under TFRS 16 is substantially unchanged from TAS 17. Lessors will continue to classify leases as either operating or finance leases using similar principles to those used under TAS 17.

As at January1, 2020, the Company and its subsidiaries had adopted TFRS 16, which the Company and its subsidiaries recognized the cumulative effects of the initial application of this financial reporting standard without restated the previous year's financial statements presented for comparative. However, the Company and its subsidiaries had chosen to comply with this financial reporting standard with the lease that was previously classified as operating lease by recognizing the liabilities under the lease as at January 1, 2020 with the present value of the remaining lease payment and discounted by the interest rate of the additional borrowing of the Company as at the initial

application date. It was recognized the contractual use rights in the amount of liabilities under lease agreements adjusted by the amount of the prepaid or accrued lease payments which were related to the lease agreement recognized in the statement of financial position before the date of application of this financial reporting standard.

The effect of the change in accounting policy is described in Note 5 to the financial statements.

Accounting Treatment Guidance on “Temporary relief measures on accounting alternatives in response to the impact of the COVID-19 situation”

The Federation of Accounting Professions announced Accounting Treatment Guidance on “Temporary relief measures on accounting alternatives in response to the impact of the COVID-19 situation”. Its objectives are to alleviate some of the impact of applying certain financial reporting standards, and to provide clarification about accounting treatments during the period of uncertainty relating to this situation.

On April 22, 2020, the Accounting Treatment Guidance was announced in the Royal Gazette and it is effective for the financial statements prepared for reporting periods ending between January 1, 2020 and December 31, 2020.

The Company and its subsidiaries have elected to apply the following temporary relief measures on accounting alternatives:

- Not to take into account forward-looking information when determining expected credit losses, in cases where use a simplified approach to determine expected credit losses.
- To measure the fair value of investments in unquoted equity instruments using the fair value as at January 1, 2020.
- Not to account for any reduction in lease payments by lessors (if any) as a lease modification, with the lease liabilities that come due in each period reduced in proportion to the reduction and depreciation of right-of-use assets and interest on lease liabilities recognized in each period reversed in proportion to the reduction, with any differences then recognized in profit or loss.
- Not to consider the COVID-19 situation as an indication that an asset may be impaired in accordance with TAS 36, Impairment of Assets.
- Not to use information relating to the COVID-19 situation that may affect the cash flow forecasts used in testing goodwill for impairment.

2.4 Financial reporting standards that become effective in the future

During the year, the Federation of Accounting Professions issued a notification of the Federation of Accounting Professions and published in the Government Gazette for the **conceptual** framework of financial reporting (new) and several revised financial reporting standards from the year 2019 by becomes effective for the accounting period beginning on or after January 1, 2021 onwards. Which such adjustments are improve/revise principles the financial reporting is as follows:

Adjustment is reference to the conceptual framework in the financial reporting standards

Several financial reporting standards are reference to “IASC’s Framework for the Preparation and Presentation of Financial Statements.” The adjustment of reference project on the conceptual framework in the financial reporting standards has updated reference or partial reference adjustment and other to describe clearly whether each document is reference to “the conceptual framework” of whic year.

Conceptual Framework for Financial Reporting

The conceptual framework for financial reporting consisted of revised definitions of assets and liabilities. Criteria for recognition assets and liabilities in the financial statements. It also includes the following new principles and guidance:

1. Measurement, including factors that must be considered in selecting the valuation criteria
2. Presentation and disclosure which includes when the income and expenses are classified into other comprehensive income.
3. Reporting entities
4. When the assets and liabilities derecognition from the financial statements

In addition, this Conceptual Framework for Financial Reporting clearly clarifies management’s stewardship of the entity’s economic resources, prudence, and measurement uncertainty of financial information.

Definition of Business

Business definition revised in the financial reporting standard No. 3 “Business Combination” describes more clearly on definition of business. The objective is for the business to establish that such transaction has to be recorded as “business combination” or “purchase of assets” or not. Adjustments are as follows:

1. Describe clearly on the consideration of “business”, activity group and acquired assets must include input data factor, key process that at least combined will significantly generate outputs.
2. Eliminate the assessment that the market partner can substitute input factor or missing process and generate further outputs from the standards.
3. Add practice guide and example to support understanding and help the company assess whether the key process is acquired.
4. Narrow down the definition of business and definition of outputs by placing interest in the product and service provided to the customer and eliminate the reference on ability to reduce cost from the standards.

5. Add the intention test as an alternative which allows to make assessment easily whether the activity group and acquired assets are business or not.

Definition of significance

The definition of significance resulted in revising the accounting standard No.1 “Presentation of Financial Statements, Presentation of Financial Statements and Accounting Standards No.8 - Accounting Policy, Change of Accounting Estimates and Error and the revision that resulted in other financial reporting standards.

The adjustment creates better understanding of the definition of significance by

1. For the definition to follow the same direction of the financial reporting standards and conceptual framework to avoid the confusion that may arise from the definition difference.
2. Include the requirements together of the accounting standard No. 1 “ Presentation of financial statements” in the definition for it to become clearer and describe how the materiality can be clearly applied.
3. Applying existing practice guidance of the definition of the materiality in the same place as the definition.

Reform of swap interest rate

The reform of swap interest rate resulted in the adjustment of the financial reporting standards No. 9 financial instruments and financial reporting standards No.7 financial instrument disclosure. Such adjustment has changed the hedge accounting requirements, especially to reduce the impact arising from the uncertainty as a result of the swap interest rate reform such as interbank offer rates-IBORs. In addition, the adjustment requires the business to provide additional information to investors regarding the relation of hedging directly impacted from any uncertainties.

The management of the Company and its subsidiaries are in the process to assess the impact of these TFRSs to the financial statements in the year when they are adopted.

2.5 Thai Financial Reporting Standard No.16 “Leases”

The Federation of Accounting Professions has revised TFRS 16 lease agreements and published in the Government Gazette on January 27, 2021 with the following revisions.

1. The Rent Concessions related to COVID-19, which is effective from June 1, 2020 with earlier application permitted. The amendment permits lessees, as a practical expedient, not to assess whether rent concessions that occur as a direct consequence of the COVID-19 pandemic and meet specified conditions are lease modifications and, instead, to account for those rent concessions as if they were not lease modifications.
2. Added the requirements for the temporary exception arising from interest rate benchmark reform, which an entity shall apply these amendments for annual reporting periods beginning on or after January 1, 2022 with earlier application permitted.

The management of the Company and its subsidiaries are in the process to assess the impact of these TFRSs to the financial statements in the year when they are adopted.

3. ACCOUNTING POLICIES

3.1 Recognition of revenues

Revenue from hospital operations which mainly consists of revenues for medical expenses, rental fee, medication fee and will be recognized when the service is provided to customers or medication has been delivered.

Revenue for medical expenses in social security system and the National Health Security Office has been recorded in accordance with rules, methods and conditions as specified units.

Service revenue is recognized when service is provided to customers.

Interest income is recognized over the period of time in consideration of the effective rate.

Dividend income is recognized when the right to receive the dividend is established.

Other revenues are recognized on accrual basis.

3.2 Recognition of expenses

Expenses are recognized on an accrual basis.

3.3 Cash and cash equivalents

Cash and cash equivalents consist of cash and deposits at financial institutions with an original maturity of 3 months or less and excluded cash at banks which are used for guarantee.

3.4 Trade and other receivables and allowance for doubtful accounts

Applicable from January 1,2020

Trade receivables are recognized initially at the amount of consideration that is unconditional unless they contain significant financing components, when they are recognized at its present value.

Trade receivables are stated at the amount expected to be collectible, the Company and its subsidiaries apply the TFRS 9 simplified approach to measuring expected credit losses which uses a simplified approach, which requires expected lifetime losses to be recognized from initial recognition of the receivables. To measure the expected credit losses, trade receivables have been grouped based on the days past due. The expected loss rates are based on the payment profiles and the corresponding historical credit losses which are adjusted to reflect the current and forward-looking information on macroeconomic factors affecting the ability of the customers to settle the receivables. The Company and its subsidiaries have identified the GDP, the unemployment rate and the consumer price index of the countries in which it sells its goods and services to be the most relevant factors, and accordingly adjusts the historical loss rates based on expected changes in these factors. The impairment losses are recognized in profit or loss within administrative expenses.

Applicable prior to January 1,2020

Trade and other receivables are stated at the amount expected to be collectible, allowance for doubtful accounts estimate from those trade and other receivables which are likely to be uncollectible.

3.5 Inventories

Inventories are stated at the lower of cost or net realizable value. Cost is calculated on first-in first-out basis.

The cost of inventories comprises all costs of purchase and other costs incurred in bringing the inventories to their present location and condition.

The cost of purchase comprises both the purchase price and costs directly attributable to the acquisition of the inventory, such as transportation charges and other direct costs incurred in acquiring the inventories less all trade discounts, allowances or rebates.

The net realizable value of inventory is estimated from the selling price in the ordinary course of business less the estimated costs to complete the sale.

3.6 Investments in associates and subsidiaries

Associates are those companies in which the Company has significant influence over the associates, that is the Company has power to participate in determining relating to the financial and operating policies of the enterprise but not up to the level of governing such policies. Investments in associated are stated by equity method in consolidated financial statements. In case of the associates have capital deficiencies the recognition of Company's portion on such investments will be equal to zero only.

Subsidiaries are those companies in which the Company has the power to control the financial and operating policies generally accompanying a shareholding of more than one-half of the voting rights.

Investments in associates and subsidiaries are stated at cost net from allowance on impairment (if any). Loss on impairment of investment will be recognized as loss in the statement of comprehensive income in the separate financial statements and investments in associates and subsidiaries are stated at equity in the consolidated financial statements.

3.7 Financial assets and financial liabilities

Classification and measurement of financial assets

The classification of financial assets depends on the entity's business model for managing the financial assets and the contractual terms of the cash flows.

The Company and its subsidiaries classify its debt instruments in the following categories:

- those to be measured subsequently at fair value (either through other comprehensive income or through profit or loss); and
- those to be measured at amortised cost.

The Company and its subsidiaries reclassify debt instruments when and only when its business model for managing those assets changes.

The equity instruments held must be irrevocably classified to two measurement categories; i) at fair value through profit or loss (FVPL), or ii) at fair value through other comprehensive income (FVOCI) without recycling to profit or loss.

At initial recognition, the Company and its subsidiaries measure a financial asset at its fair value plus or minus, in the case of a financial asset not at FVPL, transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at FVPL are expensed in profit or loss.

Financial assets with embedded derivatives are considered in their entirety when determining whether their cash flows are solely payment of principal and interest.

Subsequent measurement of debt instruments depends on the Company and its subsidiaries' business model for managing the asset and the cash flow characteristics of the financial assets. There are three measurement categories into which the Company and its subsidiaries classify its debt instruments:

- Amortized cost: A financial assets will be measured at amortized cost when the financial asset is held within a business model whose objective is to hold financial assets in order to collect contractual cash flows. In addition, the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. Interest income from these financial assets is included in financial income using the effective interest rate method. Any gain or loss arising on derecognition is recognised directly in profit or loss and presented in other gains/(losses) together with foreign exchange gains and losses. Impairment losses are presented in profit or loss.
- FVOCI: A financial assets will be measured at FVOCI when it is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets. In addition, the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. Movements in the carrying amount are taken through other comprehensive income, except for the recognition of impairment gains or losses, interest income and related foreign exchange gains and losses which are recognized in profit or loss. When the financial asset is

derecognized, the cumulative gain or loss previously recognised in other comprehensive income is reclassified from equity to profit or loss and recognized on other gains/(losses). Interest income from these financial assets is included in finance income using the effective interest rate method. Foreign exchange gains and losses are presented in other gains/(losses) and impairment expenses are presented as separate line item in the statement of comprehensive income.

- FVPL: Assets that do not meet the criteria for amortised cost or FVOCI are measured at FVPL. A gain or loss on a debt investment that is subsequently measured at FVPL is recognized in profit or loss and presented net within other gains/(losses) in the period in which it arises.

Dividends from such investments continue to be recognised in profit or loss when the Company and its subsidiaries's right to receive payments is established.

Changes in the fair value of financial assets at FVPL are recognised in other gains/(losses) in the statement of income as applicable. Impairment losses (and reversal of impairment losses) on equity investments measured at FVOCI are not reported separately from other changes in fair value.

Classification and measurement of financial liabilities and equity

Financial instruments issued by the Company and its subsidiaries must be classified as financial liabilities or equity securities by considering contractual obligations.

- Where the Company and its subsidiaries have an unconditional contractual obligation to deliver cash or another financial asset to another entity, it is considered a financial liability unless there is a predetermined or possible settlement for a fixed amount of cash in exchange of a fixed number of the Company and its subsidiaries's own equity instruments.
- Where the Company and its subsidiaries have no contractual obligation or have an unconditional right to avoid delivering cash or another financial asset in settlement of the obligation, it is considered an equity instrument.

At initial recognition, the Company and its subsidiaries measure financial liabilities at fair value. The Company and its subsidiaries reclassify all financial liabilities as subsequently measured at amortised cost, except for derivatives.

Recognition and derecognition

The Company and its subsidiaries shall recognize a financial asset or a financial liability in its statement of financial position when, and only when, the Company and its subsidiaries become party to the contractual provisions of the instrument. Regular way purchases and sales of financial assets are recognized on trade-date, the date on which the Company and its subsidiaries commit to purchase or sell the asset. Financial assets are derecognized when the rights to receive cash flows from the financial assets have expired or have been transferred and the Company and its subsidiaries have transferred substantially all the risks and rewards of ownership of the financial assets.

Classification and measurement of financial liabilities

Financial liabilities measured subsequently at amortized cost. The effective interest method is a method of calculating the amortized cost of a financial liability and of allocating interest expense over the relevant period. Gains and losses are recognized in profit or loss when the liabilities are derecognized as well as through the EIR amortization process. In determining amortized cost, the Group takes into account any discounts or premiums on acquisition and fees or costs that are an integral part of the EIR. The EIR amortization is included in finance costs in profit or loss.

Impairment of financial assets

The Company and its subsidiaries recognized an allowance for expected credit losses on its financial assets measured at amortized cost, without requiring a credit-impaired event to have occurred prior to the recognition. The Group accounts for changes in expected credit losses in stages, with differing methods of determining allowance for credit losses and the effective interest rate applied at each stage. An exception from this approach is that for trade receivables that do not contain a significant financing component, the Company and its subsidiaries applied a simplified approach to determine the lifetime expected credit losses.

3.8 Goodwill

The Company and its subsidiaries use the acquisition method to account for business combinations and measure the cost of the acquisition being the fair value at the acquisition date of consideration transferred, and the amount of any non-controlling interest in the acquiree. For each business combination, the Company and its subsidiaries measures the non-controlling interest, if any, in the acquiree either at fair value or at the proportionate share of the acquiree's identifiable net assets.

The Company and its subsidiaries account for acquisition-related costs as expenses in the periods in which the costs are incurred and the services are received.

Goodwill is the excess of the cost of the business combination over the Company's interest in the fair value of the identifiable net assets of the subsidiary. If the Company's interest in the fair value of the identifiable net assets of the subsidiary exceeds the cost of the business combination, the excess is immediately recognized as gain in profit or loss.

Goodwill is initially measured at cost at the acquisition date and after that it will be measured at cost less accumulated impairment losses. Impairment losses on goodwill are not reversed.

3.9 Investment property

Investment property is stated at cost less accumulated depreciation and allowance on impairment (if any).

Depreciation of investment property under building for rent category is calculated by the straight-line method over the estimated useful life of 20 years. Depreciation of investment property is included in determining income.

3.10 Property, plant and equipment

Land is stated at cost. Plant and equipments are stated at cost less accumulated depreciation and allowance on impairment (if any).

Cost is initially recognized upon acquisition of assets along with other direct costs attributing to acquiring such assets in the condition ready to serve the objectives, including the costs of asset demolition, removal and restoration of the asset location, which are the obligations of the Company (if any).

Expenditure related to improvement, life renewal or improvement of assets which will cause the present replacement prices of the assets materially increased will be combined as cost prices of assets.

Depreciation of plant and equipment is calculated by cost less residual value on the straight-line method over the useful lives.

Plant and equipments for the subsidiary company, which were taken in 1990, are calculated on sinking fund method, plant and equipments which were acquired after 2002, are calculated on a straight-line method over their approximate useful lives.

Plant and equipments for the subsidiary company, which were taken in 1994, are calculated on sinking fund method, plant and equipments which were acquired after 2002, are calculated on a straight-line method over their approximate useful lives.

Medical instruments of the Company, which were taken before 2013, are calculated on straight-line method over their approximate useful lives, medical instruments which were taken until 2013, are calculated on a double declining balance method.

Their approximate useful lives of plant and equipment were as follows:

<u>Type of fixed assets</u>	<u>Years</u>
Land improvements	10
Buildings and building improvements	10-50
Medical instruments and office appliances	5-25
Furniture, fixture and equipment	3-25
Appliances health center	5-10
Vehicles	5-10

Do not depreciate for construction in progress.

Review the residual value and useful lives of the assets every year.

The depreciation for each asset component is calculated on the separate components when each component has significant cost compared to the total cost of that asset.

Depreciation is included in determining income.

Gain or loss from disposal of land, plant and equipment is computed from discrepancy between net cash received and book value and recognized as other revenue or other expenses in the statement of comprehensive income.

3.11 Borrowing costs

Borrowing costs directly attributed to the acquisition or construction of an asset that necessarily takes long time to put in ready to use or available for sale state are capitalized as part of the cost of the respective asset until that asset condition is ready for its intended use. All other borrowing costs are expensed in the period they are incurred. Borrowing costs consist of interest and other costs arising from such borrowing.

3.12 Intangible assets

Intangible assets are deferred computer software which is stated at cost less accumulated amortization and allowance on impairment (if any). Amortization is calculated on a straight-line method for 3-10 years.

3.13 Impairment of non-financial assets

As at the statement of financial position date, the Company and its subsidiaries assesses whether there is an indication of asset impairment. If any such indication exists, the Company and its subsidiaries will make an estimate of the asset's recoverable amount. If the carrying amount of the asset exceeds its recoverable amount, an impairment loss is recognized in the statement of comprehensive income. In addition, impairment loss is reversed if there is a subsequent increase in the recoverable amount. The reversal shall not exceed the carrying value that would have been determined net of accumulated depreciation or amortization. The recoverable amount of the asset is the asset's value in use or fair value less costs to sell.

3.14 Leases

Applicable from January 1, 2020

At inception of a contract, the Company and its subsidiaries assess whether the contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

The Company and its subsidiaries assess the lease term for the non-cancellable period as stipulated in lease contract or the remaining period of active leases at the date of initial application (as at January 1, 2020) together with any period covered by an option to extend the lease if it is reasonably certain to be exercised or any periods covered by an option to terminate the lease if it is reasonably certain not to be exercised by considering the effect of changes in technology and/or the other circumstance relating to the extension of the lease term.

Right-of-use assets-as a lessee

Right-of-use assets are recognized at the commencement date of the lease. Right-of-use assets are stated at cost, less any accumulated depreciation and impairment losses (if any), and adjusted for any remeasurement of lease liabilities (if any). The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date, less any lease incentives received.

The cost of right-of-use assets also includes an estimate of costs to be incurred by the lessee in dismantling and removing the underlying asset, restoring the site on which it is located or restoring the underlying asset to the condition required by the terms and conditions of the lease.

Right-of-use assets are calculated by reference to their costs on a straight-line basis over the shorter of the lease term and the estimated useful lives for each of right-of-use assets.

Lease liabilities

At the commencement date of the lease, lease liabilities are stated at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable (if any) and amount expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Company and its subsidiaries and payments of penalties for terminating the lease, if the lease term reflects the Company and its subsidiaries exercising the option to terminate.

In calculating the present value of lease payments, the Company and its subsidiaries use its incremental borrowing rate, which is determined by referring to the government bond yield adjusted with risk premium depending on the lease term, at the lease commencement date if the interest rate implicit in the lease is not readily determinable. After the commencement date, the

amount of lease liabilities is increased to reflect the accretion of the interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the lease payments or a change in the assessment of an option to purchase the underlying asset.

Short-term leases and leases of low-value assets

The Company and its subsidiaries apply the short-term lease recognition exemption to its short-term leases (those leases that have a lease term of 12 months or less from the commencement date and not contain a purchase option). It also applies the lease of low-value assets recognition exemption to leases that are considered of low value. Lease payments on short-term and leases of low-value assets are recognized as expense in profit and loss on a straight-line basis over the lease term.

Applicable prior to January 1,2020

Finance lease

The contract of leased asset carried the risk and owner remuneration is mainly transferred to lessors will be classified as financial leased contract. The contract of financial lease is recorded as capital expenditure by fair value of leased asset or present value of minimum amount which has to repay in accordance with the leased contract whichever amount is lower. The amount which has to repay in each time is divided as liability portion and financial expenditure so that fixed interest rate over outstanding liability obligation burden in accordance with the financial leased contract will be recorded as long-term liability. Interest payable will be recorded in the statement of income throughout the leased contract life.

Operating Lease

Lease of assets under which all the risks and rewards of ownership are effectively retained by the lessor are classified as operating lease. Lease payments under an operating lease are recognized as expense on a straight-line basis over the lease term.

3.15 Trade and other payables

Applicable prior to January 1,2020

Trade and other payables were shown in cost method.

3.16 Employee benefits

Short-term employment benefits

The Company and its subsidiaries are recognized salary, wage, bonus and contributions to social security fund and provided fund as expenses when incurred.

Post-employment benefits (Defined contribution plans)

The Company and its subsidiaries and its employees have jointly established a provident fund. The fund is monthly contributed by employees and by the Company. The fund's assets are held in a separate trust fund and the Company's contributions are recognized as expenses when incurred.

Post-employment benefits (Defined benefit plans)

The Company and its subsidiaries have obligations in respect of the severance payments that it must pay to the employees upon retirement under the labor law. The Company treats these severance payment obligations as a defined benefit plan.

The obligation under the defined benefit plan is calculated based on the actuarial principles by a qualified independent actuary using the projected unit credit method. Such estimates are made based on various assumptions, including discount rate, future salary increase rate, staff turnover rate, mortality rate, and inflation rate.

Actuarial gains and losses for post-employment benefits of the employees are recognized immediately in other comprehensive income as a part of retained earnings.

3.17 Provisions

The Company and its subsidiaries provision are recognized when the Company has a present legal or constructive obligation as a result of past events, it is probable that an outflow of resources will be required to settle the obligation, and a reliable estimate of the amount can be made. Where the Company expects a provision to be reimbursed, the reimbursement is recognized as a separate asset but only when the reimbursement is virtually certain.

3.18 Interest-bearing liabilities

Interest-bearing liabilities are recognised initially at fair value less attributable transaction charges. Subsequent to initial recognition, interest-bearing liabilities are stated at amortised cost with any difference between cost and redemption value being recognised in profit or loss over the period of the borrowings on an effective interest basis.

3.19 Appropriation of retained earnings

The appropriation of retained earnings is attributable to the Public Company Act B.E. 2535 (1992). The Company will appropriate retained earnings at least 5% of its annual net income as legal reserve.

3.20 Income tax

Income tax comprises current income tax and deferred tax.

Current tax

The Company and its subsidiaries record income tax expense, if any, based on the amount currently payable under the Revenue Code at the income tax rates 20% of net profit before income tax, after adding back certain expenses which are non-deductible for income tax computation purposes, and less certain transactions which are exemption or allowable from income tax.

Deferred tax

Deferred tax assets and liabilities are provided on the temporary differences between the carrying amount and the tax bases of assets and liabilities at the end of the reporting period. Changes in deferred tax assets and liabilities are recognized as deferred tax income or deferred tax expense which are recognized in the profit or loss except to the extent that it relates to items recognized directly in shareholders' equity or in other comprehensive income.

The deductible temporary differences are recognized as deferred tax assets when it is probable that the Company and its subsidiaries will have future taxable profit to be available against which the deferred tax assets can be utilized. The taxable temporary differences on all taxable items are recognized as deferred tax liabilities. Deferred tax is not recognized for the following temporary difference; the initial recognition goodwill; the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit or loss; and differences relating to investments in subsidiaries and joint ventures to the extent that it is probable that they will not reverse in the foreseeable future.

Deferred tax assets and liabilities are measured at the tax rates that the Company and its subsidiaries expect to apply to the period when the deferred tax assets are realized or the deferred tax liabilities are settled, based on tax rates and tax laws that have been enacted or substantively enacted by the end of the reporting period.

At the end of each reporting period, the carrying amount of deferred tax assets are reviewed and reduced the value when it is probable that the Company and its subsidiaries will have no longer the future taxable profit that is sufficient to be available against which all or some parts of deferred tax assets are utilized.

Deferred tax assets and deferred tax liabilities are offset when there is the legal right to settle on a net basis and they relate to income taxes levied by the same tax authority on the same taxable entity.

3.21 Basic earnings per share

Basic earnings per share are calculated by dividing profit for the year with the weighted average number of the issued and paid-up shares at the end of the period.

3.22 Related parties

Enterprises and individuals that directly, or indirectly through one or more intermediaries, control, or are controlled by, or are under common control with, the company, including holding companies, subsidiaries and fellow subsidiaries are related parties of the company. Associates and individuals owning, directly or indirectly, an interest in the voting power of the company that gives them significant influence over the enterprise, key management personnel, including directors and officers of the company and close members of the family of these individuals and companies associated with these individuals also constitute related parties.

In considering each possible related party relationship, attention is directed to the substance of the relationship, and not merely the legal form.

3.23 Fair value measurement

The Company and its subsidiaries uses the market approach to measure their assets and liabilities that are required to be measured at fair value by relevant financial reporting standards, except that the cost approach or income approach is used when there is no active market or when a quoted market price is not available.

Fair value hierarchy

Level 1- Use of quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2- Use of inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (e.g. prices) or indirectly (e.g. derived from prices).

Level 3 - Use of unobservable inputs such as estimates of future cash flows.

At the end of each reporting period, the Company and its subsidiaries determine whether transfers have occurred between levels within the fair value hierarchy for assets and liabilities held at the end of the reporting period that are measured at fair value on a recurring basis.

4. SIGNIFICANT ACCOUNTING JUDGEMENTS AND ESTIMATES

The preparation of financial statements in conformity with financial reporting standards at times requires management to make subjective judgements and estimates regarding matters that are inherently uncertain. These judgements and estimates affect amounts reported in the financial statements and disclosures and actual results could differ from these estimates. Significant judgements and estimates are as follows:

Accrued revenues from hospital operations

In determines the certain amount of receivable from the social security office provided to patients with severe diseases and of chronic diseases. In this regard, the amount of such income are set, adjusted and accrued based on the latest actual collection within current relative circumstances.

Allowance for doubtful accounts

Applicable from January 1,2020

In determining an allowance for doubtful accounts, the management needs to make judgement and estimates the expected credit loss based on the payment profiles and the corresponding historical credit losses which are adjusted to reflect the current and forward-looking information on macroeconomic factors affecting the ability of the customers to settle the receivables such as GDP, the unemployment rate and the consumer price index.

Applicable prior to January 1,2020

In determining an allowance for doubtful accounts, the management needs to make judgement and estimates based upon, among other things, past collection history, aging profile of outstanding debts and the prevailing economic condition.

Impairment of investment in subsidiary

In determining reviews the impairment of investment which requires management to prepare projections of the cash flows expected to be generated by the investment in the future, and to choose a suitable discount rate in order to calculate the present value of those cash flows.

Investment property/Depreciation

In determining depreciation of investment property, the management is required to make estimates of the useful lives and residual values of the investment property and to review the useful lives and residual values when there are any changes.

In addition, the management is required to review investment property for impairment on a periodical basis and record the impairment loss when it is determined that the recoverable amount is lower than the carrying amount. This requires judgement regarding forecast of future revenues and expenses relating to the assets subject to the review.

In determining the fair value disclosure of investment property, the management used the income approach supported by current and previous valuations by an independent appraiser.

Property, plant and equipment/Depreciation

In determining depreciation of plant and equipment, the management is required to make estimates of the useful lives and residual values of the plant and equipment and to review the estimated useful lives and residual values when there are any changes.

In addition, the management is required to review property, plant and equipment for impairment on a periodical basis and record the impairment loss when it is determined that the recoverable amount is lower than the carrying amount. This requires judgement regarding forecast of future revenues and expenses relating to the assets subject to the review.

Goodwill and intangible assets

In recording the initial recognition and measurement of goodwill and other intangible assets as at the acquired date and subsequent impairment testing, the management to make estimates of cash flows to be generated by the asset or the cash generating units and to choose a suitable discount rate in order to calculate the present value of those cash flows.

Impairment of non-financial asset

The Company and its subsidiaries treat assets as impaired when they are determined that the recoverable amount is lower than the carrying amount or in assessing whether there is any indication that assets may be impaired. The determination of whether the recoverable amount lower than the carrying amount requires judgement of the management to use key assumptions underlying recoverable amounts.

Leases

Applicable from January 1,2020

In determining the lease term of contracts with renewal and termination options the Company and its subsidiaries determine the lease term as the non-cancellable term of the lease, together with any period covered by an option to extend the lease if it is reasonably certain to be exercised, or any periods covered by an option to terminate the lease, if it is reasonably certain not to be exercised. The management is required to use judgment in evaluating whether it is reasonably certain whether or not to exercise the option to renew or terminate the lease, considering all relevant factors that create an economic incentive to exercise either the renewal or termination. After the commencement date, the Company and its subsidiaries reassess the lease term if there is a significant event or change in circumstances that is within its control and affects its ability to exercise or not to exercise the option to renew or to terminate.

Applicable prior to January 1, 2020

In determining whether a lease is to be classified as an operating lease or finance lease, the management is required to use judgement in evaluating the conditions and details of the agreement whether significant risk and rewards of ownership of the leased asset has been transferred.

Post-employment benefits under defined benefit plans

The obligation under the defined benefit plan is determined based on actuarial techniques. Such determination is made based on various assumptions, including discount rate, future salary increase rate, mortality rate and staff turnover rate.

Fair valuation of financial assets and derivatives

The fair value of financial instruments that are not traded in an active market is determined by using valuation techniques. The Company and its subsidiaries use judgement to select a variety of methods and make assumptions that are mainly based on market conditions existing at the end of each reporting period. Details of key assumptions used are included in Note 36.7

5. CUMMULATIVE EFFECTS OF CHANGES IN ACCOUNTING POLICIES DUE TO THE ADOPTION OF NEW FINANCIAL REPORTING STANDARDS

As described in Note 2.3 to the interim financial statements, during the current period, the Company and its subsidiaries have impacts from adoption of TFRSs related to financial instruments and TFRS 16. The cumulative effect of the changes in accounting policies are recognized as an adjustment to retained earnings as at January 1, 2020 and the comparative information was not restated.

The changes in accounting policies due to the adoption of above financial reporting standards, are summarized below.

	Baht			
	Consolidated financial statements			
	As at December 31, 2019	The impacts of TFRSs related to financial instruments	The impacts of TFRS 16 Leases	As at January 1, 2020
Statement of financial position				
Trade receivables	592,595,058	(9,471,519)	-	583,123,539
Other non-current financial assets	-	7,360,434,110	-	7,360,434,110
Available-for-sale investments	6,314,275,539	(6,314,275,539)	-	-
Other long-term investments	971,836,651	(971,836,651)	-	-
Right-of-use assets	-	-	332,520,444	332,520,444
Deferred tax assets	27,156,447	922,533	(15,750,492)	12,328,488
Total assets	<u>19,629,854,686</u>	<u>65,772,934</u>	<u>316,769,952</u>	<u>20,012,397,572</u>

	Baht			
	Consolidated financial statements			
	As at December	The impacts of	The impacts of	As at January
	31, 2019	TFRSs related to financial instruments	TFRS 16 Leases	1, 2020
Current portion of lease liabilities	4,952,300	-	18,965,270	23,917,570
Lease liabilities	8,292,719	-	313,555,174	321,847,893
Liabilities under operation lease agreements	78,752,461	-	(78,752,461)	-
Deferred tax liabilities	699,937,849	15,020,400	-	714,958,249
Total liabilities	9,258,187,315	15,020,400	253,767,983	9,526,975,698
Retained earnings - unappropriated	2,464,706,000	55,513,904	63,001,969	2,583,221,873
Other components of shareholders' equity	1,409,714,749	(32,321,528)	-	1,377,393,221
Total equity attributable to owners of the parent	7,788,586,413	23,192,375	63,001,969	7,874,780,757
Non-controlling interests	2,583,080,958	28,340,238	-	2,611,421,196
Total shareholders' equity	10,371,667,371	51,532,612	63,001,969	10,486,201,952

	Baht			
	Separate financial statements			
	As at December	The impacts of	The impacts of	As at January
	31, 2019	TFRSs related to financial instruments	TFRS 16 Leases	1, 2020
Statement of financial position				
Trade receivables	131,271,650	(489,153)	-	130,782,497
Other non-current financial asset	-	4,401,296,413	-	4,401,296,413
Available-for-sale investments	3,674,474,522	(3,674,474,522)	-	-
Other long-term investments	726,821,891	(726,821,891)	-	-
Right-of-use assets	-	-	21,061,449	21,061,449
Total assets	10,160,072,396	(489,153)	21,061,449	10,180,644,692
Current portion of lease liabilities	4,464,212	-	3,011,471	7,475,683
Lease liabilities	7,354,911	-	18,049,978	25,404,889
Total liabilities	4,732,786,876	-	21,061,449	4,753,848,325
Retained earnings - unappropriated	1,023,110,009	(489,153)	-	1,022,620,856
Non-controlling interests of subsidiaries	490,009,847	-	-	490,009,847
Total shareholders' equity	5,427,285,520	(489,153)	-	5,426,796,367

5.1 Financial instruments

The total impact on the retained earnings as at January 1, 2020 is as follows:

	Baht	
	Consolidated	Separate
	financial statements	financial statements
Retained earnings - unappropriated as at December 31, 2019	2,464,706,000	1,023,110,009
Increase in loss allowance for trade receivables	(5,104,336)	(489,153)
Increase in gain on valuation for investment	60,618,240	-
Retained earnings - unappropriated from adoption of TFRS 9 on January 1, 2020	<u>2,520,219,904</u>	<u>1,022,620,856</u>

Classification and measurement financial assets and liabilities

On January 1, 2020 (the date of initial application), the Company and its subsidiaries's management has assessed which business models applied to the financial assets and liabilities held by the Company and its subsidiaries and has classified the financial assets and liabilities as below.

	Baht					
	Consolidated financial statements			Separate financial statements		
	FVOCI	Amortized cost	Total	FVOCI	Amortized cost	Total
Cash and cash equivalents	-	602,855,047	602,855,047	-	70,346,919	70,346,919
Trade receivable	-	583,123,539	583,123,539	-	130,782,497	130,782,497
Short-term loans to related parties	-	305,125,000	305,125,000	-	117,419,494	117,419,494
Other current asset	-	43,657,426	43,657,426	-	13,598,981	13,598,981
Fixed deposits pledged as collateral	-	36,252,346	36,252,346	-	-	-
Other non-current financial assets	7,350,434,110	10,000,000	7,360,434,110	4,391,296,413	10,000,000	4,401,296,413
Long-term loans to related parties	-	24,000,000	24,000,000	-	-	-
Long-term loans to other persons	-	5,370,000	5,370,000	-	-	-
Other non-current asset	-	7,312,284	7,312,284	-	5,112,224	5,112,224
	<u>7,350,434,110</u>	<u>1,617,695,642</u>	<u>8,968,129,752</u>	<u>4,391,296,413</u>	<u>347,260,115</u>	<u>4,738,556,528</u>

As at January 1, 2020, the Company and its subsidiaries have not designated any financial liabilities at fair value through profit or loss.

Impairment of financial assets

The Company and its subsidiaries have trade receivables that are subject to the expected credit loss model. The Company and its subsidiaries have trade receivables and long-term loans to related parties that are subject to the expected credit loss model.

Trade receivables

The Company and its subsidiaries apply the simplified approach to measuring expected credit losses, which use a lifetime expected loss allowance for all trade receivables.

To measure the expected credit losses, trade receivables have been grouped based on shared credit risk characteristics and the days past due. The expected loss rates are based on the historical payment profiles, the corresponding historical credit losses experienced and the impact of potential factor to the expected loss rates. On that basis, the loss allowance for trade receivables was as follows:

	Baht					Total
	Consolidated financial statements					
	Not yet due	Up to 3 months	3 - 6 months	6 - 12 months	Over 12 months	
As at January 1, 2020						
Gross carrying amount	488,085,262	99,366,853	13,713,765	8,393,502	48,631,759	658,191,141
Loss allowance	(5,761,828)	(12,609,407)	(2,623,466)	(5,441,142)	(48,631,759)	(75,067,602)
	Baht					Total
	Separate financial statements					
	Not yet due	Up to 3 months	3 - 6 months	6 - 12 months	Over 12 months	
As at January 1, 2020						
Gross carrying amount	113,039,038	16,690,542	1,217,142	324,928	1,419,583	132,691,233
Loss allowance	(222,838)	(52,900)	(14,178)	(199,237)	(1,419,583)	(1,908,736)

The loss allowance for trade receivables as at December 31, 2019 is reconciled to the opening loss allowance for trade receivables as at January 1, 2020 as follow:

	Baht	
	Consolidated financial statements	Separate financial statements
<u>Loss allowance for trade receivables</u>		
As at December 31, 2019	(65,596,083)	(1,419,583)
Amounts restated through opening unappropriated retained earnings	(9,471,519)	(489,153)
Opening loss allowance as at January 1, 2020	<u>(75,067,602)</u>	<u>(1,908,736)</u>

5.2 Leases

Upon initial application of TFRS 16 the Company and its subsidiaries recognized lease liabilities previously classified as operating leases at the present value of the remaining lease payments, discounted using incremental borrowing rate at January 1, 2020. For leases previously classified as finance leases, the Company and its subsidiaries recognized the carrying amount of the right-of-use assets and lease liabilities based on the carrying amounts of the lease assets and lease liabilities immediately before the date of initial application of TFRS 16.

	Baht	
	Consolidated financial statements	Separate financial statements
Operating lease commitments as at December 31, 2019	308,569,089	-
<u>Less:</u> Low value leases recognised on a straight-line basis as expenses	(85,000)	-
<u>Add:</u> Purchase or extension options reasonably certain to be exercised	118,670,821	24,275,300
<u>Less:</u> Contracts reassessed as service agreements	(4,253,650)	-
	<u>422,901,260</u>	<u>24,275,300</u>
<u>Less:</u> Deferred interest expenses	(90,380,816)	(3,213,851)
Additional lease liabilities from TFRS 16 adoption	332,520,444	21,061,449
Finance lease liabilities as at December 31, 2019	<u>13,245,019</u>	<u>11,819,123</u>
Lease liabilities recognized as at January 1, 2020	<u><u>345,765,463</u></u>	<u><u>32,880,572</u></u>
Of which are:		
Current lease liabilities	23,917,570	7,475,683
Non-current lease liabilities	<u>321,847,893</u>	<u>25,404,889</u>
	<u><u>345,765,463</u></u>	<u><u>32,880,572</u></u>

The recognized right-of-use assets relate to types of assets as at January 1, 2020 as follows:

	Baht	
	Consolidated financial statements	Separate financial statements
Land and land improvements	17,056,012	-
Leaseholds	<u>315,464,432</u>	<u>21,061,449</u>
Total right-of-use assets	<u><u>332,520,444</u></u>	<u><u>21,061,449</u></u>

6. TRANSACTIONS WITH RELATED PARTIES

The Company had significant business transactions with related parties. Such transactions were concluded on commercial terms and agreed upon bases which were ordinary course of business and summarized below:

Nature of relationships

Nature of relationships with related parties, whether directly or indirectly are as follows:

Name of parties	Nature of relationships
<u>Subsidiary companies</u>	
Princeton Park Suites Co., Ltd.	Shareholding and directorship
Chiang Mai Ram Medical Business Public Co., Ltd.	Shareholding and directorship
Beauty Design Center Co., Ltd.	Shareholding and directorship
V.precision Co., Ltd.	Shareholding and directorship
<u>Indirect subsidiary companies</u>	
Chiang Mai Ram Hospital Co., Ltd.	Shareholding by Chiang Mai Ram Medical Business Public Co., Ltd.
Hariphunchai Memorial Hospital Co., Ltd.	Shareholding by Chiang Mai Ram Medical Business Public Co., Ltd.
Ramkhamhaeng Chiangmai Hospital Co., Ltd.	Shareholding by Chiang Mai Ram Hospital Co., Ltd. and Chiang Mai Ram Medical Business Public Co., Ltd.
Theppanya Business Co., Ltd.	Shareholding by Chiang Mai Ram Hospital Co., Ltd.
<u>Associated companies</u>	
Vibharam Hospital Co., Ltd.	Shareholding and directorship
Thipayabadin Co., Ltd.	Shareholding and directorship
Bangpo General Hospital Co., Ltd.	Shareholding and directorship
<u>Indirect associated companies</u>	
Khelang Nakorn Hospital Co., Ltd.	Shareholding by Chiang Mai Ram Hospital Co., Ltd. and directorship
Pawo Hospital Co., Ltd.	Shareholding by Theppanya Business Co., Ltd. and directorship
<u>Related companies</u>	
Chao Phaya Hospital Public Co., Ltd.	Inter-shareholding and directorship
Synphaet Hospital Co., Ltd.	Inter-shareholding and directorship
Supalerk U-Thong Hospital Co., Ltd.	Shareholding
Nawanakorn Medical Co., Ltd.	Shareholding
Innovation Technology Co., Ltd.	Shareholding and directorship

Name of parties	Nature of relationships
<u>Related companies</u>	
Seriruk Hospital Co., Ltd.	Shareholding and directorship
Legacy Golf (Thailand) Co., Ltd	Share held by subsidiary and directorship
Vibharam - Pakkred Hospital Co., Ltd.	Share held by associate and directorship
Vibharam (Amatanakorn) Hospital Co., Ltd.	Share held by associate and directorship
Vibharm - Chaiprakarn Hospital Co., Ltd.	Share held by associate and directorship
Ramkhamhaeng Hospital Public Co., Ltd.	Shareholder and directorship
Sikarin Public Co., Ltd.	Shareholder and directorship
F & S 79 Co., Ltd.	Shareholder and directorship
Phayao Ram Hospital Co., Ltd.	Shareholder and directorship
Khonkaen Ram Hospital Co., Ltd.	Shareholder and directorship
Bhumpanya International Co., Ltd.	Shareholder and directorship
Chaiyapum Ram Hospital Co., Ltd.	Shareholder and directorship
Piyasiri Co., Ltd.	Shareholder and directorship
Phrae Prommit Hospital Co., Ltd.	Shareholder and directorship
Gassan Chiangmai Property Co., Ltd.	Shareholder and directorship
Gassan Khuntan Golf and Resort Co., Ltd.	Shareholder and directorship
Gassan Marina Golf Club Co., Ltd.	Shareholder and directorship
Green Resources Public Co., Ltd.	Shareholder and directorship

Pricing policy

Business transaction	Pricing policies
Income from medical treatment	At normal business prices; the same as other entities
Rental and service income	At contract prices which are agreed upon
Other revenue	At normal business prices; the same as other entities
Loans to	At market interest rates or approximates
Loans from	At market interest rates or approximates
Purchase inventory	At prices which had been agreed upon
Purchase/Disposal of fixed assets	At prices which had been agreed upon

The balances at the end of the year were as follows :-

	Baht			
	Consolidated financial statements		Separate financial statements	
	2020	2019	2020	2019
Trade receivables				
Subsidiary companies	-	-	3,952,667	204,412
Associated companies	1,082,518	349,399	46,752	41,670
Related companies	1,196,693	596,823	1,174,073	557,665
Total	<u>2,279,211</u>	<u>946,222</u>	<u>5,173,492</u>	<u>803,747</u>
Short-term loans to				
Subsidiary companies	-	-	1,250,000	11,419,494
Associated companies	15,440,200	15,000,000	15,440,200	15,000,000
Related companies	225,225,000	290,125,000	121,600,000	91,000,000
Total	<u>240,665,200</u>	<u>305,125,000</u>	<u>138,290,200</u>	<u>117,419,494</u>
Capital decrease receivable				
Subsidiary companies	-	-	75,949,597	-
Interest receivable (other current assets)				
Subsidiary companies	-	-	25,890	211,560
Associated companies	518,261	60,514	518,261	60,514
Related companies	29,045,796	30,845,531	-	186,747
Less Allowance for doubtful accounts	<u>(28,938,675)</u>	<u>(28,938,675)</u>	<u>-</u>	<u>-</u>
Total	<u>625,382</u>	<u>1,967,370</u>	<u>544,151</u>	<u>458,821</u>
Prepaid expenses				
Related companies	1,191,318	1,168,750	1,191,318	1,168,750
Total	<u>1,191,318</u>	<u>1,168,750</u>	<u>1,191,318</u>	<u>1,168,750</u>
Accrued dividend				
Associated companies	67,450,075	-	67,450,075	-
Related companies	1,200,000	-	-	-
Total	<u>68,650,075</u>	<u>-</u>	<u>67,450,075</u>	<u>-</u>
Investment in equity				
Related companies	<u>6,148,414,872</u>	<u>5,852,630,872</u>	<u>3,742,597,872</u>	<u>3,257,107,872</u>
Long-term loans to				
Related companies	53,228,730	53,228,730	-	-
Less Allowance for doubtful accounts	<u>(29,228,730)</u>	<u>(29,228,730)</u>	<u>-</u>	<u>-</u>
Total	<u>24,000,000</u>	<u>24,000,000</u>	<u>-</u>	<u>-</u>
Trade payables				
Associated companies	-	14,609	-	-
Related companies	49,519,611	29,485,559	2,291,056	2,433,556
Total	<u>49,519,611</u>	<u>29,500,168</u>	<u>2,291,056</u>	<u>2,433,556</u>

	Baht			
	Consolidated financial statements		Separate financial statements	
	2020	2019	2020	2019
Accrued expenses				
Subsidiary companies	-	-	72,225	991,042
Associated companies	-	642,067	-	-
Related companies	206,138	122,290	-	-
Total	<u>206,138</u>	<u>764,357</u>	<u>72,225</u>	<u>991,042</u>
Advance received from shares				
Related persons	-	36,378,150	-	-
Payable from transfer share				
Subsidiary companies	-	-	-	185,845,281
Short-term loans from				
Related persons	<u>375,253,818</u>	<u>633,053,818</u>	-	-
Payable from acquisition of assets				
Related persons	<u>26,560,990</u>	<u>11,890,210</u>	-	<u>30,000</u>
Accrued interest (other current liabilities)				
Related persons	-	111,473	-	-
Other payables				
Associated companies	12,642	3,400	12,642	3,400
Related companies	<u>3,111,733</u>	<u>1,376,211</u>	<u>2,669,747</u>	<u>1,123,133</u>
Total	<u>3,124,375</u>	<u>1,379,611</u>	<u>2,682,389</u>	<u>1,126,533</u>
Long-term loans from				
Associated companies	70,000,000	-	70,000,000	-
Related companies	<u>214,000,000</u>	<u>176,000,000</u>	<u>214,000,000</u>	<u>176,000,000</u>
Total	<u>284,000,000</u>	<u>176,000,000</u>	<u>284,000,000</u>	<u>176,000,000</u>
Retention deposit (other non-current liabilities)				
Related companies	<u>1,764,272</u>	<u>1,442,235</u>	<u>1,764,272</u>	<u>1,442,235</u>
Deposit (other non-current liabilities)				
Subsidiary companies	-	-	200,000	200,000

Significant business transactions for the years ended December 31, 2020 and 2019 were as follows:

	Baht			
	Consolidated financial statements		Separate financial statements	
	2020	2019	2020	2019
Income from medical treatment				
Subsidiary companies	-	-	4,032,153	764,026
Associated companies	772,489	661,910	336,883	357,722
Related companies	<u>2,279,904</u>	<u>2,069,095</u>	<u>1,994,315</u>	<u>2,034,007</u>
Total	<u>3,052,393</u>	<u>2,731,005</u>	<u>6,363,351</u>	<u>3,155,755</u>

	Baht			
	Consolidated financial statements		Separate financial statements	
	2020	2019	2020	2019
Rental and service income				
Subsidiary companies	-	-	1,626,853	2,609,858
Related companies	60,000	53,000	60,000	53,000
Total	<u>60,000</u>	<u>53,000</u>	<u>1,686,853</u>	<u>2,662,858</u>
Dividend income				
Subsidiary companies	-	-	201,641,900	179,792,800
Associated companies	-	-	134,900,150	67,450,085
Related companies	176,566,472	200,969,649	113,280,872	114,738,849
Total	<u>176,566,472</u>	<u>200,969,649</u>	<u>449,822,922</u>	<u>361,981,734</u>
Interest income				
Subsidiary companies	-	-	199,716	211,560
Associated companies	716,663	654,544	716,663	654,544
Related companies	12,383,370	14,639,060	5,041,654	4,372,262
Total	<u>13,100,033</u>	<u>15,293,604</u>	<u>5,958,033</u>	<u>5,238,366</u>
Other income				
Associated companies	-	1,200	-	-
Related companies	64,630	-	64,630	-
Total	<u>64,630</u>	<u>1,200</u>	<u>64,630</u>	<u>-</u>
Cost of medical treatment				
Associated companies	599,342	4,164,264	112,358	2,435,560
Related companies	50,475,663	36,468,776	9,916,454	453,388
Total	<u>51,075,005</u>	<u>40,633,040</u>	<u>10,028,812</u>	<u>2,888,948</u>
Service expense				
Subsidiary companies	-	-	453,147	331,000
Associated companies	119,424	934,234	119,424	934,234
Related companies	11,247,074	11,680,568	11,247,074	11,680,568
Total	<u>11,366,498</u>	<u>12,614,802</u>	<u>11,819,645</u>	<u>12,945,802</u>
Rental expense				
Related persons	-	-	9,242	-
Miscellaneous expenses				
Subsidiary companies	-	-	6,738,066	5,543,886
Related companies	12,144,266	3,886,437	-	334,608
Total	<u>12,144,266</u>	<u>3,886,437</u>	<u>6,738,066</u>	<u>5,878,494</u>
Interest expenses				
Associated companies	653,142	-	804,781	-
Related persons	20,788,840	28,142,019	4,406,195	5,460,397
Total	<u>21,441,982</u>	<u>28,142,019</u>	<u>5,210,976</u>	<u>5,460,397</u>

	Baht			
	Consolidated financial statements		Separate financial statements	
	2020	2019	2020	2019
Purchase of inventories				
Related companies	126,285,160	87,531,346	-	-
Purchase of assets				
Related companies	81,558,780	76,264,488	16,342,039	41,562,378
Dividend paid				
Related companies	209,665,072	80,191,580	52,768,762	37,299,912
Management benefit expense				
Short-term benefits	45,582,428	112,291,934	45,582,428	47,991,549
Post-term benefits	-	28,548	-	-
Total	45,582,428	112,320,482	45,582,428	47,991,549

Management benefit expenses

Management benefit expenses represents the benefits paid to the Company and its subsidiaries management and directors such as salaries, related benefit and directors' remuneration, including the benefit paid by other means. The Company and its subsidiaries management are the persons who are defined under the Securities and Exchange Act. The management is comprised managing director or the managements who have the top position at the management level from the four lists following by the manager level.

7. CASH AND CASH EQUIVALENT

Consisted of :

	Baht			
	Consolidated financial statements		Separate financial statements	
	2020	2019	2020	2019
Cash	7,525,147	8,830,090	3,919,717	4,954,363
Bank deposit - saving accounts	334,336,718	578,007,730	47,706,147	67,829,150
Bank deposit - current accounts	(4,287,405)	15,301,430	(10,744,779)	(2,436,594)
Bank deposit - fix accounts, three-months	718,731	715,797	-	-
Total	338,293,191	602,855,047	40,881,085	70,346,919

Cash at bank - current account with credit balance, the Company has made an agreement to allow the bank to automatically transfer funds from savings account to such current account, in case of an overdraft.

8. TRADE RECEIVABLES

Trade receivables classified by aging were as follows:

	Baht			
	Consolidated financial statements		Separate financial statements	
	2020	2019	2020	2019
Accrued income	327,532,582	225,934,377	-	-
Trade receivables				
Not yet due	237,978,583	262,150,885	130,732,741	113,039,038
Over due period				
Less than and up to 3 months	77,383,201	99,366,853	8,599,195	16,690,542
Over 3 months up to 6 months	6,436,432	13,713,765	2,477,469	1,217,142
Over 6 months up to 12 months	13,755,781	8,393,502	638,698	324,928
Over 12 months	34,399,712	48,631,759	1,468,996	1,419,583
Total	697,486,291	658,191,141	143,917,099	132,691,233
Less: Allowance for doubtful accounts	(57,826,722)	(65,596,083)	(2,278,061)	(1,419,583)
Net	639,659,569	592,595,058	141,639,038	131,271,650

For the years ended December 31, 2020 and 2019, the movement of allowance for doubtful accounts were as follows :

	Baht			
	Consolidated financial statements		Separate financial statements	
	2020	2019	2020	2019
Beginning balance of the year - before adjustment	(65,596,083)	(76,215,811)	(1,419,583)	(1,195,812)
The impacts of TFRSs related to financial instruments	(9,471,519)	-	(489,153)	-
Beginning balance of the year - after adjustment	(75,067,602)	(76,215,811)	(1,908,736)	(1,195,812)
(Increase) decrease reserve during the year	(5,242,785)	(8,624,856)	(369,325)	(223,771)
Bad debt	22,483,665	19,244,584	-	-
Ending balance of the year	(57,826,722)	(65,596,083)	(2,278,061)	(1,419,583)

9. SHORT-TERM LOANS TO RELATED PARTIES

Consisted of:

	Baht			
	Consolidated financial statements		Separate financial statements	
	2020	2019	2020	2019
Related parties	240,665,200	305,125,000	138,290,200	117,419,494

Changes in the short-term loans to related parties for the years ended December 31, 2020 and 2019 were summarized as follows:

		Baht			
		Consolidated financial statements			
	Interest rate per annum (%)	As at December	Transaction during the year		As at December
		31, 2019	Increase	Decrease	31, 2020
Khonkaen Ram Hospital Co., Ltd.	7.00	18,000,000	-	-	18,000,000
Gassan Marina Golf Club Co., Ltd.	4.50	88,000,000	-	(88,000,000)	-
Gassan Chiangmai Property Co., Ltd.	4.50	7,500,000	2,000,000	(9,500,000)	-
Phayao Ram Hospital Co., Ltd.	8.00	5,625,000	-	-	5,625,000
Legacy Golf (Thailand) Co., Ltd.	4.15 - 4.50	80,000,000	-	-	80,000,000
Thippayabadin Co., Ltd.	4.75	15,000,000	775,200	(335,000)	15,440,200
Innovation Technology Co., Ltd.	4.25 - 4.80	91,000,000	45,000,000	(14,400,000)	121,600,000
Total		305,125,000	47,775,200	(112,235,000)	240,665,200

		Baht			
		Consolidated financial statements			
	Interest rate per annum (%)	As at December	Transaction during the year		As at December
		31, 2018	Increase	Decrease	31, 2019
Khonkaen Ram Hospital Co., Ltd.	7.00	18,000,000	-	-	18,000,000
Gassan Marina Golf Club Co., Ltd.	4.50	76,000,000	52,000,000	(40,000,000)	88,000,000
Gassan Chiangmai Property Co., Ltd.	4.50	7,500,000	-	-	7,500,000
Ramkhamhaeng Hospital Chiangmai Co., Ltd.	3.75 - 4.25	46,800,000	-	(46,800,000)	-
Phayao Ram Hospital Co., Ltd.	8.00	-	5,625,000	-	5,625,000
Legacy Golf (Thailand) Co., Ltd.	4.50	80,000,000	-	-	80,000,000
Thippayabadin Co., Ltd.	4.75	15,000,000	-	-	15,000,000
Innovation Technology Co., Ltd.	4.25 - 4.80	93,000,000	10,000,000	(12,000,000)	91,000,000
Total		336,300,000	67,625,000	(98,800,000)	305,125,000

		Baht			
		Separate financial statements			
	Interest rate per annum (%)	As at December	Transaction during the year		As at December
		31, 2019	Increase	Decrease	31, 2020
Princeton Park Suites Co., Ltd.	4.00	11,419,494	3,800,000	(13,969,494)	1,250,000
Thippayabadin Co., Ltd.	4.75	15,000,000	775,200	(335,000)	15,440,200
Innovation Technology Co., Ltd.	4.25 - 4.80	91,000,000	45,000,000	(14,400,000)	121,600,000
Total		117,419,494	49,575,200	(28,704,494)	138,290,200

	Baht				
	Interest rate per annum (%)	Separate financial statements			
		As at December	Transaction during the year		As at December
		31, 2018	Increase	Decrease	31, 2019
Princeton Park Suites Co., Ltd.	4.00	-	21,299,494	(9,880,000)	11,419,494
Thippayabadin Co., Ltd.	4.75	15,000,000	-	-	15,000,000
Innovation Technology Co., Ltd.	4.25 - 4.80	93,000,000	10,000,000	(12,000,000)	91,000,000
Total		108,000,000	31,299,494	(21,880,000)	117,419,494

The Company and its subsidiaries have loans to related parties in the form of promissory note and bill of exchange due at call. The interest will be paid every month. The said loan had no security.

10. INVENTORIES

Consisted of:

	Baht			
	Consolidated financial statements		Separate financial statements	
	2020	2019	2020	2019
Medicines and medical supplies	158,558,015	168,550,271	44,444,684	47,648,555
Office supplies and other supplies	5,264,103	4,853,283	1,927,273	1,275,554
Stationeries	660,787	714,726	399,107	408,664
Cuisine	448,305	441,081	149,535	99,231
Total	164,931,210	174,559,361	46,920,599	49,432,004

11. FIXED DEPOSITS PLEDGED AS COLLATERAL

As at December 31, 2020 and 2019, the subsidiary pledged fixed deposit amounted to Baht 39.41 million and Baht 36.25 million, respectively which carried the period of 6 months and 12 months, interest rate at 0.15% - 0.90% per annum and 0.55% - 1.00% per annum, respectively to guarantee to electricity using, Post Office Department and Social Security Office.

12. OTHER NON-CURRENT FINANCIAL ASSETS

Consisted of:

	Baht			
	Consolidated financial statements		Separate financial statements	
	2020	2019	2020	2019
Financial assets at fair value through other comprehensive income				
Marketable equity security (Note 12.1)	6,907,668,766	6,313,495,459	4,473,061,372	3,674,474,522
Unit trust (Note 12.2)	-	780,080	-	-
Non-marketable equity security (Note 12.3)	982,498,651	961,836,651	662,381,891	716,821,891
Financial assets at amortized cost				
Investments in debt securities held to maturity (Note 12.4)	10,000,000	10,000,000	10,000,000	10,000,000
Total other non - current financial assets	<u>7,900,167,417</u>	<u>7,286,112,190</u>	<u>5,145,443,263</u>	<u>4,401,296,413</u>

*Balances as at December 31,2019 previously presented as available-for-sale investments and Other long-term investments were reclassified to other current financial assets as mentioned in Note 5 to the financial statements.

12.1 Marketable equity security

Consisted of :

	Baht			
	Consolidated financial statements			
	Investments		Dividend income	
	2020	2019	2020	2019
Investments in marketable equity security - common stock	4,271,681,736	3,781,551,934	141,451,816	160,833,441
<u>Add</u> Unrealized gain on valuation of available-for-sale investments	<u>2,635,987,030</u>	<u>2,531,943,525</u>		
Total	<u>6,907,668,766</u>	<u>6,313,495,459</u>	<u>141,451,816</u>	<u>160,833,441</u>
	Baht			
	Separate financial statements			
	Investments		Dividend income	
	2020	2019	2020	2019
Investment in marketable equity security - common stock	3,550,507,671	3,061,962,214	77,777,705	75,948,062
<u>Add</u> Unrealized gain on valuation of available-for-sale investments	<u>922,553,701</u>	<u>612,512,308</u>		
Total	<u>4,473,061,372</u>	<u>3,674,474,522</u>	<u>77,777,705</u>	<u>75,948,062</u>

The movement of investments in marketable equity security - common stock for the years ended December 31, 2020 and 2019, were as follows:

	Baht			
	Consolidated financial statements		Separate financial statements	
	2020	2019	2020	2019
Beginning book value	6,313,495,459	3,656,549,151	3,674,474,522	1,349,069,720
Purchase investments	490,129,802	1,962,541,103	488,545,457	1,944,585,441
Sale investments	-	(42,776,059)	-	(1,478,256)
Changes in fair value	104,043,505	737,181,264	310,041,393	382,297,617
Ending book value	<u>6,907,668,766</u>	<u>6,313,495,459</u>	<u>4,473,061,372</u>	<u>3,674,474,522</u>

Changes in unrealized gain on remeasuring available-for-sale investments for the years ended December 31, 2020 and 2019, were as follows :

	Baht		
	As at December	Transaction during the year	As at December
	31, 2019	Increase (decrease)	31, 2020
<u>Consolidated/Separate financial statements</u>			
The separate			
- Sikarin Public Co., Ltd.	538,231,549	431,212,000	969,443,549
- Thai Nakarin Hospital Public Co., Ltd.	(54,265,521)	6,604,824	(47,660,697)
- Ramkhamhaeng Hospital Public Co., Ltd.	133,450,381	(147,366,906)	(13,916,525)
- Other companies	(4,904,101)	19,591,475	14,687,374
Total	<u>612,512,308</u>	<u>310,041,393</u>	<u>922,553,701</u>
<u>Indirect subsidiary company</u>			
Chiang Mai Ram Hospital Co., Ltd.			
- Ramkhamhaeng Hospital Public Co., Ltd.	1,922,929,000	(189,706,000)	1,733,223,000
- Other companies	(3,497,783)	(16,291,888)	(19,789,671)
Total	<u>2,531,943,525</u>	<u>104,043,505</u>	<u>2,635,987,030</u>

	Baht		
	As at December	Transaction during the year	As at December
	31, 2018	Increase (decrease)	31, 2019
<u>Consolidated/Separate financial statements</u>			
The separate			
- Sikarin Public Co., Ltd.	234,191,512	304,040,037	538,231,549
- Thai Nakarin Hospital Public Co., Ltd.	560,435	(54,825,956)	(54,265,521)
- Ramkhamhaeng Hospital Public Co., Ltd.	-	133,450,381	133,450,381
- Other companies	(4,537,256)	(366,845)	(4,904,101)
Total	<u>230,214,691</u>	<u>382,297,617</u>	<u>612,512,308</u>

	Baht		
	As at December	Transaction during the year	As at December
	31, 2018	Increase (decrease)	31, 2019
<u>Consolidated financial statements</u>			
<u>Direct subsidiary company</u>			
Princeton Park Suites Co., Ltd.			
- Other companies	(6,645,352)	6,645,352	-
<u>Indirect subsidiary company</u>			
Chiang Mai Ram Hospital Co., Ltd.			
- Ramkhamhaeng Hospital Public Co., Ltd.	1,571,110,600	351,818,400	1,922,929,000
- Other companies	82,322	(3,580,105)	(3,497,783)
Total	<u>1,794,762,261</u>	<u>737,181,264</u>	<u>2,531,943,525</u>

Ramkhamhaeng Hospital Public Co., Ltd.

As at December 31, 2020 and 2019, the Company has pledged this share of Ramkhamhaeng Hospital Co., Ltd. in the amount of shares 10,000,000, with a financial institution to secure the credit facilities as discussed in Note 23 to the financial statements.

Sikarin Public Co., Ltd.

As at December 31, 2020, the Company has pledged this share of Sikarin Co., Ltd. in the amount of shares 244,000,000, with a financial institution to secure the credit facilities as discussed in Note 20 and 23 to the financial statements.

12.2 Unit trust

The movement for the years ended December 31, 2020 and 2019 was as follows:

	Baht			
	Consolidated financial statements		Separate financial statements	
	2020	2019	2020	2019
Beginning book value	780,080	766,088	-	-
Sale investments	(733,519)	-	-	-
Change in value	(46,561)	13,992	-	-
Ending book value	<u>-</u>	<u>780,080</u>	<u>-</u>	<u>-</u>

12.3 Non-marketable equity security

The movement for the year ended December 31, 2020 and 2019 was as follows:

	Baht			
	Consolidated financial statements		Separate financial statements	
	2020	2019	2020	2019
Balance, beginning of the year - before adjustment	961,836,651	879,848,051	716,821,891	473,121,891
The impacts of TFRSs related to financial instruments	75,102,000	-	-	-
Balance, beginning of the year - after adjustment	1,036,938,651	879,848,051	716,821,891	473,121,891
Purchase investments	-	81,988,600	-	243,700,000
Change in value	(54,440,000)	-	(54,440,000)	-
Balance, end of the year	982,498,651	961,836,651	662,381,891	716,821,891

Detail of non-marketable equity security as at December 31, 2020 and 2019 Consisted of :

Name of company	Type of Business	Paid-up capital (Baht)		Proportion of share holding (%)	
		2020	2019	2020	2019
<u>Related companies (shareholding and co-director)</u>					
<u>Separate financial statements</u>					
Chao Phaya Hospital Public Co., Ltd.	Hospital	589,019,360	589,019,360	7.69	7.69
Supalerk U-thong Hospital Co., Ltd.	Hospital	50,000,000	50,000,000	6.00	6.00
Innovation Technology Co., Ltd.	Consulting	75,000,000	75,000,000	7.00	7.00
Seriruk Hospital Co., Ltd.	Hospital	100,000,000	100,000,000	10.00	10.00
Synphaet Hospital Co., Ltd.	Hospital	1,000,000,000	1,000,000,000	10.00	10.00
Nawanakorn Medical Co., Ltd.	Hospital	375,000,000	375,000,000	4.43	4.43
Legacy Golf (Thailand) Co., Ltd.	Golf course	1,300,000,000	1,300,000,000	10.00	10.00
<u>Consolidated financial statements</u>					
Phayao Ram Hospital Co., Ltd.	Hospital	7,500,000	7,500,000	2.36	2.36
Khonkaen Ram Hospital Co., Ltd.	Hospital	80,000,000	80,000,000	3.54	3.54
Bhumpanya International Co., Ltd.	Education	600,000,000	600,000,000	4.71	4.71
Chaiyapum Ram Hospital Co., Ltd.	Hospital	558,000,000	558,000,000	0.10	0.10
Nan-Ram Hospital Co., Ltd.	Hospital	150,000,000	150,000,000	3.14	3.14
Gassan Marina Golf Club Co., Ltd.	Golf course and hotel	2,000,000,000	2,000,000,000	4.61	4.61
<u>Other company (shareholding but not co-director)</u>					
<u>Consolidated financial statements</u>					
Phitsanulok Inter Medical Co, Ltd.	Hospital	160,000,000	160,000,000	2.06	2.06

Name of company	Baht					
	At cost method		Fair value		Dividend income	
	2020	2019	2020	2019	2020	2019
<u>Related companies (shareholding and co-director)</u>						
<u>Separate financial statements</u>						
Chao Phaya Hospital Public Co., Ltd.	78,862,491	78,862,491	78,862,491	78,862,491	10,871,822	10,871,822
Supalerk U-thong Hospital Co., Ltd.	3,875,000	3,875,000	875,000	875,000	-	-
Innovation Technology Co., Ltd.	8,290,000	8,290,000	8,290,000	8,290,000	575,000	575,000
Seriruk Hospital Co., Ltd.	10,000,000	10,000,000	10,000,000	10,000,000	-	-
Synphaet Hospital Co., Ltd.	429,000,000	429,000,000	429,000,000	429,000,000	35,000,000	33,200,000
Nawanakorn Medical Co., Ltd.	18,094,400	18,094,400	18,094,400	18,094,400	2,991,330	1,495,665
Legacy Golf (Thailand) Co., Ltd.	117,260,000	171,700,000	117,260,000	171,700,000	-	-
Total	665,381,891	719,821,891	662,381,891	716,821,891	49,438,152	46,142,487
<u>Less Allowance for impairment of investments</u>						
Supalerk U-thong Hospital Co., Ltd	(3,000,000)	(3,000,000)	-	-	-	-
Net - in separate financial statements	662,381,891	716,821,891	662,381,891	716,821,891	49,438,152	46,142,487
<u>Consolidated financial statements</u>						
Phayao Ram Hospital Co., Ltd.	375,000	375,000	375,000	375,000	-	2,250,000
Khonkaen Ram Hospital Co., Ltd.	13,050,000	13,050,000	88,152,000	88,152,000	1,200,000	1,200,000
Bhumpanya International Co., Ltd.	60,000,000	60,000,000	-	-	-	-
Chaiyapum Ram Hospital Co., Ltd.	1,200,000	1,200,000	581,760	581,760	-	-
Nan-Ram Hospital Co., Ltd.	10,000,000	10,000,000	10,000,000	10,000,000	-	-
Gassan Marina Golf Club Co., Ltd.	220,000,000	220,000,000	220,000,000	220,000,000	-	-
Total	304,625,000	304,625,000	319,108,760	319,108,760	1,200,000	3,450,000
<u>Less Allowance for impairment of investments</u>						
Bhumpanya International Co., Ltd.	(60,000,000)	(60,000,000)	-	-	-	-
Chaiyapum Ram Hospital Co., Ltd.	(618,240)	(618,240)	-	-	-	-
Total	(60,618,240)	(60,618,240)	-	-	-	-
Net	244,006,760	244,006,760	319,108,760	319,108,760	1,200,000	3,450,000
<u>Other company (shareholding but not co-director)</u>						
<u>Consolidated financial statements</u>						
Phitsanulok Inter Medical Co., Ltd.	1,008,000	1,008,000	1,008,000	1,008,000	-	-
Net - in consolidated financial statements	907,396,651	961,836,651	982,498,651	1,036,938,651	50,638,152	49,592,487

The Group has chosen to measure fair value of investments in unquoted equity securities as at December 31,2020 using the fair value as at January 1,2020 in accordance with the temporary relief measures as mentioned in Note 2.3 to the financial statements.

Investment in Legacy Golf (Thailand) Co., Ltd.

At the Board of Directors meeting No.2/2020 held on May 15, 2020 passed to approved the Company adjust the value of shares of Legacy Golf (Thailand) Co., Ltd. from Princeton Park Suites Co., Ltd., at cost on June 30, 2019 in the amount of Baht 171.70 million is the book value as at December 31, 2019 in the amount of Baht 117.26 million.

Investment in Synphaet Hospital Co., Ltd.

On July 25, 2019, the Company is eligible to purchase the shares of Synphaet Hospital Co., Ltd. according to the existing ratio for 900,000 shares at Baht 80 per share amount Baht 72.00 million.

Investment in Nan-Ram Hospital Co., Ltd.

At the Board of Directors' meeting No.9/2019 held on September 19, 2019 of indirect subsidiary, Chiang Mai Ram Hospital Co., Ltd., it has invested in Nan-Ram Hospital Co., Ltd., totalling 1,000,000 shares of Baht 10 per share in the amount of Baht 10.00 million at share holding 6.67% . The indirect subsidiary has already paid for the shares in the full amount.

12.4 Investments in debt securities held to maturity

The movement for the years ended December 31, 2020 and 2019 was as follows:

	Baht			
	Consolidated financial statements		Separate financial statements	
	2020	2019	2020	2019
Beginning book value	10,000,000	10,000,000	10,000,000	10,000,000
Change in value	-	-	-	-
Ending book value	10,000,000	10,000,000	10,000,000	10,000,000

13. INVESTMENTS IN ASSOCIATES

13.1 Investments in associated companies accounted for using the cost and equity method which consisted of :

Name of company	Type of business	Paid-up capital (Baht)		Proportion of share holding (%)	
		2020	2019	2020	2019
<u>Consolidated financial statements / Separate financial statements</u>					
<u>Direct associated company</u>					
Vibharam Hospital Co., Ltd.	Hospital	2,000,000,000	1,654,803,530	33.73	40.76
Thippayabadin Co., Ltd.	Trading medical instrument	450,000,000	450,000,000	38.18	33.33
Bangpo General Hospital Co., Ltd.	Hospital	350,000,000	350,000,000	28.57	28.57

Name of company	Type of business	Paid-up capital (Baht)		Proportion of share holding (%)	
		2020	2019	2020	2019
<u>Consolidated financial statements</u>					
<u>Indirect associated companies</u>					
Khelang Nakorn Hospital Co., Ltd.	Hospital	89,708,200	89,708,200	11.99	11.99
Pawo Hospital Co., Ltd.	Hospital	11,625,750	11,625,750	23.54	23.54
		<u>Baht</u>			
		<u>At equity method</u>		<u>At cost method</u>	
Name of company		2020	2019	2020	2019
<u>Consolidated financial statements / Separate financial statements</u>					
<u>Direct associated company</u>					
Vibharam Hospital Co., Ltd.		1,690,154,047	1,844,434,138	1,304,865,788	1,304,865,788
Thippayabadin Co., Ltd.		21,127,292	70,726,462	172,500,000	172,500,000
Bangpo General Hospital Co., Ltd.		318,939,772	312,300,353	300,000,000	300,000,000
<u>Less</u> Allowance for impairment of investments in Thippayabadin Co., Ltd.				(136,005,080)	-
Total				1,641,360,708	1,777,365,788
<u>Consolidated financial statements</u>					
<u>Indirect associated companies</u>					
Khelang Nakorn Hospital Co., Ltd.		109,516,558	110,655,531	30,882,500	30,882,500
Pawo Hospital Co., Ltd.		10,344,577	15,835,382	29,813,600	29,813,600
<u>Less</u> Allowance for impairment of investments in Pawo Hospital Co., Ltd.		-	-	(13,978,218)	(13,978,218)
Total		2,150,082,246	2,353,951,866	1,688,078,590	1,824,083,670

13.2 Share of profit (loss) of associates for the years ended December 31, 2020 and 2019 were as follows :

Name of company	<u>Baht</u>	
	<u>Consolidated financial statements</u>	
	2020	2019
<u>Direct associated company</u>		
Vibharam Hospital Co., Ltd.		
Share of profit (loss)	(111,922,565)	240,537,147
Arising from the change of shareholding	91,832,946	-
Thippayabadin Co., Ltd.		
Share of profit (loss)	(21,467,943)	(11,118,845)
Arising from the change of shareholding	(28,131,226)	-
Bangpo General Hospital Co., Ltd.	6,204,279	11,508,521
<u>Indirect associated companies</u>		
Khelang Nakorn Hospital Co., Ltd.	6,620,626	16,002,073
Pawo Hospital Co., Ltd.	(5,490,806)	2,805,043
Total	(62,354,689)	259,733,939

The share of profit (loss) of directly associated company - Vibharam Hospital Company Limited as shown above for the years ended December 31, 2020 and 2019, were the net amount of the elimination each transaction for Baht 8.56 million and Baht 9.19 million, respectively, as a result of acquiring the dividend that the Company has paid to the associated company.

13.3 Share of other comprehensive income (loss) of associates for the years ended December 31, 2020 and 2019 were as follows :

Name of company	Baht	
	Consolidated financial statements	
	2020	2019
<u>Direct associated company</u>		
Vibharam Hospital Co., Ltd.		
Loss on remeasuring available-for -sale investments	(7,851,110)	(98,666,283)
Actuarial loss on define employee benefit plans	-	(1,961,766)
Bangpo General Hospital Co., Ltd.		
Actuarial gain on define employee benefit plans	435,139	-
<u>Indirect associated companies</u>		
Khelang Nakorn Hospital Co., Ltd.		
Actuarial loss on define employee benefit plans	-	(304,457)
Total	<u>(7,415,971)</u>	<u>(100,932,506)</u>

13.4 Dividend income from investment in associated companies for the years ended December 31, 2020 and 2019 were as follows :

Name of company	Baht	
	2020	2019
<u>Consolidated /separate financial statements</u>		
<u>Direct associated company</u>		
Vibharam Hospital Co., Ltd.	134,900,150	67,450,085
<u>Consolidated financial statements</u>		
<u>Indirect associated companies</u>		
Khelang Nakorn Hospital Co., Ltd.	7,759,599	6,846,705
Total	<u>142,659,749</u>	<u>74,296,790</u>

Summarized financial information in respect of Vibharam Hospital Co., Ltd. (Associated company) of the material associate;

	Baht	
	2020	2019
Current assets	1,853,728,041	1,388,504,810
Non-current assets	8,597,589,327	8,692,710,885
Current liabilities	2,799,147,724	2,408,809,572
Non-current liabilities	1,299,912,617	1,762,923,145

	Baht	
	2020	2019
Revenue	3,785,577,336	4,884,914,393
Profit for the year	(334,561,274)	626,134,445
Other comprehensive loss for the year	(163,159,035)	(335,458,461)
Total comprehensive income (loss) for the year	(497,720,309)	290,675,984

Reconciliation of the above summarized financial information to the carrying amount of the interest in Vibharam Hospital Co., Ltd. recognized in the consolidated financial statements;

	Baht	
	2020	2019
Net assets	5,699,486,822	5,141,775,089
Proportion of the interest	33.73	40.76
Other adjustments		
- Unrealized profit from investment available-for-sale Vibhavadi Medical Center Public Company Limited in the financial statements of the associate that is not included and received as share of profit from investment in associated in Company's financial statements	(209,632,427)	(268,543,182)
- Other	(22,650,431)	(17,703,971)
Carrying amount of the interest	<u>1,690,154,047</u>	<u>1,844,434,138</u>

Aggregate information of associates that are not individually material

	Baht	
	2020	2019
The share of profit (loss) from continuing operations	(42,265,070)	19,196,792
The share of total comprehensive income (loss)	435,139	(304,457)
Aggregate carrying amount of the interests in these associates	459,928,199	509,517,728

Investment in Vibharam Hospital Co., Ltd.

In the year 2020 the associated company had a capital increase in the ordinary shares by a related company from the rights to purchase the ordinary shares capital increase of such company in the amount of Baht 14,187,720 shares and the portion disclaimed by the former shareholders of 16,300,977 shares, totaling capital increase shares of 30,488,697 shares. Such capital increase of the related company has resulted in the shareholding of the Company in the associated company to change from 40.76 percent to 33.73 percent and to have a difference arising from the change of shareholding of Baht 91.83 million. The transaction is recognised as share of profit in the associated company in the consolidated financial statements.

As at December 31, 2020 and 2019, the Company has pledged the share certificate of Vibharam Hospital Co., Ltd. in the amount of shares 25,160,358, with a financial institution to secure the credit facilities as discussed in Note 19 to the financial statements.

Investment in Thippayabadin Co., Ltd.

At the Annual General Meeting of the shareholder's associated company 1/2020 held on July 20, 2020, the shareholders approved specific capital reduction of shareholders who are unrelated to Vibhavadi Medical Center PCL. in the amount of Baht 57.16 million resulting in the registered capital of Baht 450.00 million remaining Baht 392.84 million by reducing the number of shares to 78,568,000 ordinary shares at the price of 5.00 Baht per share. Therefore, the Company's shareholding proportion has changed from 33.33% to 38.18% and difference from change proportion was amount of Baht 28.13 million in the consolidated statement of income.

14. INVESTMENTS IN SUBSIDIARIES

Investments in subsidiaries consisted of :

Name of company	Type of business	Paid-up capital (Baht)		Proportion of share holding (%)	
		2020	2019	2020	2019
<u>Shareholding by the Company</u>					
Princeton Park Suites Co., Ltd.	Hotel	65,000,000	260,000,000	99.99	99.99
Chiang Mai Ram Medical Business Public Co., Ltd.	Hospital	402,312,500	402,312,500	83.55	83.55
Beauty Design Center Co., Ltd.	Beauty Business	7,500,000	7,500,000	50.00	50.00
V.precision Co., Ltd.	Anti Aging Center	1,250,000	-	70.00	-
<u>Shareholding by direct subsidiary companies</u>					
Chiang Mai Ram Hospital Co., Ltd.	Hospital	400,000,000	400,000,000	47.09	47.09
Hariphunchai Memorial Co., Ltd. (shareholding by Chiang Mai Ram Medical Business Public Co., Ltd.)	Hospital	150,000,000	150,000,000	72.43	72.43
Ramkhamhaeng Chiangmai Hospital Co., Ltd. (shareholding by Chiang Mai Ram Hospital Co., Ltd. and Chiang Mai Ram Medical Business Public Co., Ltd.)	Hospital	1,000,000,000	440,000,000	45.53	45.14
<u>Shareholding by indirect subsidiary company</u>					
Theppanya Business Co., Ltd. (shareholding by Chiang Mai Ram Hospital Co., Ltd.)	Hospital	236,000,000	236,000,000	47.09	47.09

Name of company	Baht					
	At equity method		Separate financial statements			
	2020	2019	At cost method		Dividend income	
	2020	2019	2020	2019	2020	2019
Princeton Park Suites Co., Ltd.	16,204,730	214,194,918	150,537,651	345,537,651	-	-
Chiang Mai Ram Medical Business Public Co., Ltd.	3,583,498,231	3,696,846,032	1,638,467,138	1,638,467,138	196,641,900	174,792,800
Beauty Design Center Co., Ltd.	22,822,430	7,651,158	14,145,281	14,145,281	5,000,000	5,000,000
V.precision Co., Ltd.	782,424	-	874,995	-	-	-
Total	3,623,307,815	3,918,692,108	1,804,025,065	1,998,150,070	201,641,900	179,792,800

The subsidiaries that have material non-controlling interests

The Company has consolidated Chiang Mai Ram Medical Business Public Co., Ltd. that have material non-controlling interest:

Name of Company	Place of incorporation and principal place of business	Proportion of ownership interests and voting rights held by non-controlling interests		Baht			
		2020	2019	Comprehensive income allocated to non-controlling interests		Accumulated non-controlling interests	
				2020	2019	2020	2019
Chiang Mai Ram Medical Business Public Co., Ltd.	Thai	16.45	16.45	(14,429,188)	308,008,330	2,498,500,246	2,566,337,786
Beauty Design Center Co., Ltd.	Thai	50.00	50.00	16,005,407	12,651,158	32,747,579	16,743,172
V.precision Co., Ltd.	Thai	30.00	-	(40,102)	-	333,903	-
Total				<u>1,536,117</u>	<u>320,659,488</u>	<u>2,531,581,728</u>	<u>2,583,080,958</u>

Summarized financial information in respect of Chiang Mai Ram Medical Business Public Co., Ltd. amounts before intragroup eliminations.

	Baht	
	2020	2019
Current assets	939,607,094	1,228,018,433
Non-current assets	9,810,747,517	8,922,992,537
Current liabilities	2,556,451,324	2,560,582,025
Non-current liabilities	2,762,132,125	1,987,770,293
Non-Controlling interests	1,858,838,878	1,894,062,605
Revenue	3,784,361,527	4,059,252,192
Profit attributable to the non-controlling interests	45,469,459	171,102,808
Other comprehensive income (loss) to the non-controlling interests	(26,432,043)	136,905,522
Dividends paid to non-controlling interests		34,409,180
Net cash provided by from operating activities	619,276,326	904,525,374
Net cash used in investing activities	(1,236,580,513)	(1,046,378,513)
Net cash provided by (used in) financing activities	384,320,709	401,063,670
Net cash increase (decrease)	<u>(232,983,478)</u>	<u>259,210,531</u>

For the Company

At the Board of Director's meeting of Company 4/2020 held on August 13, 2020, the meeting has resolved to approved the invested in V.precision Co., ltd, totaling 500,000 shares of Baht 10 per share in the amount of Baht 5.00 million at shareholding 70% and such Company had been paid-up at the rate of 25% of the share totaling Baht 0.87 million and already paid of the share.

Princeton Park Suites Co., Ltd.

On September 25, 2019, the Board of Directors of the Company had a resolution to adjust the investment structure for the subsidiary - Princeton Park Suites Co., Ltd. to transfer the total shares of Beauty Design Center Co., Ltd. which as direct subsidiary of 100,000 shares or shareholding 50 percent with the book value of Baht 14.15 million and shares of Legacy Golf (Thailand) Co., Ltd. which as other long-term investment, directly to the company of 13,000,000 shares or shareholding 10 percent with the book value Baht 71.70 million, directly to the company. As at December 31, 2019, the Company has not yet paid for such shares that have been transferred in the amount of Baht 185.85 million.

At the Annual General Meeting of the shareholder's subsidiary company 1/2020 held on April 10, 2020, the shareholders approved decrease of registered capital of the subsidiary from the existing amount of Baht 260 million to Baht 65 million. The decreased registered capital is the 39,000,000 unissued ordinary shares at par value of Baht 5 totaling of Baht 195 million. The Subsidiary has registered the capital decrease with the Department of Business Development on May 15, 2020.

Later, On May 15, 2020, the Board of Directors of the Company has a resolution to adjust value in transfer the shares of Legacy Golf (Thailand) Co., Ltd. decrease with the book value as at December 31, 2019 amount of Baht 54.44 million. As a result payable from transfer share amount Baht 131.41 million. The Company paid the compensation payable from transfer share by deducting debt and the right to receive the subsidiary's outstanding refunds consisted of loan in the amount of Baht 11.97 million, accrued interest in the amount of Baht 0.39 million and the right to receive from capital decrease of the subsidiary in amount of Baht 195 million, totaling Baht 207.36 million as a result the Company had to receive the capital decrease receivable amount of Baht 75.95 million, As at December 31, 2020, the Company has not yet received.

Chiang Mai Ram Medical Business Public Co., Ltd.

On December 25, 2018, Board of directors of the its subsidiaries, resolved to approve Chiang Mai Ram Medical Business Public Co., Ltd. and Chiang Mai Ram Hospital Co., Ltd. to invest in the ordinary shares of Ramkhamhaeng Chiangmai Hospital Co., Ltd. which is a newly established company on October 30, 2018 with the registered capital of Baht 1 million. On March 1, 2019, the registered capital has been increased to Baht 400 million. Chiang Mai Ram Medical Business Public Co., Ltd. and Chiang Mai Ram Hospital Co., Ltd. will invest in such company 18% and 63% of the shares issued and paid up of such company, respectively. On February 27, 2019, such company has call up 30% of registered capital from Chiang Mai Ram Medical Business Public Co., Ltd. amounted Baht 21.60 million and from its subsidiary, Chiang Mai Ram Hospital Co., Ltd. amounted Baht 75.60 million totaling of Baht 97.20 million. The capital increase has been registered by Ramkhamhaeng Chiangmai Hospital Co., Ltd. on March 1, 2019.

The carrying amounts of net asset of Ramkhamheang Chiangmai Hospital Co., Ltd. as at March 1, 2019, which was the nearest date to the acquisition date included in the Company's consolidated financial statement are available as follows :

	<u>Baht</u>
<u>Assets</u>	
Cash and cash equivalents	21,123,299
Other current assets	700,037
Property, plant and equipment	40,594,859
Advance payment of assets	57,268,500
<u>Liabilities</u>	
Accrued expenses	<u>(517,047)</u>
Net assets	119,169,648
<u>Less</u> Non-controlling interests	<u>(23,209,233)</u>
Share of net assets acquired	95,960,415
Excess of investment over the acquirer's interest in the book value of the acquiree's net assets	<u>1,239,585</u>
Total purchase consideration - cash	97,200,000
<u>Less</u> Transfer loans for payment capital	(46,800,000)
Cash and cash equivalents in subsidiary acquired	<u>(21,123,299)</u>
Cash outflow on acquisition of investment, net of cash and cash equivalents acquired	<u><u>29,276,701</u></u>

The subsidiaries identifies the fair value of assets and liabilities that consolidated on the acquisition date by the book value of Ramkhamheang Chiangmai Hospital Co., Ltd. So, the Company recorded excess of investment over the acquirer's interest in the book value of the acquiree's net assets as expenses in the statement of comprehensive income.

On May 2, 2019, such company has call up Baht 7 each, Chiang Mai Ram Medical Business Public Co.,Ltd. paid amounted Baht 50.40 million and Chiang Mai Ram Hospital Co., Ltd. paid amounted Baht 179.79 million totaled amounted Baht 230.19 million, resulting in subsidiary - Chiang Mai Ram Hospital Co., Ltd. held in such company to increase from 63.00% to 63.85% totaled of the subsidiary group are 81.85% .

On July 26, 2019, such company has registered the capital increase for 4 million shares at Baht 10 per share, amounted Baht 40.00 million. Chiang Mai Ram Medical Business Public Co., Ltd. had paid the share amounted Baht 7.20 million and from its subsidiary, Chiang Mai Ram Hospital Co., Ltd. amounted Baht 25.82 million totaled Baht 33.02 million, resulting in subsidiary - Chiang Mai Ram Hospital Co., Ltd. held in such company to increase from 63.85% to 63.91% totaled 81.91% and the difference from purchasing shares in the subsidiary from non-controlling interests was amount Baht 14,418.20, represented as shareholders' equity in consolidated financial statements. The Company and its subsidiary have already paid for the shares in the full amount.

On December 4, 2019, the subsidiary - Ramkhamhaeng Chiangmai Hospital Co., Ltd. has a resolution to increase the registered capital for 56 million shares at Baht 10.00 per share amounted to Baht 560.00 million. Chiang Mai Ram Medical Business Public Company Limited has paid the shares amounted to Baht 40.32 million and the subsidiary - Chiang Mai Ram Hospital Co., Ltd. has paid the shares amounted to Baht 146.48 million. Resulting from such transaction, the Company has the advance payment for shares subscription of Baht 40.32 million stated in the separate financial statements and has the advance received for shares subscription of Baht 36.38 million in the consolidated financial statements. The subsidiary - Ramkhamhaeng Chiangmai Hospital Co., Ltd. has registered the capital increase with the Department of Business Development on February 14, 2020.

As at December 31, 2020 and 2019, the Company has pledged this shares of Chiang Mai Ram Medical Business Public Co., Ltd. in the amount of shares 2,020,000,000 and shares 1,680,000,000, respectively, with a financial institution to secure the credit facilities as discussed in Notes 20 and 23 to the financial statements.

As at December 31, 2020 and 2019, the subsidiary has pledged share of Chiang Mai Ram Hospital Co., Ltd. and Hariphunchai Memorial Co., Ltd. in the total amount of shares 43,005,000 with a financial institution to secure the credit facilities as discussed in Note 20 to the financial statements.

15. INVESTMENT PROPERTY

Investment property consisted of:

	Baht				
	Consolidated financial statements				
	Balance as at December 31, 2019	Transaction during the year			Balance as at December 31, 2020
	Increase	Decrease	Transfer in (out)		
<u>At cost</u>					
Land	171,553,809	-	-	-	171,553,809
Buildings for rent	236,153,320	8,282,102	-	83,024,983	327,460,405
Total	407,707,129	8,282,102	-	83,024,983	499,014,214
<u>Less</u> Accumulated depreciation					
Buildings for rent	(30,747,770)	(16,341,546)	-	-	(47,089,316)
Investment property - net	<u>376,959,359</u>				<u>451,924,898</u>
	Baht				
	Consolidated financial statements				
	Balance as at December 31, 2018	Transaction during the year			Balance as at December 31, 2019
	Increase	Decrease	Transfer in (out)		
<u>At cost</u>					
Land	171,553,809	-	-	-	171,553,809
Buildings for rent	101,555,630	146,862	-	134,450,828	236,153,320
Total	273,109,439	146,862	-	134,450,828	407,707,129
<u>Less</u> Accumulated depreciation					
Buildings for rent	(24,876,958)	(5,870,812)	-	-	(30,747,770)
Investment property - net	<u>248,232,481</u>				<u>376,959,359</u>

	Baht				
	Separate financial statements				
	Balance as at	Transaction during the year			Balance as at
	December 31, 2019	Increase	Decrease	Transfer in (out)	December 31, 2020
<u>At cost</u>					
Land	150,770,000	-	-	-	150,770,000
Buildings for rent	170,461,574	8,282,102	-	83,024,983	261,768,659
Total	321,231,574	8,282,102	-	83,024,983	412,538,659
<u>Less</u> Accumulated depreciation					
Buildings for rent	(23,850,888)	(14,145,822)	-	-	(37,996,710)
Investment property - net	<u>297,380,686</u>				<u>374,541,949</u>

	Baht				
	Separate financial statements				
	Balance as at	Transaction during the year			Balance as at
	December 31, 2018	Increase	Decrease	Transfer in (out)	December 31, 2019
<u>At cost</u>					
Land	150,770,000	-	-	-	150,770,000
Buildings for rent	35,863,884	146,862	-	134,450,828	170,461,574
Total	186,633,884	146,862	-	134,450,828	321,231,574
<u>Less</u> Accumulated depreciation					
Buildings for rent	(20,169,801)	(3,681,087)	-	-	(23,850,888)
Investment property - net	<u>166,464,083</u>				<u>297,380,686</u>

During 2019, the Company transferred the some of property, plant and equipment “Vi Plaza” which is building for rent to the investment property as discussed in Note 15 to the financial statements.

The Company’s investment property is land and buildings for rent. In 2018, the Company’ investment property had its fair value in the amount of Baht 182.10 million, which was appraised by independent appraisal.

For the years ended December 31, 2020 and 2019, the Company and its subsidiaries had rental income from investment property in the amount of Baht 60.99 million and Baht 26.58 million (the Separate amount of Baht 56.28 million and Baht 5.23 million), respectively and operating expenses in the amount of Baht 30.75 million and Baht 11.25 million (the Separate amount of Baht 28.50 million and Baht 29.00 million), respectively which were recognized in the statement of comprehensive income.

Investment property of the Company are mortgaged as collateral of credit facilities from financial institutions as discussed in Note 20 to the financial statements.

16. PROPERTY, PLANT AND EQUIPMENT

Consisted of :

	Baht				
	Consolidated financial statements				
	Balance as at	Transaction during the year			Balance as at
	December 31, 2019	Increase	Decrease	Transfer in (out)	December 31, 2020
<u>At cost</u>					
Land and land improvements	3,763,904,019				3,763,904,019
Building and building improvement	3,661,325,833	54,776,441	-	36,292,162	3,752,394,436
Medical instruments and office appliances	1,796,829,854	142,104,339	(88,340,095)	-	1,850,594,098
Furniture fixture and equipment	1,463,227,183	42,701,143	(17,576,708)	53,200,462	1,541,552,080
Appliances health center	9,913,554	3,112	(1,308)	-	9,915,358
Vehicle	149,148,245	281,573	(1,028,687)	-	148,401,131
Assets in progress	515,497,932	1,196,835,700	-	(172,517,607)	1,539,816,025
Total	<u>11,359,846,620</u>	<u>1,436,702,308</u>	<u>(106,946,798)</u>	<u>(83,024,983)</u>	<u>12,606,577,147</u>
<u>Less Accumulated depreciation</u>					
Land improvements	(20,209,658)	(2,280,733)	-	-	(22,490,391)
Building and building improvement	(1,911,622,037)	(175,636,082)	-	-	(2,087,258,119)
Medical instruments and office appliances	(1,255,125,604)	(113,081,491)	85,708,863	-	(1,282,498,232)
Furniture fixture and equipment	(1,023,557,706)	(102,690,002)	17,383,275	-	(1,108,864,433)
Appliances health center	(17,644,664)	(214,419)	1,308	-	(17,857,775)
Vehicle	(106,947,162)	(11,580,460)	1,012,186	-	(117,515,436)
Total	<u>(4,335,106,831)</u>	<u>(405,483,187)</u>	<u>104,105,632</u>	<u>-</u>	<u>(4,636,484,386)</u>
Properly, plant and equipment, net	<u>7,024,739,789</u>				<u>7,970,092,761</u>

	Baht				
	Consolidated financial statements				
	Balance as at	Transaction during the year			Balance as at
	December 31, 2018	Increase	Decrease	Transfer in (out)	December 31, 2019
<u>At cost</u>					
Land and land improvements	3,173,580,458	585,604,330	-	4,719,231	3,763,904,019
Building and building improvement	3,485,737,783	160,079,157	(1,741,016)	17,249,909	3,661,325,833
Medical instruments and office appliances	1,747,211,749	109,927,012	(64,930,754)	4,621,847	1,796,829,854
Furniture fixture and equipment	1,433,968,556	32,986,973	(16,637,959)	12,909,613	1,463,227,183
Appliances health center	9,700,932	293,822	(81,200)	-	9,913,554
Vehicle	141,767,262	9,526,870	(2,145,887)	-	149,148,245
Assets in progress	150,791,252	538,703,108	-	(173,996,428)	515,497,932
Total	<u>10,142,757,992</u>	<u>1,437,121,272</u>	<u>(85,536,816)</u>	<u>(134,495,828)</u>	<u>11,359,846,620</u>

Baht					
Consolidated financial statements					
	Balance as at	Transaction during the year			Balance as at
	December 31, 2018	Increase	Decrease	Transfer in (out)	December 31, 2019
<u>Less Accumulated depreciation</u>					
Land improvements	(17,956,315)	(2,253,343)	-	-	(20,209,658)
Building and building improvement	(1,744,718,988)	(168,644,062)	1,741,013	-	(1,911,622,037)
Medical instruments and office appliances	(1,209,206,739)	(110,279,733)	64,360,868	-	(1,255,125,604)
Furniture fixture and equipment	(931,907,162)	(108,142,050)	16,491,506	-	(1,023,557,706)
Appliances health center	(17,278,245)	(447,618)	81,199	-	(17,644,664)
Vehicle	(96,191,903)	(12,691,624)	1,936,365	-	(106,947,162)
Total	<u>(4,017,259,352)</u>	<u>(402,458,430)</u>	<u>84,610,951</u>	<u>-</u>	<u>(4,335,106,831)</u>
Property, plant and equipment, net	<u>6,125,498,640</u>				<u>7,024,739,789</u>
Baht					
Separate financial statements					
	Balance as at	Transaction during the year			Balance as at
	December 31, 2019	Increase	Decrease	Transfer in (out)	December 31, 2020
<u>At cost</u>					
Land and land improvements	484,206,727				484,206,727
Building and building improvement	1,471,875,523	384,033	-	36,292,163	1,508,551,719
Medical instruments and office appliances	557,960,264	23,588,981	(4,050)	-	581,545,195
Furniture fixture and equipment	283,855,369	12,767,824	(415,152)	858,960	297,067,001
Vehicle	9,913,554	3,113	(1,308)	-	9,915,359
Appliances health center	79,596,324	-	-	-	79,596,324
Assets in progress	153,575,551	37,736,466	-	(120,176,105)	71,135,912
Total	<u>3,040,983,312</u>	<u>74,480,417</u>	<u>(420,510)</u>	<u>(83,024,982)</u>	<u>3,032,018,237</u>
<u>Less Accumulated depreciation</u>					
Land improvements	(4,095,772)	(459,237)	-	-	(4,555,009)
Building and building improvement	(952,456,809)	(67,531,751)	-	-	(1,019,988,560)
Medical instruments and office appliances	(460,760,589)	(27,938,923)	3,444	-	(488,696,068)
Furniture fixture and equipment	(253,744,648)	(12,683,614)	392,402	-	(266,035,860)
Vehicle	(17,644,665)	(214,418)	1,307	-	(17,857,776)
Appliances health center	(56,332,738)	(5,702,282)	-	-	(62,035,020)
Total	<u>(1,745,035,221)</u>	<u>(114,530,225)</u>	<u>397,153</u>	<u>-</u>	<u>(1,859,168,293)</u>
Property, plant and equipment, net	<u>1,295,948,091</u>				<u>1,172,849,944</u>

	Baht					
	Separate financial statements					
	Balance as at	Transaction during the year				Balance as at
	December 31, 2018	Increase	Decrease	Transfer in (out)		December 31, 2019
<u>At cost</u>						
Land and land improvements	484,206,727	-	-	-	484,206,727	
Building and building improvement	1,455,990,941	1,428,974	-	14,455,608	1,471,875,523	
Medical instruments and office appliances	538,683,096	16,405,321	(1,750,000)	4,621,847	557,960,264	
Furniture fixture and equipment	273,885,817	8,901,820	(651,410)	1,719,142	283,855,369	
Vehicle	9,700,932	293,822	(81,200)	-	9,913,554	
Appliances health center	74,939,599	4,656,725	-	-	79,596,324	
Assets in progress	123,559,587	185,308,389	-	(155,292,425)	153,575,551	
Total	<u>2,960,966,699</u>	<u>216,995,051</u>	<u>(2,482,610)</u>	<u>(134,495,828)</u>	<u>3,040,983,312</u>	
<u>Less Accumulated depreciation</u>						
Land improvements	(3,636,535)	(459,237)	-	-	(4,095,772)	
Building and building improvement	(885,808,312)	(66,648,497)	-	-	(952,456,809)	
Medical instruments and office appliances	(430,615,784)	(31,894,802)	1,749,997	-	(460,760,589)	
Furniture fixture and equipment	(239,701,454)	(14,669,557)	626,363	-	(253,744,648)	
Vehicle	(17,278,245)	(447,619)	81,199	-	(17,644,665)	
Appliances health center	(48,821,172)	(7,511,566)	-	-	(56,332,738)	
Total	<u>(1,625,861,502)</u>	<u>(121,631,278)</u>	<u>2,457,559</u>	<u>-</u>	<u>(1,745,035,221)</u>	
Property, plant and equipment, net	<u>1,335,105,197</u>				<u>1,295,948,091</u>	

During 2019, the Company has objective to use some of building in Vi Plaza from operation assets to rental assets instead. Therefore, the company transferred property and equipment to the investment property at cost of Baht 134.45 million, starting from October 9, 2019 onwards.

As at December 31, 2020 and 2019, land with construction, plant and medical equipment of the Company and its subsidiaries with net book value of Baht 4,038.54 million and Baht 2,715.42 million (the Separate amount of Baht 316.27 million and Baht 322.24 million), respectively, were mortgaged as collateral of credit facilities from financial institutions as discussed in Note 20 and 23 to the financial statements.

As at December 31, 2020 and 2019, the Company and its subsidiaries had fixed assets with the depreciation fully calculated but still in use which had a cost value of Baht 1,914.47 million and Baht 1,841.04 million (the Separate amount of Baht 709.15 million and Baht 690.33 million), respectively.

As at December 31, 2020 and 2019, medical instruments and vehicle of the Company and its subsidiaries acquired under finance leases, have net book value of Baht 8.94 million and Baht 14.73 million (the Separate amount of Baht 7.63 million and Baht 12.80 million), respectively.

As at December 31, 2020 and 2019, the Company and its subsidiary had interest expense which is borrowing costs amounting to Baht 16.51 million and Baht 4.49 million (the Separate amount of Baht 0.00 million and Baht 2.88 million), respectively, with a capitalization at the rate 2.51 - 2.69 per annum and 3.00 - 3.50% per annum (the Separate amount of rate 0.00% per annum and 3.00% per annum), respectively.

Chiang Mai Ram Medical Business Public Co., Ltd.

On November 19, 2018, the subsidiary - Ramkhamhaeng Chiangmai Hospital Co., Ltd. had entered into the letter of agreement to buy to sell of land for 8 plots together with buildings with Sukhumvit Asset Management Co., Ltd. The land is situated in Tha Sala, Mueang Chiangmai District, Chiangmai with the total area of 12-0-62 rais (or equal to 4,862 square wah). The total selling price is Baht 381.79 million. The buyer is responsible the fees for registration of land ownership transfers and other expenses related to the transfer of land ownership. The seller is responsible for the withholding tax and specific business tax. The subsidiary had deposited the land amounted Baht 38.18 million.

During the year 2019, the subsidiary had to pay the remaining portion of land fee and other expenses related to the transfer of land ownership total amounted Baht 348.46 million. The total cost of land is Baht 386.64 million and registered of land ownership transfers on May 17, 2019.

17. Right-of-use assets

The net book value of right-of-use assets related to lease contracts and the movement for the year ended December 31, 2020 are presented below.

	Baht	
	Consolidated financial statements	Separate Financial statements
Cost		
As at December 31, 2019	-	-
Effects of the adoption of TFRS16		
as at January 1, 2020	332,520,444	21,061,449
As at January 1, 2020	332,520,444	21,061,449
Addition	-	-
As at December 31, 2020	332,520,444	21,061,449
Accumulated depreciation		
As at December 31, 2019	-	-
Effects of the adoption of TFRS16		
as at January 1, 2020	-	-
As at January 1, 2020		
Depreciation for the year	(29,593,071)	(3,403,050)
Depreciation - written-off	302,927,373	17,658,399
As at December 31, 2020		
Net book value	-	-
As at December 31, 2019	332,520,444	21,061,449
As at January 1, 2020	302,927,373	17,658,399

18. GOODWILL

Consisted of:

	Baht	
	Consolidated financial statements	
	2020	2019
1. Goodwill from acquisition investment in Chiang Mai Ram Medical Business Public Co., Ltd. by the Company	424,723,212	424,723,212
2. Goodwill in the consolidated financial statements of Chiang Mai Ram Medical Business Public Co., Ltd., which is a reverse acquisition of Chiang Mai Ram Medical Business Public Co., Ltd., the legal parent but considered to be the acquires for accounting purpose, whose controlled by Chiang Mai Ram Hospital Co., Ltd., the legal subsidiary company but considered to be the acquirer for accounting purpose, after ordinary share exchange on February 25, 2008.	89,343,728	89,343,728
3. Goodwill from acquisition investment in Hariphunchai Memorial Hospital Co., Ltd. by Chiang Mai Ram Medical Business Public Co., Ltd.	209,148,791	209,148,791
Total	<u>723,215,731</u>	<u>723,215,731</u>

19. DEFERRED TAX ASSETS AND DEFERRED TAX LIABILITIES

Deferred tax assets and deferred tax liabilities as follow :

	Baht			
	Consolidated financial statements		Separate financial statements	
	2020	2019	2020	2019
Deferred tax assets	12,578,546	27,156,447	16,396,514	14,792,182
Deferred tax liabilities	(716,825,460)	(699,937,849)	(184,396,596)	(122,699,615)
Deferred tax assets (liabilities) - net	<u>(704,246,914)</u>	<u>(672,781,402)</u>	<u>(168,000,082)</u>	<u>(107,907,433)</u>

Changes for the years ended December 31, 2020 and 2019 were summarized as follows:

	Baht					
	Consolidated financial statements					
	Balance as at	The impacts from	Balance as at	Revenue (expenses) during the period		Balance as at
	December 31, 2019	adoption of	January 1, 2020	In profit or loss	In other	December 31, 2020
	financial reporting			comprehensive		
	standards			income		
Deferred tax assets:						
Trade receivables	6,972,336	922,533	7,894,869	(614,868)	-	7,280,001
Provisions for employee benefits	48,344,002	-	48,344,002	4,861,760	-	53,205,762
Straight line method of rental	15,750,492	(15,750,492)	-	-	-	-
Other	385,230	-	385,230	93,945	-	479,175
Total	<u>71,452,060</u>	<u>(14,827,959)</u>	<u>56,624,101</u>	<u>4,340,837</u>	<u>-</u>	<u>60,964,938</u>

Baht						
Consolidated financial statements						
	Balance as at	The impacts from adoption of financial reporting standards	Balance as at	Revenue (expenses) during the period		Balance as at
	December 31, 2019		January 1, 2020	In profit or loss	In other comprehensive income	December 31, 2020
Deferred tax liabilities:						
Lease agreements	197,154	-	197,154	(311,299)	-	(114,145)
Gain on remeasuring investments	623,702,191	15,020,400	638,722,591	-	20,808,701	659,531,292
Fair value adjustment of assets regarding						
business combinations	120,334,117	-	120,334,117	(3,651,412)	(10,888,000)	105,794,705
Total	744,233,462	15,020,400	759,253,862	(3,962,711)	9,920,701	765,211,852
Deferred tax assets (liabilities) - net	(672,781,402)					(704,246,914)

Baht				
Consolidated financial statements				
	Balance as at	Revenue (expenses) during the year		Balance as at
	December 31, 2018	In profit or loss	In other comprehensive income	December 31, 2019
Deferred tax assets:				
Trade receivables		13,865,194	(6,892,858)	6,972,336
Employee benefits obligations		29,827,360	11,913,216	48,344,002
Straight line method of rental		14,604,569	1,145,923	15,750,492
Unrealized loss on remeasuring available-for-sale investments		1,329,071	-	(1,329,071)
Other		385,230	-	385,230
Total		60,011,424	6,166,281	71,452,060
Deferred tax liabilities:				
Financial lease contracts		(236,436)	(433,590)	197,154
Unrealized gain on remeasuring available-for-sale investments		477,592,211	-	(146,109,980)
Fair value adjustment of assets regarding business combinations		124,042,759	3,708,642	120,334,117
Total		601,398,534	3,275,052	744,233,462
Deferred tax assets (liabilities) - net		(541,387,110)		(672,781,402)

	Baht			
	Separate financial statements			
	Balance as at	Revenue (expenses) during the year		Balance as at
	December 31, 2019	In profit or loss	In other comprehensive income	December 31, 2020
Deferred tax assets:				
Trade receivables	283,917	171,695	-	455,612
Employee benefits obligations	14,508,265	1,432,637	-	15,940,902
Total	14,792,182	1,604,332	-	16,396,514
Deferred tax liabilities:				
Financial lease contracts	197,154	(311,298)	-	(114,144)
Unrealized gain on remeasuring available-for-sale investments	122,502,461	-	62,008,279	184,510,740
Total	122,699,615	(311,298)	62,008,279	184,396,596
Deferred tax assets (liabilities) - net	(107,907,433)			(168,000,082)

	Baht			
	Separate financial statements			
	Balance as at	Revenue (expenses) during the year		Balance as at
	December 31, 2018	In profit or loss	In other comprehensive income	December 31, 2019
Deferred tax assets:				
Trade receivables	239,163	44,754	-	283,917
Employee benefits obligations	10,693,526	2,771,946	1,042,793	14,508,265
Straight line method of rental	16,000	(16,000)	-	-
Total	10,948,689	2,800,700	1,042,793	14,792,182
Deferred tax liabilities:				
Financial lease contracts	(236,436)	(433,590)	-	197,154
Unrealized gain on remeasuring available-for-sale investments	46,042,938	-	(76,459,523)	122,502,461
Total	45,806,502	(433,590)	(76,459,523)	122,699,615
Deferred tax assets (liabilities) - net	(34,857,813)			(107,907,433)

20. BANK OVERDRAFTS AND SHORT-TERM LOANS FROM FINANCIAL INSTITUTIONS

Consisted of:

	Baht			
	Consolidated financial statements		Separate financial statements	
	2020	2019	2020	2019
Bank overdrafts	6,899,659	2,944,206	-	-
Short-term loans from financial institutions	2,599,000,000	2,675,000,000	1,870,000,000	2,045,000,000
Total	2,605,899,659	2,677,944,206	1,870,000,000	2,045,000,000

As at December 31, 2020 and 2019, the Company and its subsidiaries had overdraft and short-term loan facilities with several domestic financial institutions amounted to Baht 4,580 million and Baht 3,515 million (the Separate amount of Baht 3,495 million and Baht 2,565 million), respectively. The interest bear at the rates of MOR and 2.38 - 4.20% per annum and rates of MOR and 2.38 - 4.20% per annum, respectively, and guaranteed by the investment property of the Company guaranteed by the investment property of the Company and its subsidiaries, land with construction and buildings of the Company and its subsidiaries and guaranteed by the shares of associated company and shares of subsidiaries as discussed in Notes 13,14,15 and 16 to the financial statements.

21. LOANS FROM RELATED PARTIES

Changes in the loans from related parties for the years ended December 31, 2020 and 2019 were summarized as follows:

	Baht				
	Consolidated financial statements				
	As at December	Transaction during the year			As at December
	31, 2019	Increase	Decrease		31, 2020
<u>Associated company</u>					
Bangpo General Hospital Co., Ltd.					
Long-term	-	70,000,000	-	70,000,000	
Related company					
Green Resources Public Co., Ltd.					
Long-term	-	27,000,000	(7,000,000)	20,000,000	
<u>Related persons</u>					
Company's directors and relative					
Short-term	633,053,818	-	(257,800,000)	375,253,818	
Long-term	176,000,000	227,000,000	(209,000,000)	194,000,000	
Total	<u>809,053,818</u>	<u>324,000,000</u>	<u>(473,800,000)</u>	<u>659,253,818</u>	
Baht					
Consolidated financial statements					
As at December	Transaction during the year		As at December		
31, 2018	Increase	Decrease	31, 2019		
<u>Related persons</u>					
Company's directors and relative					
Short-term	589,853,818	64,000,000	(20,800,000)	633,053,818	
Long-term	192,000,000	312,000,000	(328,000,000)	176,000,000	
Total	<u>781,853,818</u>	<u>376,000,000</u>	<u>(348,800,000)</u>	<u>809,053,818</u>	

	Baht				
	Separate financial statements				
	As at December	Transaction during the year			As at December
	31, 2019	Increase	Decrease		31, 2020
<u>Associated company</u>					
Bangpo General Hospital Co., Ltd.					
Long-term	-	70,000,000	-	70,000,000	
<u>Related company</u>					
Green Resources Public Co., Ltd.					
Long-term	-	27,000,000	(7,000,000)	20,000,000	
<u>Related persons</u>					
Company's directors and relative					
Long-term	176,000,000	227,000,000	(209,000,000)	194,000,000	
Total	<u>176,000,000</u>	<u>324,000,000</u>	<u>(216,000,000)</u>	<u>284,000,000</u>	

	Baht				
	Separate financial statements				
	As at December	Transaction during the year			As at December
	31, 2018	Increase	Decrease		31, 2019
<u>Related persons</u>					
Company's directors and relative					
Long-term	192,000,000	312,000,000	(328,000,000)	176,000,000	

Related persons

As at December 31, 2020 and 2019, the Company had loans from related persons in term of promissory notes, by issuing the 11 and 11 promissory notes, respectively which is due within 2 years and interest payable on quarterly basis at the interest rate of 2.75% - 3.00% per annum and 3.00% - 3.50% per annum, respectively, under the condition that lenders are able to call for their loans before maturity and the Company can repay its loans before maturity

As at December 31, 2020 and 2019, the subsidiaries had short-term loans from related parties in term of promissory notes for a period of repayment 3 months and interest at the rates of 2.94% - 3.35% per annum and rate of 3.50% - 4.50% per annum, respectively. Such loans have on any securities guaranteed.

Associated company

As at December 31, 2020, the Company had loans from related company in term of promissory notes which is due within June 30, 2021 and interest payable on quarterly basis at the interest rate of 2.75% per annum.

22. SHORT-TERM LOANS FROM OTHER PERSONS

Changes in the short-term loans from other persons for the years ended December 31, 2020 and 2019 were summarized as follows:

	Baht			
	Consolidated financial statements			
	As at December	Transaction during the year		As at December
	31, 2019	Increase	Decrease	31, 2020
Other persons	70,800,000	28,000,000	(13,500,000)	85,300,000

	Baht			
	Consolidated financial statements			
	As at December	Transaction during the year		As at December
	31, 2018	Increase	Decrease	31, 2019
Other persons	68,400,000	6,000,000	(3,600,000)	70,800,000

As at December 31, 2020 and 2019, the subsidiaries had short-term loans from other persons in term of promissory notes for a period of repayment 3 months and interest at the rates of 2.94% - 3.75% per annum and rate of 3.75% - 4.00% per annum, respectively. Such loan has no any securities guaranteed.

23. LONG-TERM LOANS FROM FINANCIAL INSTITUTIONS

Consisted of:

	Baht			
	Consolidated financial statements		Separate financial statements	
	2020	2019	2020	2019
Long-term loans	4,556,465,513	3,503,390,508	2,039,175,230	1,823,252,413
<u>Less</u> Current portion	(1,065,160,006)	(843,183,339)	(563,345,720)	(447,679,053)
Net	3,491,305,507	2,660,207,169	1,475,829,510	1,375,573,360

Changes in the long-term loans from the financial institutions for the years ended December 31, 2020 and 2019 were as follows :

	Baht			
	Consolidated financial statements		Separate financial statements	
	2020	2019	2020	2019
Balance, beginning of the year	3,503,390,508	2,105,354,098	1,823,252,413	1,067,661,716
Addition loan during the year	2,013,000,000	2,364,858,130	760,000,000	1,414,858,130
Repayment of loan during the year	(959,924,995)	(966,821,720)	(544,077,183)	(659,267,433)
Balance, end of the year	4,556,465,513	3,503,390,508	2,039,175,230	1,823,252,413

As at December 31, 2020 and 2019, the Company and its subsidiaries had long-term loan facilities from local commercial banks in the amount of Baht 7,475 million and Baht 7,035 million (the Separate amount of Baht 2,915 million and Baht 3,315 million), respectively, consist of:

The Company had loans from a local commercial bank consist of:

The first loan: On May 20, 2015, the Company entered into a loan agreement in Baht currency with a local commercial bank in the credit facility amount of Baht 200 million (withdrawal at once). The principal will be repaid by monthly basis at Baht 3.70 million and has grace period for 7 months after first withdrawal. The loan has a term of repayment within 54 months and the first installment of loans on November 2015, bear interest at the rate of 3.80% per annum. As at December 31, 2019, loan balance of Baht 15.00 million and in 2020, the Company had fully paid the principal.

The second loan: On October 9, 2015 the Company entered into a loan agreement in Baht currency with a local commercial bank in the credit facility amount of Baht 200 million (withdrawal at once). The principal will be repaid by monthly basis at Baht 3.70 million and has grace period for 7 months after first withdrawal. The loan has a term of repayment within 54 months and the first installment of loans on April 2016, bear interest at the rate of 3.80% per annum. As at December 31, 2019, loan balance of Baht 3.50 million and in 2020, the Company had fully paid the principal.

The third loan: On October 26, 2016, the Company entered into a loan agreement in Baht currency with a local commercial bank in the credit facility amount of Baht 200 million has been withdrawal amounting to Baht 160 million. The principal will be repaid by monthly basis at Baht 4.17 million and has grace period for 12 months after first withdrawal. The loan has a term of repayment within 60 months and the first installment of loans on October 2017, bear interest at the rate of 3.90% per annum. As at December 31, 2019, loan balance of Baht 56.58 million and in 2020, the Company had fully paid the principal.

The fourth loan: On June 16, 2017, the Company entered into a loan agreement in Baht currency with a local commercial bank in the credit facility amount of Baht 200 million which has been withdrawn amounting to Baht 200 million. The loan has a term of repayment within 36 months. The principal will be repaid by monthly basis at Baht 6.67 million after withdrawal the sixth installment of loan. The interest at the rate of short-term THBFIX 6 month (6M THBFIX) plus 1.35% per annum. The Company has entered into hedging agreement from interest rate with such bank at the fixed interest rate of 3.60% per annum. As at December 31, 2019, loan balance of Baht 39.92 million and in 2020, the Company had fully paid the principal.

The fifth loan: On July 17, 2017, the Company entered into a loan agreement in Baht currency with a local commercial bank in the credit facility amount of Baht 200 million which has been withdrawn amounting to Baht 165 million. The loan has a term of repayment within 36 months. The principal will be repaid by monthly basis at Baht 6.67 million after withdrawal the sixth installment of loan. The interest at the rate 3.60% per annum. As at December 31, 2019, loan balance of Baht 4.92 million and in 2020, the Company had fully paid the principal.

The sixth loan: On September 11, 2017, the Company entered into a loan agreement in Baht currency with a local commercial bank in the credit facility amount of Baht 200 million which has been withdrawn amounting to Baht 190 million. The loan has a term of repayment within 36 months. The principal will be repaid by monthly basis at Baht 6.33 million after withdrawal the sixth installment of loan. The interest at the rate 3.40% per annum for the first Baht 50 million and 3.25% for Baht 140 million. As at December 31, 2019, loan balance of Baht 43.33 million and in 2020, the Company had fully paid the principal.

The seventh loan: On July 15, 2018, the Company entered into a loan agreement with a local commercial bank in the credit facility amount of Baht 200 million which has been withdrawn fully amount. The loan has a term of repayment within 36 months. The principal will be repaid by monthly basis at Baht 6.67 million after withdrawal the sixth installment of loan. The interest at the rate of short-term THBFIX 6 month (6M THBFIX) plus 1.35% per annum. The Company has entered into hedging agreement from interest rate with such bank at the fixed interest rate of 3.40% per annum. As at December 31, 2020 and 2019, loan balance of Baht 39.92 million and Baht 119.96 million, respectively.

The eighth loan: On November 1, 2018, the Company entered into a loan agreement in Baht currency with a local commercial bank in the credit facility amount of Baht 300 million which has been withdrawn amounting to Baht 230 million. The loan has a term of repayment within 36 months after withdrawal the first installment of loan. The interest at the rate 3.60% per annum. As at December 31, 2020 and 2019, loan balance of Baht 178.00 million and Baht 220.00 million, respectively.

The ninth loan: On February 12, 2019, the Company entered into a loan agreement with a local commercial bank in the credit facility amount of Baht 420 million which has been withdrawn fully amount. The loan has a term of repayment within 60 months. The interest at the rate of 1 year fixed deposit plus 1.75% per annum. As at December 31, 2020 and 2019, loan balance of Baht 316.16 million and Baht 372.80 million, respectively.

The loan was repaid principal on monthly basis are as follows:

<u>After withdrawal the first installment of loan</u>	<u>Repaid by monthly (Million Baht)</u>
Installment 1-24	4.72
Installment 25-59	8.57
Installment 60	Repay the rest of principal and interest under the loan agreement

The tenth loan: On February 14, 2019, the Company entered into a loan agreement with a local commercial bank in the credit facility amount of Baht 800 million which has been withdrawn fully amount. The loan has a repayment term of 84 months with the principal payment monthly at Baht 10.26 million per month after withdrawal the sixth installment. The interest at the rate MLR minus 3.60% per annum. As at December 31, 2020 and 2019, loan balance of Baht 638.09 million and Baht 752.38 million, respectively.

The eleventh loan: On November 19, 2019 the Company entered into a loan agreement in Baht currency with a local commercial bank in the credit facility amount of Baht 194.86 million which has been withdrawn fully amount. The loan has a repayment term of 60 months with the principal payment quarterly at Baht 10.00 million per 3 months after withdrawal. The interest at the rate 3.80% per annum. As at December 31, 2020 and 2019, loan balance of Baht 147.00 million and Baht 194.86 million, respectively.

The twelfth loan: On May 24, 2020, the Company entered into a loan agreement with a local commercial bank in the credit facility amount of Baht 300 million which has been withdrawn amounting to Baht 260 million. The loan has a term of repayment within 36 months. The interest as the rate of 3.60% per annum. As at December 31, 2020, loan balance of Baht 260.00 million.

The thirteenth loan: On July 7, 2020, the Company entered into a loan agreement with a local commercial bank in the credit facility amount of Baht 500 million which has been withdrawn amounting to Baht 330 million, the loan has a repayment term of 60 months with principal payment monthly at Baht 8 million per month. The interest at the rate of 3.80% per annum. As at December 31, 2020, loan balance of Baht 460.00 million.

Its subsidiaries had loans from the local commercial bank consist of:

Chiang Mai Ram Medical Business Public Co.,Ltd.

The fourteenth loan: On August 26, 2016, Chiang Mai Ram Medical Business Public Co.,Ltd. Has entered into a loan agreement in Baht currency with a local commercial bank in the credit facility amount Baht 370 million which has been withdrawn amounting to Baht 370 million. The loan has a tem of repayment within 60 months. The principal will be repaid by monthly basis at Baht 6.17 million, bear interest at the rate of 3 month fixed deposit plus per 2% annum. As at December 31, 2020 and 2019, loan balance of Baht 49.16 million and Baht 123.20 million, respectively

The fifteenth loan: On August 16, 2019, the subsidiary entered into a loan agreement in Baht currency with a local commercial bank in the credit facility amount of Baht 1,200 million which has been withdrawn amounting to Baht 400 million. The loan has a term of repayment within 72 months by starting the loan repayment from the 9th month since the contract date. The interest at the rate of MLR - 3.668% per annum. As at December 31, 2020 and 2019, loan balance of Baht 941.90 million and Baht 400.00 million, respectively.

The loan was repaid principal on monthly basis are as follows:

<u>After withdrawal the first installment of loan</u>	<u>Repaid by monthly (million baht)</u>
Installment 1 - 71	8.30
Installment 72	Repay the rest of principal and interest under the loan agreement

Chiang Mai Ram Hospital Co., Ltd

The sixteenth loan: On June 17, 2016, Chiang Mai Ram Hospital Co.,Ltd. Has entered into a loan agreement in Baht currency with a local commercial bank in the credit facility amount Baht 250 million which has been withdrawn amounting Baht 250 million. The loan has a repayment term of 60 months with the principal payment monthly at Baht 4.20 per month at the interest rate of MLR minus 2% per annum. As at December 31, 2020 and 2019, loan balance of Baht 23.20 million and Baht 73.60 million, respectively.

The seventeenth loan: On May 24, 2017, Chiang Mai Ram Hospital Co., Ltd., entered into a loan agreement in Baht currency with a local commercial bank in the credit facility amount of Baht 600 million which has been withdrawn amounting to Baht 600 million. The loan has a term of repayment within 84 months. The interest at the rate of 1 year fixed deposit plus 1.75% per annum. As at December 31, 2020 and 2019, loan balance of Baht 319.80 million and Baht 413.40 million, respectively.

The loan was repaid principal on monthly basis are as follows:

<u>After withdrawal the first installment of loan</u>	<u>Repaid by monthly (million baht)</u>
Installment 1-24	5.50
Installment 25-83	7.80
Installment 84	Repay the rest of principal and interest under the loan agreement

The eighteenth loan: On March 14, 2019, Chiang Mai Ram Hospital Co., Ltd., entered into a loan agreement with a local commercial bank in the credit facility amount of Baht 250 million which has been withdrawn fully amount. The loan has a term of repayment within 60 months. The interest at the rate of 1 year fixed deposit plus 1.75% per annum. As at December 31, 2020 and 2019, loan balance of Baht 161.80 million and Baht 212.20 million, respectively.

The loan was repaid principal on monthly basis are as follows:

<u>After withdrawal the first installment of loan</u>	<u>Repaid by monthly (million baht)</u>
Installment 1 - 59	4.20
Installment 60	Repay the rest of principal and interest under the loan agreement

The nineteenth loan: On August 16, 2019, the Company entered into a loan agreement in Baht currency with a local commercial bank in the credit facility amount of Baht 800 million which has been withdrawn amounting to Baht 300 million. The loan has a term of repayment within 72 months by starting the loan repayment from the 9th month since the contract date. The interest at the rate of MLR - 3.668% per annum. As at December 31, 2020 and 2019, loan balance of Baht 355.41 million and Baht 300.00 million, respectively.

The loan was repaid principal on monthly basis are as follows:

<u>After withdrawal the first installment of loan</u>	<u>Repaid by monthly (million baht)</u>
Installment 1 - 71	4.75
Installment 72	Repay the rest of principal and interest under the loan agreement

Theppanya Business Co.,Ltd.

The twentieth loan: On June 2, 2017, Theppanya Business Co., Ltd., entered into a loan agreement in Baht currency with a local commercial bank in the credit facility amount of Baht 250 million which has been withdrawn amounting to Baht 250 million. The loan has a term of repayment within 84 months. The principal will be repaid by monthly basis at Baht 2.98 million after withdrawal the first installment of loan. The interest at the rate 3.50% per annum. As at December 31, 2020 and 2019, loan balance of Baht 122.02 million and Baht 157.74 million, respectively.

The twentieth one loan: On December 21, 2020, Theppanya Business Co., Ltd., entered into a loan agreement in Baht currency with a local commercial bank in the credit facility amount of Baht 40 million which has been withdrawn amounting to Baht 40 million. The loan has a term of repayment within 60 months. The principal will be repaid by monthly basis at Baht 0.67 million after withdrawal the first installment of loan. The interest at the rate 3.00% per annum. As at December 31, 2020, loan balance of Baht 40.00 million.

Hariphunchai Memorial Hospital Co., Ltd.

The twentieth two loan: On January 17, 2019, Hariphunchai Memorial Hospital Co., Ltd. entered into a loan agreement in Baht currency with a local commercial bank in the credit facility amount of Baht 800 million which has been withdrawn amounting to Baht 132 million. The loan has a term of repayment within 60 months. The interest at the rate of MLR - 3.55% per annum. As at December 31, 2020, loan balance of Baht 504.00 million.

The loan was repaid principal on monthly basis are as follows:

<u>After withdrawal the first installment of loan</u>	<u>Repaid by monthly (Baht)</u>
Installment 1 - 16	1,000,000
Installment 17 - 40	4,000,000
Installment 41 - 59	8,500,000
Installment 60	Repay the rest of principal and interest under the loan agreement

These long-term loans from the financial institutions were secured by the mortgage of the Company's and its subsidiaries' land with construction, plant and medical equipment and investment property and pledged this share of subsidiaries and related company as discussed in Note 12,14 and 16 to the financial statements.

24. LEASE LIABILITIES

The carrying amounts of lease liabilities and the movement for the year ended December 31, 2020 are presented below.

	Baht	
	Consolidated financial statements	Separate financial statements
Balance as at December 31, 2019	13,245,019	11,819,123
The impacts of the adoption of TFRS 16	332,520,444	21,061,449
Balance as at January 1, 2020	345,765,463	32,880,572
Increase of interest	11,906,587	1,266,422
Payments	(35,500,541)	(8,284,560)
Balance as at December 31, 2020	322,171,509	25,862,434
<u>Less</u> Current portion due within one year	(24,963,097)	(7,264,729)
Lease liabilities - net of current portion	<u>297,208,412</u>	<u>18,597,705</u>

The following are the amounts recognized in profit or loss:

	Baht	
	Consolidated financial statements	Separate financial statements
Depreciation of right-of-use assets	33,824,770	7,634,749
Interest expense on lease liabilities	12,391,189	1,266,422
Leases of low - value assets	390,470	330,470
Total	<u>46,606,429</u>	<u>9,231,641</u>

As at December 31, 2020 and 2019, the Company and its subsidiaries had outstanding financial leases agreements with several local leasing companies comprised of 11 agreements and 10 agreements, respectively as follows:

The Company had outstanding finance leases agreements of vehicle and medical equipment of 8 agreements and 8 agreements, respectively, in the total leases amount of Baht 19.65 million and Baht 19.65 million, respectively with a term of payment in 48 - 60 months, and repaid in monthly of Baht 0.36 million and Baht 0.36 million, respectively.

The subsidiaries had outstanding finance leases agreements of vehicle of agreements in the total leases amount of Baht 4.14 million with a term of payment in 60 months, and repaid in monthly of Baht 0.07 million.

Under the term of leases agreement referred to above the Company and its subsidiaries will have to comply with certain conditions and restrictions as specified in the leases agreements.

25. EMPLOYEE BENEFIT OBLIGATIONS

The statements of financial position

	Baht			
	Consolidated financial statements		Separate financial statements	
	2020	2019	2020	2019
Defined benefit obligations at the beginning of the year	241,720,015	149,136,803	72,541,329	53,467,632
Benefits paid by the plan	(6,776,976)	(6,085,030)	(3,376,808)	(3,019,401)
Past service costs and interest				
- change a considered a post-employment plan amendment	-	36,825,219	-	8,247,818
Current service costs and interest	37,417,058	28,825,897	10,539,987	8,631,316
Actuarial (gain) loss on define employee benefit plans	(4,032,757)	33,017,126	-	5,213,964
Defined benefit obligations at the end of the year	<u>268,327,340</u>	<u>241,720,015</u>	<u>79,704,508</u>	<u>72,541,329</u>

Expenses recognized in the statement of comprehensive income

For the years ended December 31, 2020 and 2019

	Baht			
	Consolidated financial statements		Separate financial statements	
	2020	2019	2020	2019
Past service costs and interest	-	36,825,219	-	8,247,818
Current service costs				
Cost of medical treatment	23,408,933	14,612,789	5,965,317	4,308,690
Administrative expenses	9,028,744	7,028,072	3,065,584	2,122,627
Management benefit expenses	45,102	28,548	-	-
Interest on obligation	4,934,279	7,156,488	1,509,086	2,199,999
Total	<u>37,417,058</u>	<u>65,651,116</u>	<u>10,539,987</u>	<u>16,879,134</u>

Gain (loss) from the estimate based on actuarial principles recognized in the other comprehensive income for the years ended December 31, 2020 and 2019 arise from :-

	Baht			
	Consolidated financial statements		Separate financial statements	
	2020	2019	2020	2019
Improvement from experience	5,013,937	(10,812,402)	-	(489,722)
Demographic assumption	-	12,603,449	-	13,465,010
Financial assumption	(981,180)	(34,808,173)	-	(18,189,252)
Total	<u>4,032,757</u>	<u>(33,017,126)</u>	<u>-</u>	<u>(5,213,964)</u>

Principal actuarial assumptions in the estimates base on the actuarial principles.

	Percentage			
	Consolidated financial statements		Separate financial statements	
	2020	2019	2020	2019
Discount rate	1.53 - 2.76	1.67 - 2.76	1.85	1.85
Salary increase rate	3.00 - 6.12	3.00 - 6.12	6.00	6.00
Employee turnover rate	0.00 - 26.37	0.00 - 26.37	0.00 - 20.45	0.00 - 20.45
Disability rate	10.00 of mortality rate	10.00 of mortality rate	10.00 of mortality rate	10.00 of mortality rate
Mortality rate	100.00 of mortality rate	100.00 of mortality rate	100.00 of mortality rate	100.00 of mortality rate
	according to Thai	according to Thai	according to Thai	according to Thai
	mortality table 2017 male	mortality table 2017 male	mortality table 2017	mortality table 2017
	and female tables	and female tables	male and female tables	male and female tables

Sensitivity analysis

The results of sensitivity analysis for significant assumptions that affect the present value of the long-term employee benefit obligations as at December 31, 2020 and 2019 are summarized below:

	Baht			
	Consolidate financial statements		Separate financial statements	
	2020	2019	2020	2019
Discount rate				
1% Increase	(34,484,004)	(33,830,333)	(9,011,710)	(8,131,815)
1% Decrease	44,721,389	39,134,788	10,875,770	9,780,064
Salary increase rate				
1% Increase	45,740,243	37,489,350	11,175,936	9,270,346
1% Decrease	(36,021,307)	(31,275,871)	(9,457,052)	(7,912,471)
Turnover rate				
10% Increase	(12,361,822)	(11,716,664)	(4,435,835)	(3,942,156)
10% Decrease	15,748,302	12,918,266	4,967,530	4,403,269

On April 5, 2019, the Labour Protection Act has been enacted in the Royal Gazette. The Labour Protection Act includes a requirement that an employee who is terminated after having been employed by the same employer for an uninterrupted period of 20 years or more, receives severance payment of 400 days of wages at the most recent rate, which is increased from the current maximum rate of 300 days. This Act shall come into force after the expiration of thirty days from the enacted date in the Royal Gazette onwards. This change is considered a post-employment benefits plan amendment. The effect of the change is recognized past service costs as expenses in the income statement.

26. SHARE CAPITAL

At the Annual General Meeting of Shareholders of the company for the year 2015 held on April 28, 2015, the shareholders approved an issuance of the warrant to purchase of ordinary share of Vibhavadi Medical Center Public Company Limited No. 2 (VIBHA-W2) at the amount of 1,048,097,120 units to the Company's existing shareholders at a ratio of 12 existing shares per 1 warrant and on June 15, 2015, the Company issued such warrants at free of charge to the Company's existing shareholders on a proportion basis. Details of which are as follows:

Type of warrant	:	Warrants to purchase of ordinary shares of Vibhavadi Medial Center Public Company Limited Series#2 (VIBHA-W2)
Type	:	Transferable named certificate
Offering / Allocation	:	Offered to existing shareholders
Amount of warrants	:	1,048,093,059 units
Offering price	:	Baht 0 per unit
Terms of warrants	:	5 years from the issuing date
Exercise ratio	:	1 unit of warrant per new 1 ordinary share
Exercise price	:	Baht 1.00 per share
Exercise period	:	On the last business day of September throughout the warrant term
First exercise date	:	September 30, 2015
Last exercise date	:	June 12, 2020

At the Annual General Meeting of Shareholders of the Company for the year 2017 held on April 27, 2017, the shareholders approved an issuance of the warrant to purchase of ordinary share of Vibhavadi Medical Center Public Company Limited No. 2 (VIBHA-W3) at the amount of 1,012,587,386 units to the Company's existing shareholders at a ratio of 13 existing shares per 1 warrant and on June 15, 2017, the Company issued such warrants at free of charge to the Company's existing shareholders on a proportion basis. Details of which are as follows:

Type of warrant	:	Warrants to purchase of ordinary shares of Vibhavadi Medial Center Public Company Limited Series#3 (VIBHA-W3)
Type	:	Transferable named certificate
Offering / Allocation	:	Offered to existing shareholders
Amount of warrants	:	1,012,582,207 units
Offering price	:	Baht 0 per unit
Terms of warrants	:	5 years from the issuing date
Exercise ratio	:	1 unit of warrant per new 1 ordinary share
Exercise price	:	Baht 3.00 per share
Exercise period	:	On the last business day of September throughout the warrant term
First exercise date	:	September 30, 2017
Last exercise date	:	June 14, 2022

And at the Annual General Meeting of Shareholders of the Company for the year 2017 held on April 27, 2017, and the Extraordinary General Meeting No.1/2017 held on November 21, 2017, to allocate the warrants to purchase ordinary shares of the Company to directors and employees of the company and/or its subsidiaries

(ESOP-W2) amount 300 million units and on June 15, 2018, the Company issued such warrants at free of charge. Details of which are as follows:

Type of warrant	:	warrants to purchase ordinary shares of the Company to directors and employees of the company and/or its subsidiaries (ESOP-W2)
Offering / Allocation	:	Offered to the Company to directors and employees of the company and/or its subsidiaries
Amount of warrants	:	300,000,000 units
Offering price	:	Baht 0 per unit
Terms of warrants	:	5 years from the issuing date
Exercise ratio	:	1 unit of warrant per new 1 ordinary share
Exercise price	:	Baht 3.00 per share
Exercise period	:	On the last business day of September throughout the warrant term
First exercise date	:	September 28, 2018
Last exercise date	:	June 14, 2023

At the Annual General Meeting of Shareholders of the Company for the year 2018 held on April 26, 2018, the meeting has resolved to approved the annual dividend payment at the rate of Baht 0.036 per share or 90.66 percent of the Company's net profit (based on the Company's separate financial statements). Since the condition of rights adjustment pursuant to Clause 5.5 of the warrants covenants of rights and duties of the issuer and holders of the warrants to purchase ordinary shares of the company no.2 and 3 (VIBHA-W2 and VIBHA-W3), effective date for adjust on May 9, 2018.

Therefore, the Company will have adjustment of rights of the warrants to purchase ordinary shares of the Company No.2 and 3 (VIBHA-W2 and VIBHA-W3). The Exercise price and Exercise ratio as follows:

1. VIBHA-W2

New Exercise price	:	Baht 0.999 per share
New Exercise ratio	:	1 warrant shall be entitled to purchase 1.00086 ordinary shares

2. VIBHA-W3

New Exercise price	:	Baht 2.997 per share
New Exercise ratio	:	1 warrant shall be entitled to purchase 1.00086 ordinary shares

Movements of the Company's warrants during the year are as follows :-

Warrant	Units				
	Number of warrants outstanding as at December 31, 2019	Number of warrants issued during the period	Number of warrants exercised during the period	Number of warrants not exercised during the period	Number of warrants outstanding as at December 31, 2020
VIBHA-W2	361,657,614	-	310,981,154	50,676,460	-
VIBHA-W3	1,011,623,932	-	-	-	1,011,623,932
ESOP-W2	300,000,000	-	-	-	300,000,000
Total	1,673,281,546	-	310,981,154	50,676,460	1,311,623,932

The exercises warrants for the years ended December 31, 2020 and 2019 and registration of share increasing for exercised warrants were summarized as follows:

				Baht		
				Consolidated / Separate financial statements		
				2020		
Warrant	Exercise date	Registration of share date	Number of Exercised warrant	Share capital increase	Share premium account	Amount
VIBHA-W2	June 12,2020	July 9, 2020	310,981,154	31,124,830	279,812,226	310,937,056
			310,981,154	31,124,830	279,812,226	310,937,056
				Baht		
				Consolidated / Separate financial statements		
				2019		
Warrant	Exercise date	Registration of share increasing date	Number of Exercised warrant	Share capital increase	Share premium account	Amount
VIBHA-W2	September 30, 2019	October 11, 2019	65,039,132	6,509,505	58,520,450	65,029,955
VIBHA-W3	September 30, 2019	October 11, 2019	153,846	15,398	446,074	461,472
			65,192,978	6,524,903	58,966,524	65,491,427

27. LEGAL RESERVE

Under the provisions of the Limited Public Company Act B.E 2535, the Company is required to appropriate at least 5 % of its annual net income after deduction of the deficit brought forward (if any) as legal reserve until the reserve equal to 10 % of authorized share capital. The reserve is not available for dividend distribution. As at December 31, 2019, the Company appropriated the legal reserve amounted to Baht 2.92 million.

28. APPROPRIATION OF RETAINED EARNING

For the Company

At the Annual General Meeting of Shareholders for the year 2020, held on April 29, 2020, the shareholders approve the payment of dividends to the shareholders of the Company for the performance result of the fiscal year 2019, at the rate of Baht 0.045 per share, totaling Baht 596.91 million and the appropriation of profits as a legal reserve in the amount of Baht 2.93 million. The Company fixed the names of shareholders who are entitled to received dividend, whose names appear in the Register of Shareholders on May 11, 2020. The Company paid the dividends to the shareholders on May 27, 2020.

At the Annual General Meeting of shareholders of the Company for the year 2019, held on April 29, 2019, the shareholders approved the dividend payment of for the performance result of the fiscal year 2018, at the rate of Baht 0.040 per share, totaling Baht 527.97 million and the appropriation of profits as a legal reserve in the amount of Baht 14.48 million. The Company fixed the names of shareholders who are entitled to received dividend, whose names appear in the Register of Shareholders on May 9, 2019. The dividend was paid to the shareholders on May 23, 2019.

For the subsidiary company - Chiang Mai Ram Medical Business Public Co., Ltd.

At the Annual General Meeting of Shareholders of a direct subsidiary for the year 2020, held on April 29, 2020, the shareholders approved the dividend payment for the operating result from January 1, 2019 to December 31, 2019 at Baht 0.0585 per share to shareholders of 4,023.13 million ordinary shares amounting to Baht 235.35 million. The shareholders whose names appear in the Share Register as at March 17, 2020, shall be entitled to receive the dividends. Such subsidiary paid the dividends to the shareholders on May 25, 2020.

At the Annual General Meeting of Shareholders of a direct subsidiary for the year 2019, held on April 29, 2019, the shareholders approved the dividend payment for the operating result from January 1, 2018 to December 31, 2018 at Baht 0.052 per share to shareholders of 4,023.13 million ordinary shares amounting to Baht 209.20 million. The shareholders whose names appear in the Share Register as at March 15, 2019, shall be entitled to receive the dividends. The dividends was paid to the shareholders on May 15, 2019.

For the indirect subsidiary company - Chiang Mai Ram Hospital Co., Ltd.

At the Annual General Meeting of the shareholder's subsidiary company for the year 2020 held on April 25, 2020, the shareholders approved to pay dividend for the year 2019 from the operating result since January 1, 2019 to December 31, 2019 at the rate of Baht 2.50 per share, totaling Baht 100 million. The dividends was paid to the shareholders on February 23, 2021.

At the Annual General Meeting of the shareholder's subsidiary company for the year 2019, held on April 27, 2019, the shareholders approved to pay dividend for the year 2018 from the operating result since January 1, 2018 to December 31, 2018 at the rate of Baht 2.50 per share, totaling Baht 100.00 million. The dividend was paid to shareholders on May 15, 2019.

For the indirect subsidiary company - Hariphunchai Memorial Hospital Co., Ltd.

At the Annual General Meeting of the shareholder's subsidiary company for the year 2019, held on April 27, 2019, the shareholders approved to pay dividend for the year 2018 from the operating result since January 1, 2018 to December 31, 2018 at the rate of Baht 0.50 per share, totaling Baht 15.00 million. The dividend was paid to shareholders on May 31, 2019.

29. CAPITAL MANAGEMENT

The primary objective of capital management of the Company and its subsidiaries is to ensure that it has an appropriate financial structure and preserves the ability to continue its business as a going concern. According to the statement of financial position as at December 31, 2020, the Group's debt-to-equity ratio was 0.99 : 1 (as at December 31, 2019 was 0.89 : 1) and the Company's was 0.80 : 1 (as at December 31, 2019 was 0.87: 1).

30. REVENUE FROM SOCIAL SECURITY

In 2019, the Social Security Office had notified by the letter informing the results of the examination of the use of medical services in the case of high-cost diseases in 2016 and 2017 by the random data checking for medical services. The Social Security Office had found the incorrect percentage of AdjRW from the amount that the hospital should receive. But the subsidiaries were able to proceed with the dispute according to the period specified by the Social Security Office. However, the subsidiaries expected that the medical service fees would be refunded from the Social Security Office from information and past experience amounted Baht 187.25 million by calculating from the percentage information of AdjRW that the Social Security Office had found incorrect.

Therefore, the subsidiaries agreed to the results of the examination of medical service in 2015 due to the above transaction that was under the appeal would also be refunded amounted Baht 64.08 million by calculating from the percentage information of AdjRW that the Social Security Office had found incorrect. The subsidiaries recorded the reduction of the revenue from the medical treatment in the statement of comprehensive income for the year 2019 with the same amount. Later in 2020, the subsidiaries had received the letter of appeal notification from the Social Security Office but the appeal did not work. The management reviewed the recoverable amount for the year 2015 in the total amount of Baht 92.01 million. the subsidiaries recorded the reduction of the medical treatment in the statement of comprehensive income for year ended December 31, 2020 in the amount of Baht 36.45 million.

From information and past experience, the subsidiaries expected that the medical service fees would be refunded, in 2020, the subsidiaries recorded the money received from the Social Security Office amount Baht 43.92 million as at advance received from the Social Security Office.

As at December 31, 2020 and 2019, the balance funds received in advance from Social Security Office is Baht 331.69 million and Baht 251.32 million, respectively.

31. EXPENSES BY NATURE

Significant expenses by nature for the years ended December 31, 2020 and 2019 were as follows:

	Baht			
	Consolidated financial statements		Separate financial statements	
	2020	2019	2020	2019
Medical supplies and other supplies	1,040,987,066	1,040,987,066	312,491,672	350,004,057
Expenses from external medical service	172,802,935	172,802,935	67,898,628	39,926,535
Cost of lab and x-ray	135,557,879	135,557,879	26,938,699	33,180,828
Doctor fee	1,475,902,925	1,475,902,925	490,925,082	552,997,851
Cost of nutriment	72,898,910	72,898,910	7,367,929	9,975,707
Employee benefit expenses	1,497,417,296	1,497,417,296	506,899,206	554,555,618
Management benefit expense	111,565,682	111,565,682	45,582,428	47,991,549
Depreciation and amortization expenses	413,382,201	413,382,201	130,686,968	127,535,920
Repair and maintenance expenses	105,485,442	105,485,442	39,903,835	39,721,412
Utility expense	132,361,932	132,361,932	46,021,682	47,349,080

32. PROVIDENT FUND

The Company established a contributory registered provident fund covering all permanent employees in accordance with the Provident Fund Act B.E.2530.

Under the provident fund plan, employees' and Company's contributions are equivalent to certain percentages of employees' basic salaries. The employees are entitled to the Company's contributions in accordance with the rules and regulations of the fund and on the length of service with the Company. The Company appointed a fund manager to manage the fund in accordance with the terms and conditions prescribed in the Provident Fund Act.

The Company's contributions for the years ended December 31, 2020 and 2019 were amounted to Baht 4.85 million and Baht 4.54 million, respectively.

33. INCOME TAX EXPENSES

33.1 Major components of income tax expenses for the years ended December 31, 2020 and 2019 consisted of:

	Baht			
	Consolidated financial statements		Separate financial statements	
	2020	2019	2020	2019
Income tax expenses shown in profit or loss :				
Current income tax:				
Income tax for the year	132,042,530	215,886,634	52,044,812	84,754,151
Deferred tax:				
Changes in temporary differences relating to the				
original recognition and reversal	(8,303,548)	(9,441,335)	(1,915,630)	(2,367,110)
Total	<u>123,738,982</u>	<u>206,445,299</u>	<u>50,129,182</u>	<u>82,387,041</u>
Income tax relating to components of other comprehensive income:				
Deferred tax relating to gain (loss) from :-				
Remeasuring available-for-sale investments	9,920,701	147,439,051	62,008,280	76,459,523
Actuarial on define employee benefit plans	-	(6,603,425)	-	(1,042,793)
Total	<u>9,920,701</u>	<u>140,835,626</u>	<u>62,008,280</u>	<u>75,416,730</u>

33.2 A numerical reconciliation between income tax expense and the product of accounting profit multiplied by the applicable tax rate for the years ended December 31, 2020 and 2019 which are summarized as follows:

	Baht			
	Consolidated financial statements		Separate financial statements	
	2020	2019	2020	2019
Accounting profit for the year	662,257,768	1,199,244,862	604,631,358	796,043,542
The applicable tax rate (%)	20	20	20	20
Income tax expense at the applicable tax rate	132,451,554	239,848,972	120,926,272	159,208,708
Reconciliation items:				
Tax effect of expenses that are not deductible in determining tax profit:				
- Expenses not allowed as expenses in determining taxable profit	20,923,288	62,538,362	27,809,044	1,245,254
Tax effect of income or profit that are not required in determining taxable profit:				
- Exemption of non-taxable dividend income	(31,919,583)	(33,218,462)	(92,751,582)	(73,866,685)
- Share of profit of associates	12,470,938	(51,946,788)	-	-
- Others	(11,604,974)	(15,214,243)	(5,854,552)	(4,200,236)
Unrecognized tax losses on deferred tax assets	1,417,759	4,437,458	-	-
Total reconciliation items	(8,712,572)	(33,403,673)	(70,797,090)	(76,821,667)
Total income tax expense	123,738,982	206,445,299	50,129,182	82,387,041

33.3 A numerical reconciliation between the average effective tax rate and the applicable tax rate for the years ended December 31, 2020 and 2019 are summarized as follows:

	Consolidated financial statements			
	2020		2019	
	Tax amount (Baht)	Tax rate (%)	Tax amount (Baht)	Tax rate (%)
Accounting profit before income tax expenses for the year	662,257,768		1,199,244,862	
Income tax expenses at the applicable tax rate	132,451,554	20.00	239,848,972	20.00
Reconciliation items	(8,712,572)	(1.32)	(33,403,673)	(2.79)
Income tax expenses at the average effective tax rate	123,738,982	18.68	206,445,299	17.21

	Separate financial statements			
	2020		2019	
	Tax amount (Baht)	Tax rate (%)	Tax amount (Baht)	Tax rate (%)
Accounting profit before income tax expenses for the year	604,631,358		796,043,542	
Income tax expenses at the applicable tax rate	120,926,272	20.00	159,208,708	20.00
Reconciliation items	(70,797,090)	(11.71)	(76,821,667)	(9.65)
Income tax expenses at the average effective tax rate	50,129,182	8.29	82,387,041	10.35

34. OPERATING SEGMENT

The Company and its subsidiaries operate in 2 main reportable operating segments in one geographical area, Thailand as follows :

Type of operating segment	Nature of operating segment
Hospital	General Hospital, Hospital in Social Security and the National Health Security Office systems
Others	Rental and Hotel services

The operating segment's performance is regularly reviewed by the chief operating decision maker who is the Executive Directors in order to make decisions about the allocation of resources to the segment and assess its performance. The Company and its subsidiaries assess the performance of the operating segment by using the operating profit or loss as the basis consistent with that used to assess operating profit or loss in the financial statements.

Operating segment information for the years ended December 31, 2020 and 2019 were as follows :

	Baht					
	Consolidated financial statements					
	Hospital		Others		Total	
	2020	2019	2020	2019	2020	2019
Revenue from services	5,909,504,131	6,450,680,338	114,944,776	95,213,190	6,024,448,907	6,545,893,528
Cost of services	(4,406,035,846)	(4,678,123,924)	(79,845,496)	(100,459,102)	(4,485,881,342)	(4,778,583,026)
Gross profit	1,503,468,285	1,772,556,414	35,099,280	(5,245,912)	1,538,567,565	1,767,310,502
Unallocated other income (other expenses)						
Dividend income					192,089,968	210,425,919
Gain on sale of investment					-	180,526
Other income					121,711,160	116,161,383
Administrative expenses					(925,035,511)	(953,466,030)
Finance cost					(202,720,725)	(201,101,377)
Share of profit of associates					(62,354,689)	259,733,939
Income tax expenses					(123,738,982)	(206,445,299)
Profit for the year					538,518,786	992,799,563

35. EARNINGS PER SHARE

Basic earnings per share is calculated by dividing the profit for the years by the weighted average number of ordinary shares which are issued and paid-up during the years after adjusting the number of ordinary shares to reflect the impact of the changing of par value as discussed in Note 24 to the financial statements. The prior year basic earnings per share has been recalculated as if the changing of par value had been changed at the beginning of the earliest year reported.

Diluted earnings per share is computed by dividing profit for the years by the aggregate amount of the weighted average number of ordinary shares issued during the years and the weighted average number of ordinary shares which the Company may have to issue for conversion of warrants to ordinary shares.

For the years ended December 31, 2020 and 2019.

	Consolidated financial statements		Separate financial statements	
	2020	2019	2020	2019
Profit for the year of parent company (Baht)	449,799,642	809,045,597	554,502,176	713,656,501
Weighted average number of ordinary shares (Shares)	13,414,288,594	13,214,026,936	13,414,288,594	13,214,026,936
Weighted average number of ordinary shares under warrants (VIBHA-W2) (Shares)	162,054,231	410,125,132	162,054,231	410,125,132
Weighted average number of ordinary shares under warrants (VIBHA-W3) (Shares)	1,011,623,932	1,011,738,579	1,011,623,932	1,011,738,579
Weighted average number of ordinary shares under warrants (VIBHA-W3) (Shares)	300,000,000	300,000,000	300,000,000	300,000,000
Number of ordinary shares that would have been issued at fair value (Shares)	(104,854,559)	(213,497,466)	(104,854,559)	(213,497,466)
Weighted average number of ordinary share plus effect of assumed conversion (Shares)	14,783,112,198	14,722,393,181	14,783,112,198	14,722,393,181
Basic earnings per share (Baht per share)	0.0335	0.0612	0.0413	0.0540
Diluted earnings per share (Baht per share)	0.0304	0.0550	0.0375	0.0485

36. FINANCIAL INSTRUMENTS

36.1 Risk management

The Company and its subsidiaries manage their financial risk exposure on financial assets and financial liabilities in the normal business by its internal management and control system, and the Company and its subsidiaries do not hold or issue derivative financial instruments for speculative or trading purposes.

36.2 Classification and measurement financial assets and liabilities

On January 1, 2020 (the date of initial application of new financial reporting standards), the Company and its subsidiaries's management have assessed which business models applied to the financial assets and liabilities and have classified the financial assets and liabilities balances as at January 1, 2020 has been disclosed in Note 5 and balances as st December 31,2020 as follows:

	Baht					
	Consolidated financial statements			Separate financial statements		
	FVOCI	Amortized cost	Total	FVOCI	Amortized cost	Total
Cash and cash equivalents	-	338,293,191	338,293,191	-	40,881,085	40,881,085
Trade receivable	-	639,659,569	639,659,569	-	141,639,038	141,639,038
Short-term loans to related parties	-	240,665,200	240,665,200	-	138,290,200	138,290,200
Other current asset	-	67,954,978	67,954,978	-	95,036,197	95,036,197
Fixed deposits pledged as collateral	-	39,406,478	39,406,478	-	-	-
Other non-current financial assets	7,890,167,417	10,000,000	7,900,167,417	5,135,443,263	10,000,000	5,145,443,263
Long-term loans to related parties	-	24,000,000	24,000,000	-	-	-
Long-term loans to other persons	-	18,945,000	18,945,000	-	-	-
Other non-current asset	-	7,255,642	7,255,642	-	4,873,391	4,873,391
	<u>7,890,167,417</u>	<u>1,386,180,058</u>	<u>9,276,347,475</u>	<u>5,135,443,263</u>	<u>430,719,911</u>	<u>5,566,163,174</u>

Financial liabilities as at December 31, 2020 the Company and its subsidiaries has classified as amortized cost.

36.3 Interest rate risk

The Company and its subsidiaries are exposed to interest rate risk relates primarily to its cash at banks, bank overdrafts, short-term loans, long-term and lease liability. However, most of the Company's financial assets and liabilities bear floating interest rates or fixed interest rates which are close to the market. However, the management believed that the future fluctuation on market interest rate would not provided significant effect to their operations and cash flows, therefore; no financial derivative was adopted to manage such risks.

As at December 31, 2020 and 2019, the significant financial assets and financial liabilities classified by types of interest rates were as follows:

	Baht			
	Consolidated financial statements			
	As at December 31, 2020			
	Floating interest rate	Fixed interest rates	Non-interest bearing	Total
Financial assets				
Cash and cash equivalents	335,055,449	-	3,237,742	338,293,191
Trade receivables	-	-	639,659,569	639,659,569
Short-term loans to related parties	-	240,665,200	-	240,665,200
Fixed deposits pledged as collateral	39,406,478	-	-	39,406,478
Investments	-	10,000,000	10,040,249,663	10,050,249,663
Long-term loans to related parties	-	24,000,000	-	24,000,000
Long-term loans to other persons	-	18,945,000	-	18,945,000

	Baht			
	Consolidated financial statements			
	As at December 31, 2020			
	Floating interest rate	Fixed interest rates	Non-interest bearing	Total
<u>Financial liabilities</u>				
Bank overdrafts and short-term loans from financial institutions	485,899,659	2,120,000,000	-	2,605,899,659
Trade payables	-	-	335,023,990	335,023,990
Short-term loans from related parties	-	375,253,818	-	375,253,818
Short-term loan from other persons	-	85,300,000	-	85,300,000
Long-term loans from financial institutions	3,931,545,513	624,920,000	-	4,556,465,513
Liabilities under finance lease agreements	-	322,171,509	-	322,171,509
Long-term loans from related parties	-	284,000,000	-	284,000,000

	Baht			
	Consolidated financial statements			
	As at December 31, 2019			
	Floating interest rate	Fixed interest rates	Non-interest bearing	Total
<u>Financial assets</u>				
Cash and cash equivalents	578,723,527	-	24,131,520	602,855,047
Trade receivables	-	-	592,595,058	592,595,058
Short-term loans to related parties	-	305,125,000	-	305,125,000
Fixed deposits pledged as collateral	36,252,346	-	-	36,252,346
Investments	-	-	9,640,064,056	9,640,064,056
Long-term loans to related parties	-	24,000,000	-	24,000,000
Long-term loans to other persons	-	5,370,000	-	5,370,000

<u>Financial liabilities</u>				
Bank overdrafts and short-term loans from financial institutions	2,944,206	2,675,000,000	-	2,677,944,206
Trade payables	-	-	342,149,832	342,149,832
Short-term loans from related parties	-	633,053,818	-	633,053,818
Short-term loan from other persons	-	70,800,000	-	70,800,000
Long-term loans from financial institutions	2,965,199,045	538,191,463	-	3,503,390,508
Liabilities under finance lease agreements	-	13,245,019	-	13,245,019
Long-term loans from related parties	-	176,000,000	-	176,000,000

	Baht			
	Separate financial statements			
	As at December 31, 2020			
	Floating interest rate	Fixed interest rates	Non-interest bearing	Total
<u>Financial assets</u>				
Cash and cash equivalents	47,706,147	-	(6,825,062)	40,881,085
Trade receivables	-	-	141,639,038	141,639,038
Short-term loans to related parties	-	138,290,200	-	138,290,200
Investments	-	10,000,000	8,580,828,496	8,590,828,496
<u>Financial liabilities</u>				
Bank overdrafts and short-term loans from financial institutions	-	1,870,000,000	-	1,870,000,000
Trade payables	-	-	-	-
Long-term loans from financial institutions	1,414,255,230	624,920,000	-	2,039,175,230
Liabilities under finance lease agreements	-	25,862,434	-	25,862,434
Long-term loans from related parties	-	284,000,000	-	284,000,000

	Baht			
	Separate financial statements			
	As at December 31, 2019			
	Floating interest rate	Fixed interest rates	Non-interest bearing	Total
<u>Financial assets</u>				
Cash and cash equivalents	67,829,150	-	2,517,769	70,346,919
Trade receivables	-	-	131,271,650	131,271,650
Short-term loans to related parties	-	117,419,494	-	117,419,494
Investments	-	-	8,176,812,271	8,176,812,271
<u>Financial liabilities</u>				
Bank overdrafts and short-term loans from financial institutions	-	2,045,000,000	-	2,045,000,000
Trade payables	-	-	109,712,596	109,712,596
Long-term loans from financial institutions	1,285,060,950	538,191,463	-	1,823,252,413
Liabilities under finance lease agreements	-	11,819,123	-	11,819,123
Long-term loans from related parties	-	176,000,000	-	176,000,000

36.4 Credit risk

The Company and its subsidiaries are exposed to credit risk primarily relating to trade accounts receivable and short-term/long-term loans to related parties. The management of the Company and its subsidiaries manage this risk by establishing appropriate credit control policies and procedures. Therefore, it does not expect to incur material losses from debt collection more than the amount already provided in the allowance for doubtful accounts.

36.5 Foreign currency risk

The Company and its subsidiaries do not hold risk from fluctuation of exchange rate in the overseas currencies since the trading activity of the Company and its subsidiaries companies are performed with domestic business.

36.6 Liquidity risk

The Company and its subsidiaries manage its liquidity risk by maintaining adequate level of cash and cash equivalents to support the Company and its subsidiaries' operations as well as securing short-term credit facilities from financial institutions for reserve as necessary and to reduce the impact of fluctuations in cash flow.

36.7 Fair value

The Company and its subsidiaries use the market approach to measure their assets and liabilities that are required to be measured at fair value by relevant financial reporting standards, except that the cost approach or income approach is used when there is no active market or when a quoted market price is not available.

Fair value hierarchy

- Level 1- Use of quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2- Use of inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (e.g. prices) or indirectly (e.g. derived from prices).
- Level 3 - Use of unobservable inputs such as estimates of future cash flows.

As at December 31, 2020 and 2019, the Company and its subsidiaries had the following assets and liabilities that were measured at fair value using different levels of inputs as follows :-

	Baht			
	Consolidated financial statements			
	As at December 31, 2020			
	Level 1	Level 2	Level 3	Total
Other non - current financial assets				
Non-marketable equity security	-	-	982,498,651	982,498,651
Marketable equity security	6,907,668,766	-	-	6,907,668,766
Total	6,907,668,766	-	982,498,651	7,890,167,417

	Baht			
	Consolidated financial statements			
	As at December 31, 2019			
	Level 1	Level 2	Level 3	Total
Other non - current financial assets				
Non-marketable equity security	-	-	961,836,651	961,836,651
Unit trust	-	780,080	-	780,080
Marketable equity security	6,313,495,459	-	-	6,313,495,459
Total	6,313,495,459	780,080	961,836,651	7,276,112,190

	Baht			
	Separate financial statements			
	As at December 31, 2019			
	Level 1	Level 2	Level 3	Total
Other non - current financial assets				
Non-marketable equity security	-	-	662,381,891	662,381,891
Marketable equity security	4,473,061,372	-	-	4,473,061,372
Total	4,473,061,372	-	662,381,891	5,135,443,263

	Baht			
	Separate financial statements			
	As at December 31, 2018			
	Level 1	Level 2	Level 3	Total
Other non - current financial assets				
Non-marketable equity security	-	-	716,821,891	716,821,891
Marketable equity security	3,674,474,522	-	-	3,674,474,522
Total	3,674,474,522	-	716,821,891	4,391,296,413

During the current year, there were no transfers within the fair value hierarchy.

Valuation techniques and inputs for Level 2 and 3 valuations

Level 2 fair value of investments in investment units which are not listed on the Stock Exchange of Thailand, is determined by using the net assets value per unit as announced by the fund managers.

Level 3 fair values for other non-marketable equity instruments are based on the valuation are annual revenue growth rate, expected earnings before interest tax depreciation and amortisation (EBITDA), expected net profit margin, dividend yield, relevant information of comparable equity securities and relevant risk factors.

37. RECONCILIATION OF LIABILITIES ARISING FROM FINANCING ACTIVITIES

Changes in the liabilities arising from financing activities for the years ended December 31, 2020 and 2019 are as follows:

	Baht			
	Consolidated financial statements			
	Balance as at	Cash flows	Non-cash transaction	Balance as at
	January 1, 2020	Increase (decrease)*	Increase	December 31, 2020
Short-term loans from financial institutions	2,677,944,206	(67,109,375)	-	2,610,834,831
Short-term loans from related parties	633,053,818	(257,800,000)	-	375,253,818
Short-term loans from other persons	70,800,000	14,500,000	-	85,300,000
Long-term loans from financial institutions	3,503,390,508	1,053,075,005	-	4,556,465,513
Liabilities under finance lease agreements	13,245,019	(16,870,664)	325,797,154	322,171,509
Long-term loans from related parties	176,000,000	108,000,000	-	284,000,000
Total	<u>7,074,433,551</u>	<u>833,794,966</u>	<u>325,797,154</u>	<u>8,234,025,671</u>

	Baht			
	Consolidated financial statements			
	Balance as at	Cash flows	Non-cash transaction	Balance as at
	January 1, 2019	Increase (decrease)*	Increase	December 31, 2019
Short-term loans from financial institutions	1,585,794,960	1,092,149,246	-	2,677,944,206
Short-term loans from related parties	589,853,818	43,200,000	-	633,053,818
Short-term loans from other persons	68,400,000	2,400,000	-	70,800,000
Long-term loans from financial institutions	2,105,354,098	1,398,036,410	-	3,503,390,508
Liabilities under finance lease agreements	19,826,556	(9,964,263)	3,382,726	13,245,019
Long-term loans from related parties	192,000,000	(16,000,000)	-	176,000,000
Total	<u>4,561,229,432</u>	<u>2,509,821,393</u>	<u>3,382,726</u>	<u>7,074,433,551</u>

	Baht			
	Separate financial statements			
	Balance as at	Cash flows	Non-cash transaction	Balance as at
	January 1, 2020	Increase (decrease)*	Increase	December 31, 2020
Short-term loans from financial institutions	2,045,000,000	(175,000,000)	-	1,870,000,000
Long-term loans from financial institutions	1,823,252,413	215,922,817	-	2,039,175,230
Liabilities under finance lease agreements	11,819,123	(7,018,139)	21,061,450	25,862,434
Long-term loans from related parties	176,000,000	108,000,000	-	284,000,000
Total	<u>4,056,071,536</u>	<u>141,904,678</u>	<u>21,061,450</u>	<u>4,219,037,664</u>

	Baht			
	Separate financial statements			
	Balance as at	Cash flows	Non-cash transaction	Balance as at
	January 1, 2019	Increase (decrease)*	Increase	December 31, 2019
Short-term loans from financial institutions	915,000,000	1,130,000,000	-	2,045,000,000
Long-term loans from financial institutions	1,067,661,716	755,590,697	-	1,823,252,413
Liabilities under finance lease agreements	17,174,825	(8,738,428)	3,382,726	11,819,123
Long-term loans from related parties	192,000,000	(16,000,000)	-	176,000,000
Total	<u>2,191,836,541</u>	<u>1,860,852,269</u>	<u>3,382,726</u>	<u>4,056,071,536</u>

* Financing cash flows included net proceed and repayment cash transactions in the statements of cash flows.

38. COMMITMENTS

As at December 31, 2020, the Company and its subsidiaries had commitments as follows:

- 38.1 The Company and its subsidiaries had capital commitments in respect of the construction of plant and equipment amounting to Baht 347.23 million (the Separate at Baht 49.25 million).
- 38.2 The Company and its subsidiaries had commitment to pay for medical maintenance contracts and others outstanding, as follows:

	Baht	
	Consolidated	Separate
	<u>financial statements</u>	<u>financial statements</u>
<u>Payment within</u>		
1 year	23,712,584	13,867,318
2 - 5 years	21,700,044	14,413,811
	<u>45,412,628</u>	<u>28,281,129</u>

39. CONTINGENT LIABILITIES

As at December 31, 2020, the Company and its subsidiaries had contingent liabilities as follows:

- 39.1 The Company had contingently liable for financial institutions guarantees issued to government agency amounted to Baht 5.13 million.
- 39.2 The Company had contingently liable for financial institutions guarantees issued to government agency for subsidiary amounted to Baht 7.39 million.
- 39.3 The subsidiaries had contingently liable for bank guarantee for electricity usage, post office department social security office and bank aval, amounted to Baht 51.05 million.

40. CORONAVIRUS DISEASE 2019 PANDEMIC

The Coronavirus disease 2019 pandemic is continuing to evolve, resulting in an economic slowdown and adversely impacting most businesses and industries as a whole. The situation affects the results of operations of the Company and its subsidiaries, recognition and measurement of assets and liabilities in the financial statements. Nevertheless, the management will continue to monitor the ongoing development and regularly assess the financial impact in respect of the valuation of assets, provisions and contingent liabilities.

41. EVENTS AFTER THE REPORTING PERIOD

For the Company

According to the resolution of the Board of Directors' Meeting on a special agenda No.1/2021 held on January 19, 2021, it had a resolution to approve the Company's investment in the capital increase ordinary shares of Thippayabadin Co.,Ltd. for 26,000,000 shares at Baht 5.00 per share in the amount of Baht 130,000,000 resulting in the registered capital of Thippayabadin Co.,Ltd. to increase from 392,840,000 to 522,840,000. This investment is an exercise of rights to purchase capital increase shares of the existing shareholders by the shareholding proportion 38.18 percent or 9,926,800 shares at Baht 5 per share or Baht 49,634,000. The Company will pay for the shares within January 30, 2021.

On February 25, 2021, the Board of Company's Director's Meeting passed a resolution to propose to the Annual General Meeting of shareholders for the year 2021 to adopt a resolution to pay dividend of Baht 0.040 per share, or a total of Baht 543.03 million, to the shareholders in respect of profit for the year 2020. The dividend will be paid after it is approved by the Annual General Meeting of Company's shareholders.

For the subsidiary company - Chiang Mai Ram Medical Business Public Co., Ltd.

On February 25, 2021, the Board of subsidiary company's Director's Meeting passed a resolution to propose to the Annual General Meeting of shareholders for the year 2021 to adopt a resolution to pay dividend of Baht 0.052 per share, or a total of Baht 209.20 million, to the shareholders in respect of the retained earning. The dividend will be paid after it is approved by the Annual General Meeting of subsidiary's shareholders.

42. APPROVAL OF FINANCIAL STATEMENTS

These financial statements were authorized for issue by the Board of Directors of the Company on February 25, 2021.